[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"$fWxsT5qRfGNJ2MWPXdVsYDYB_0Fe9m_lMe-TjPm2x0a8":3},{"sponsor":4,"sponsorVariants":5,"totalTrials":6,"truncated":7,"activeTrials":8,"phase3Count":9,"totalEnrollment":10,"activePrograms":11,"nonDrugCount":12,"topConditions":13,"upcomingReadouts":36,"phaseBuckets":86,"rows":93},"Children's Hospital Medical Center, Cincinnati",[4],653,false,167,29,1404190,62,425,[14,17,19,22,25,28,31,33],{"name":15,"count":16},"Autism Spectrum Disorder",18,{"name":18,"count":16},"Attention Deficit Hyperactivity Disorder",{"name":20,"count":21},"Cystic Fibrosis",16,{"name":23,"count":24},"Pain",15,{"name":26,"count":27},"Acute Kidney Injury",13,{"name":29,"count":30},"Sickle Cell Disease",12,{"name":32,"count":30},"Obesity",{"name":34,"count":35},"Eosinophilic Esophagitis",11,[37,42,47,52,57,62,67,72,77,81],{"nctId":38,"briefTitle":39,"date":40,"intervention":41},"NCT01966731","Realizing Effectiveness Across Continents With Hydroxyurea (REACH)","2018-07-01","Hydroxyurea",{"nctId":43,"briefTitle":44,"date":45,"intervention":46},"NCT03492944","Contrast Enhanced Ultrasound in Human Crohn's Disease-Lumason","2024-06-12","Ultrasound Microbubble Contrast Agent",{"nctId":48,"briefTitle":49,"date":50,"intervention":51},"NCT04481048","Antioxidant Therapy With N-acetylcysteine for Children With Neurofibromatosis Type 1","2024-06-25","N-Acetyl cysteine",{"nctId":53,"briefTitle":54,"date":55,"intervention":56},"NCT04219280","Evaluating Treatment of ADHD in Children with Down Syndrome","2025-09-30","Quillivant XR",{"nctId":58,"briefTitle":59,"date":60,"intervention":61},"NCT05418049","Evaluating the Neurophysiologic and Clinical Effects of Single Dose Drug Challenge","2025-10-28","Baclofen",{"nctId":63,"briefTitle":64,"date":65,"intervention":66},"NCT02848560","Monitoring Response to Orkambi in Cystic Fibrosis Lung Disease by Inhaled Xenon MRI","2025-10-31","Hyperpolarized Xenon",{"nctId":68,"briefTitle":69,"date":70,"intervention":71},"NCT04467957","Non-contrast Lung Perfusion Mapping Applied for New Insights in Cystic Fibrosis","2025-12-31","Initiation of CFTR Modulator",{"nctId":73,"briefTitle":74,"date":75,"intervention":76},"NCT04793867","Regional Phenotyping of CF and Non-CF Bronchiectasis","2026-03-31","Xenon",{"nctId":78,"briefTitle":79,"date":80,"intervention":71},"NCT04259970","Hyperpolarized Imaging for New Treatments","2026-05-01",{"nctId":82,"briefTitle":83,"date":84,"intervention":85},"NCT04216927","NO During CPB in Neonates to Reduce Risk of AKI","2026-06-30","Nitric Oxide",[87,88,89,90,91,92],"EARLY_PHASE1","PHASE1","PHASE2","PHASE3","PHASE4","NA",[94,131,160,220,238,256,285,311,336,362,383,411,446,464,489,539,636,671,707,768,812,856,890,926,961,984,1002,1020,1038,1056,1081,1099,1121,1145,1173,1199,1217,1242,1260,1278,1302,1330,1355,1381,1411,1444,1488,1514,1532,1554,1580,1602,1627,1651,1669,1730,1755,1775,1794,1814,1837,1867,1894,1975,1999,2023,2050,2068,2093,2118,2136,2161,2188,2206,2233,2251,2269,2287,2305,2359,2413,2450,2479,2505,2527,2558,2580,2602,2631,2649,2680,2698,2716,2734,2761,2779,2805,2823,2847,2870,2888,2915,2940,2958,2983,3010,3032,3057,3081,3099,3117,3135,3153,3171,3189,3207,3264,3311,3337,3366,3400,3433,3461,3488,3520,3544,3568,3591,3609,3627,3651,3669,3687,3705,3723,3741,3759,3785,3809,3832,3858,3886,3904,3930,3953,3978,4003,4025,4051,4073,4096,4120,4142,4166,4189,4213,4231,4257,4283,4305,4330,4353,4374,4402,4428,4452,4478,4496,4519,4543,4579,4621,4657,4679,4712,4734,4752,4773,4797,4819,4837,4855,4873,4896,4921,4944,4969,4987,5012,5037,5055,5073,5091,5109,5132,5150,5168,5191,5209,5231,5256,5274,5304,5322,5345,5363,5388,5413,5435,5459,5477,5499,5522,5554,5580,5619,5650,5678,5712,5736,5761,5779,5797,5815,5838,5860,5878,5903,5921,5939,5961,5983,6006,6028,6052,6070,6088,6106,6130,6154,6172,6195,6219,6243,6261,6284],{"intervention":95,"totalTrials":96,"cells":97},"129Xe",2,{"EARLY_PHASE1":98,"PHASE1":101,"PHASE2":103,"PHASE3":105,"PHASE4":107,"NA":129},{"trials":99,"activeCount":100},[],0,{"trials":102,"activeCount":100},[],{"trials":104,"activeCount":100},[],{"trials":106,"activeCount":100},[],{"trials":108,"activeCount":96,"soonestReadout":114},[109,120],{"nctId":110,"briefTitle":111,"status":112,"phases":113,"primaryCompletion":114,"completion":115,"start":116,"enrollment":30,"conditions":117,"interventions":119},"NCT04995562","Use of Hyperpolarized 129Xe MR Lung Imaging in Infants","RECRUITING",[91],"2027-05-01","2028-05-01","2020-05-06",[118],"Lungs; Developmental Disorder",[95],{"nctId":121,"briefTitle":122,"status":112,"phases":123,"primaryCompletion":124,"completion":124,"start":125,"enrollment":126,"conditions":127,"interventions":128},"NCT05517655","BEGIN Novel ImagiNG Biomarkers",[91],"2028-11-01","2022-05-01",44,[20],[95],{"trials":130,"activeCount":100},[],{"intervention":71,"totalTrials":96,"cells":132},{"EARLY_PHASE1":133,"PHASE1":135,"PHASE2":137,"PHASE3":139,"PHASE4":141,"NA":158},{"trials":134,"activeCount":100},[],{"trials":136,"activeCount":100},[],{"trials":138,"activeCount":100},[],{"trials":140,"activeCount":100},[],{"trials":142,"activeCount":96,"soonestReadout":70},[143,152],{"nctId":68,"briefTitle":69,"status":144,"phases":145,"primaryCompletion":70,"completion":146,"start":147,"enrollment":148,"conditions":149,"interventions":150},"ACTIVE_NOT_RECRUITING",[91],"2026-12-31","2020-11-15",26,[20],[71,151],"Hyperpolarized Xenon 129",{"nctId":78,"briefTitle":79,"status":144,"phases":153,"primaryCompletion":80,"completion":146,"start":154,"enrollment":155,"conditions":156,"interventions":157},[91],"2020-01-13",64,[20],[71],{"trials":159,"activeCount":100},[],{"intervention":161,"totalTrials":162,"cells":163},"Methylphenidate",4,{"EARLY_PHASE1":164,"PHASE1":176,"PHASE2":178,"PHASE3":180,"PHASE4":182,"NA":218},{"trials":165,"activeCount":100},[166],{"nctId":167,"briefTitle":168,"status":169,"phases":170,"primaryCompletion":171,"completion":171,"start":172,"enrollment":173,"conditions":174,"interventions":175},"NCT02874690","Eye Tracking as a Predictor of Methylphenidate Response in Autism With ADHD","COMPLETED",[87],"2017-08-03","2016-02-19",40,[15,18],[161],{"trials":177,"activeCount":100},[],{"trials":179,"activeCount":100},[],{"trials":181,"activeCount":100},[],{"trials":183,"activeCount":217,"soonestReadout":189},[184,197,206],{"nctId":185,"briefTitle":186,"status":187,"phases":188,"primaryCompletion":189,"completion":190,"start":191,"enrollment":192,"conditions":193,"interventions":195},"NCT07300956","Treating Young Children With Attention Deficit Hyperactivity Disorder","NOT_YET_RECRUITING",[91],"2030-02","2030-07","2026-02",370,[194],"Attention-Deficit\u002FHyperactivity Disorder (ADHD)",[196,161],"Guanfacine",{"nctId":198,"briefTitle":199,"status":169,"phases":200,"primaryCompletion":201,"completion":201,"start":202,"enrollment":203,"conditions":204,"interventions":205},"NCT01238822","Response Variability in Children With Attention Deficit Hyperactivity Disorder (ADHD)",[91],"2009-06","2006-06",96,[18],[161,161,161],{"nctId":207,"briefTitle":208,"status":169,"phases":209,"primaryCompletion":210,"completion":210,"start":211,"enrollment":148,"conditions":212,"interventions":216},"NCT01933217","Methylphenidate for Attention Problems After Pediatric TBI",[91],"2016-08","2013-11",[213,214,215],"Traumatic Brain Injury","TBI","ADHD",[161],1,{"trials":219,"activeCount":100},[],{"intervention":196,"totalTrials":217,"cells":221},{"EARLY_PHASE1":222,"PHASE1":224,"PHASE2":226,"PHASE3":228,"PHASE4":230,"NA":236},{"trials":223,"activeCount":100},[],{"trials":225,"activeCount":100},[],{"trials":227,"activeCount":100},[],{"trials":229,"activeCount":100},[],{"trials":231,"activeCount":217,"soonestReadout":189},[232],{"nctId":185,"briefTitle":186,"status":187,"phases":233,"primaryCompletion":189,"completion":190,"start":191,"enrollment":192,"conditions":234,"interventions":235},[91],[194],[196,161],{"trials":237,"activeCount":100},[],{"intervention":151,"totalTrials":217,"cells":239},{"EARLY_PHASE1":240,"PHASE1":242,"PHASE2":244,"PHASE3":246,"PHASE4":248,"NA":254},{"trials":241,"activeCount":100},[],{"trials":243,"activeCount":100},[],{"trials":245,"activeCount":100},[],{"trials":247,"activeCount":100},[],{"trials":249,"activeCount":217,"soonestReadout":70},[250],{"nctId":68,"briefTitle":69,"status":144,"phases":251,"primaryCompletion":70,"completion":146,"start":147,"enrollment":148,"conditions":252,"interventions":253},[91],[20],[71,151],{"trials":255,"activeCount":100},[],{"intervention":257,"totalTrials":217,"cells":258},"Genetic Sequencing",{"EARLY_PHASE1":259,"PHASE1":261,"PHASE2":263,"PHASE3":265,"PHASE4":267,"NA":283},{"trials":260,"activeCount":100},[],{"trials":262,"activeCount":100},[],{"trials":264,"activeCount":100},[],{"trials":266,"activeCount":100},[],{"trials":268,"activeCount":217,"soonestReadout":274},[269],{"nctId":270,"briefTitle":271,"status":272,"phases":273,"primaryCompletion":274,"completion":275,"start":276,"enrollment":277,"conditions":278,"interventions":281},"NCT05659147","Imaging Biomarkers of Pancreatic Function and Disease","ENROLLING_BY_INVITATION",[91],"2026-12","2027-12","2023-01-18",195,[279,280],"Pancreatitis","Diabetes Mellitus",[257,282],"Secretin",{"trials":284,"activeCount":100},[],{"intervention":286,"totalTrials":217,"cells":287},"Advanced Medical Therapy",{"EARLY_PHASE1":288,"PHASE1":290,"PHASE2":292,"PHASE3":294,"PHASE4":296,"NA":309},{"trials":289,"activeCount":100},[],{"trials":291,"activeCount":100},[],{"trials":293,"activeCount":100},[],{"trials":295,"activeCount":100},[],{"trials":297,"activeCount":217,"soonestReadout":274},[298],{"nctId":299,"briefTitle":300,"status":144,"phases":301,"primaryCompletion":274,"completion":274,"start":302,"enrollment":303,"conditions":304,"interventions":308},"NCT04128995","Surgical or Medical Treatment",[91],"2019-12-15",88,[305,306,307],"Diabetes Mellitus, Type 2","Pediatric Obesity","Bariatric Surgery Candidate",[286],{"trials":310,"activeCount":100},[],{"intervention":312,"totalTrials":217,"cells":313},"129-Xe",{"EARLY_PHASE1":314,"PHASE1":316,"PHASE2":318,"PHASE3":320,"PHASE4":322,"NA":334},{"trials":315,"activeCount":100},[],{"trials":317,"activeCount":100},[],{"trials":319,"activeCount":100},[],{"trials":321,"activeCount":100},[],{"trials":323,"activeCount":217,"soonestReadout":328},[324],{"nctId":325,"briefTitle":326,"status":112,"phases":327,"primaryCompletion":328,"completion":328,"start":329,"enrollment":330,"conditions":331,"interventions":333},"NCT04991389","Improving Outcomes in Pediatric Obstructive Sleep Apnea With Computational Fluid Dynamics",[91],"2027-09-01","2019-08-15",120,[332],"Obstructive Sleep Apnea",[312],{"trials":335,"activeCount":100},[],{"intervention":337,"totalTrials":217,"cells":338},"PK-optimized oral hydroxyurea at MTD until 15 years of age.",{"EARLY_PHASE1":339,"PHASE1":341,"PHASE2":343,"PHASE3":345,"PHASE4":347,"NA":360},{"trials":340,"activeCount":100},[],{"trials":342,"activeCount":100},[],{"trials":344,"activeCount":100},[],{"trials":346,"activeCount":100},[],{"trials":348,"activeCount":217,"soonestReadout":274},[349],{"nctId":350,"briefTitle":351,"status":112,"phases":352,"primaryCompletion":274,"completion":353,"start":354,"enrollment":355,"conditions":356,"interventions":359},"NCT07177300","Effectiveness of Nontraditional Hydroxyurea Algorithms: Novel and Clinical Evaluations (ENHANCE)",[91],"2028-12","2024-12-19",50,[357,358],"Sickle Cell Anemia (HbSS)","Sickle-β0-thalassemia (HbSβ0)",[337],{"trials":361,"activeCount":100},[],{"intervention":56,"totalTrials":217,"cells":363},{"EARLY_PHASE1":364,"PHASE1":366,"PHASE2":368,"PHASE3":370,"PHASE4":372,"NA":381},{"trials":365,"activeCount":100},[],{"trials":367,"activeCount":100},[],{"trials":369,"activeCount":100},[],{"trials":371,"activeCount":100},[],{"trials":373,"activeCount":217,"soonestReadout":55},[374],{"nctId":53,"briefTitle":54,"status":112,"phases":375,"primaryCompletion":55,"completion":55,"start":376,"enrollment":377,"conditions":378,"interventions":380},[91],"2020-10-02",100,[379,215],"Down Syndrome",[56],{"trials":382,"activeCount":100},[],{"intervention":282,"totalTrials":96,"cells":384},{"EARLY_PHASE1":385,"PHASE1":387,"PHASE2":389,"PHASE3":391,"PHASE4":393,"NA":399},{"trials":386,"activeCount":100},[],{"trials":388,"activeCount":100},[],{"trials":390,"activeCount":100},[],{"trials":392,"activeCount":100},[],{"trials":394,"activeCount":217,"soonestReadout":274},[395],{"nctId":270,"briefTitle":271,"status":272,"phases":396,"primaryCompletion":274,"completion":275,"start":276,"enrollment":277,"conditions":397,"interventions":398},[91],[279,280],[257,282],{"trials":400,"activeCount":100},[401],{"nctId":402,"briefTitle":403,"status":169,"phases":404,"primaryCompletion":405,"completion":405,"start":406,"enrollment":407,"conditions":408,"interventions":410},"NCT02869893","MRCP: A Reliable, Non Invasive Method for Staging Chronic Pancreatitis in Pediatrics",[92],"2017-04-06","2016-08-10",57,[409],"Healthy Volunteers",[282],{"intervention":412,"totalTrials":96,"cells":413},"Oxygen",{"EARLY_PHASE1":414,"PHASE1":416,"PHASE2":418,"PHASE3":432,"PHASE4":442,"NA":444},{"trials":415,"activeCount":100},[],{"trials":417,"activeCount":100},[],{"trials":419,"activeCount":100},[420],{"nctId":421,"briefTitle":422,"status":423,"phases":424,"primaryCompletion":425,"completion":425,"start":426,"enrollment":427,"conditions":428,"interventions":430},"NCT00410150","Heliox-Powered Albuterol Therapy in the Treatment of Children Admitted With Acute Asthma Exacerbation","TERMINATED",[89],"2007-12","2006-04",42,[429],"Status Asthmaticus",[431,412],"Helium-oxygen-driven albuterol nebulizer",{"trials":433,"activeCount":217,"soonestReadout":84},[434],{"nctId":82,"briefTitle":83,"status":112,"phases":435,"primaryCompletion":84,"completion":84,"start":436,"enrollment":173,"conditions":437,"interventions":441},[90],"2023-01-10",[438,439,440],"AKI","CHD - Congenital Heart Disease","Surgery",[85,412],{"trials":443,"activeCount":100},[],{"trials":445,"activeCount":100},[],{"intervention":85,"totalTrials":217,"cells":447},{"EARLY_PHASE1":448,"PHASE1":450,"PHASE2":452,"PHASE3":454,"PHASE4":460,"NA":462},{"trials":449,"activeCount":100},[],{"trials":451,"activeCount":100},[],{"trials":453,"activeCount":100},[],{"trials":455,"activeCount":217,"soonestReadout":84},[456],{"nctId":82,"briefTitle":83,"status":112,"phases":457,"primaryCompletion":84,"completion":84,"start":436,"enrollment":173,"conditions":458,"interventions":459},[90],[438,439,440],[85,412],{"trials":461,"activeCount":100},[],{"trials":463,"activeCount":100},[],{"intervention":465,"totalTrials":217,"cells":466},"Secondary Prophylaxis",{"EARLY_PHASE1":467,"PHASE1":469,"PHASE2":471,"PHASE3":473,"PHASE4":485,"NA":487},{"trials":468,"activeCount":100},[],{"trials":470,"activeCount":100},[],{"trials":472,"activeCount":100},[],{"trials":474,"activeCount":217,"soonestReadout":479},[475],{"nctId":476,"briefTitle":477,"status":187,"phases":478,"primaryCompletion":479,"completion":480,"start":191,"enrollment":481,"conditions":482,"interventions":484},"NCT07146048","A Non-Inferiority Trial of Stopping Penicillin in Early Rheumatic Heart Disease: GOAL-Stop",[90],"2029-02-20","2029-12-31",922,[483],"Rheumatic Heart Disease",[465],{"trials":486,"activeCount":100},[],{"trials":488,"activeCount":100},[],{"intervention":490,"totalTrials":491,"cells":492},"Infliximab",3,{"EARLY_PHASE1":493,"PHASE1":495,"PHASE2":497,"PHASE3":499,"PHASE4":511,"NA":513},{"trials":494,"activeCount":100},[],{"trials":496,"activeCount":100},[],{"trials":498,"activeCount":100},[],{"trials":500,"activeCount":217,"soonestReadout":505},[501],{"nctId":502,"briefTitle":503,"status":112,"phases":504,"primaryCompletion":505,"completion":505,"start":506,"enrollment":507,"conditions":508,"interventions":510},"NCT05660746","Precise Infliximab Exposure and Pharmacodynamic Control",[89,90],"2027-03-31","2023-07-01",180,[509],"Crohn Disease",[490],{"trials":512,"activeCount":100},[],{"trials":514,"activeCount":100},[515,527],{"nctId":516,"briefTitle":517,"status":169,"phases":518,"primaryCompletion":519,"completion":520,"start":521,"enrollment":522,"conditions":523,"interventions":526},"NCT02799615","Anti-TNF Therapy for Refractory Colitis in Hospitalized Children",[],"2019-02-11","2019-11","2016-05",38,[524,525],"Colitis, Ulcerative","Bowel Diseases, Inflammatory",[490],{"nctId":528,"briefTitle":529,"status":169,"phases":530,"primaryCompletion":531,"completion":531,"start":532,"enrollment":533,"conditions":534,"interventions":537},"NCT04131504","Precision Crohn's Disease Management Utilizing Predictive Protein Panels (ENvISION)",[],"2023-10-31","2019-10-16",239,[535,536],"Crohn's Disease","IBD",[490,538],"Adalimumab",{"intervention":41,"totalTrials":540,"cells":541},9,{"EARLY_PHASE1":542,"PHASE1":552,"PHASE2":554,"PHASE3":593,"PHASE4":613,"NA":615},{"trials":543,"activeCount":217,"soonestReadout":146},[544],{"nctId":545,"briefTitle":546,"status":144,"phases":547,"primaryCompletion":146,"completion":548,"start":549,"enrollment":377,"conditions":550,"interventions":551},"NCT05662098","Alternative Dosing And Prevention of Transfusions (ADAPT)",[87],"2027-12-31","2022-06-16",[29],[41],{"trials":553,"activeCount":100},[],{"trials":555,"activeCount":491,"soonestReadout":40},[556,565,575,582],{"nctId":557,"briefTitle":558,"status":272,"phases":559,"primaryCompletion":146,"completion":146,"start":560,"enrollment":561,"conditions":562,"interventions":564},"NCT03948867","Stroke Prevention With Hydroxyurea Enabled Through Research and Education (SPHERE)",[89],"2019-04-24",202,[563],"Sickle Cell Anemia in Children",[41],{"nctId":566,"briefTitle":567,"status":169,"phases":568,"primaryCompletion":569,"completion":569,"start":570,"enrollment":571,"conditions":572,"interventions":574},"NCT02556099","EXTEND EXpanding Treatment for Existing Neurological Disease",[89],"2023-01-16","2014-08",43,[573],"Sickle Cell Anemia",[41],{"nctId":38,"briefTitle":39,"status":144,"phases":576,"primaryCompletion":40,"completion":577,"start":578,"enrollment":579,"conditions":580,"interventions":581},[88,89],"2033-08","2014-06",635,[29],[41],{"nctId":583,"briefTitle":584,"status":144,"phases":585,"primaryCompletion":586,"completion":587,"start":588,"enrollment":589,"conditions":590,"interventions":592},"NCT06171217","Realizing Effectiveness Across Continents With Hydroxyurea",[89],"2027-10-04","2033-10-04","2023-10-27",811,[29,591],"Children",[41,41],{"trials":594,"activeCount":100},[595,605],{"nctId":596,"briefTitle":597,"status":423,"phases":598,"primaryCompletion":599,"completion":600,"start":601,"enrollment":602,"conditions":603,"interventions":604},"NCT01425307","Transcranial Doppler (TCD) With Transfusions Changing to Hydroxyurea",[90],"2015-03","2015-11","2011-08",159,[573],[41],{"nctId":606,"briefTitle":607,"status":423,"phases":608,"primaryCompletion":609,"completion":609,"start":610,"enrollment":522,"conditions":611,"interventions":612},"NCT01531387","Sparing Conversion to Abnormal TCD (Transcranial Doppler) Elevation (SCATE)",[90],"2014-01","2012-05",[573],[41],{"trials":614,"activeCount":100},[],{"trials":616,"activeCount":217,"soonestReadout":274},[617,626],{"nctId":618,"briefTitle":619,"status":144,"phases":620,"primaryCompletion":274,"completion":274,"start":621,"enrollment":622,"conditions":623,"interventions":625},"NCT02286154","Therapeutic Response Evaluation and Adherence Trial (TREAT)",[92],"2014-10",150,[624],"Anemia, Sickle Cell",[41],{"nctId":627,"briefTitle":628,"status":169,"phases":629,"primaryCompletion":630,"completion":631,"start":632,"enrollment":633,"conditions":634,"interventions":635},"NCT02769845","SACRED A Prospective Research Study to Reduce Stroke in Children With Sickle Cell Anemia",[92],"2019-07-01","2022-10-01","2016-03-16",283,[573],[41],{"intervention":637,"totalTrials":96,"cells":638},"Hyperpolarized 129 Xenon",{"EARLY_PHASE1":639,"PHASE1":641,"PHASE2":643,"PHASE3":665,"PHASE4":667,"NA":669},{"trials":640,"activeCount":100},[],{"trials":642,"activeCount":100},[],{"trials":644,"activeCount":96,"soonestReadout":659},[645,655],{"nctId":646,"briefTitle":647,"status":112,"phases":648,"primaryCompletion":649,"completion":650,"start":651,"enrollment":377,"conditions":652,"interventions":654},"NCT02316379","Use of Hyperpolarized 129Xe MR Lung Imaging in Adults for Calibration",[88,89],"2030-08-24","2031-08-24","2015-02",[653],"Respiratory Disorders",[637],{"nctId":656,"briefTitle":657,"status":112,"phases":658,"primaryCompletion":659,"completion":660,"start":661,"enrollment":662,"conditions":663,"interventions":664},"NCT02272049","Use of Hyperpolarized Xenon Gas for Lung Imaging in Children and Adults",[88,89],"2028-12-31","2029-08-31","2014-12",300,[653],[637],{"trials":666,"activeCount":100},[],{"trials":668,"activeCount":100},[],{"trials":670,"activeCount":100},[],{"intervention":672,"totalTrials":96,"cells":673},"Viral Specific VST",{"EARLY_PHASE1":674,"PHASE1":676,"PHASE2":678,"PHASE3":701,"PHASE4":703,"NA":705},{"trials":675,"activeCount":100},[],{"trials":677,"activeCount":100},[],{"trials":679,"activeCount":96,"soonestReadout":274},[680,691],{"nctId":681,"briefTitle":682,"status":112,"phases":683,"primaryCompletion":274,"completion":275,"start":684,"enrollment":685,"conditions":686,"interventions":690},"NCT02532452","Third Party Viral Specific T-cells (VSTs)",[89],"2015-09-02",750,[687,688,689],"Viral Infection","Viral Reactivation","Infection in an Immunocompromised Host",[672],{"nctId":692,"briefTitle":693,"status":112,"phases":694,"primaryCompletion":695,"completion":695,"start":696,"enrollment":685,"conditions":697,"interventions":699},"NCT02048332","Donor-Derived Viral Specific T-cells (VSTs)",[88,89],"2027-01","2014-02-05",[698,687,688],"Allogeneic Stem Cell Transplant",[700],"Viral specific VST",{"trials":702,"activeCount":100},[],{"trials":704,"activeCount":100},[],{"trials":706,"activeCount":100},[],{"intervention":708,"totalTrials":491,"cells":709},"cyclophosphamide",{"EARLY_PHASE1":710,"PHASE1":712,"PHASE2":714,"PHASE3":745,"PHASE4":764,"NA":766},{"trials":711,"activeCount":100},[],{"trials":713,"activeCount":100},[],{"trials":715,"activeCount":217,"soonestReadout":274},[716,734],{"nctId":717,"briefTitle":718,"status":112,"phases":719,"primaryCompletion":274,"completion":353,"start":720,"enrollment":721,"conditions":722,"interventions":727},"NCT02143830","HSCT for Patients With Fanconi Anemia Using Risk-Adjusted Chemotherapy",[89],"2014-04",70,[723,724,725,726],"Fanconi Anemia","Severe Marrow Failure","Myelodysplastic Syndrome (MDS)","Acute Myelogenous Leukemia (AML)",[728,729,730,731,732,733],"Busulfan","Cyclophosphamide","Fludarabine","rabbit ATG","G-CSF","Peripheral blood stem cell",{"nctId":735,"briefTitle":736,"status":169,"phases":737,"completion":738,"start":739,"enrollment":126,"conditions":740,"interventions":742},"NCT00002803","Combination Chemotherapy or Observation Following Surgery in Treating Infants With Neuroblastoma",[89],"2002-02","1995-07",[741],"Neuroblastoma",[708,743,744],"doxorubicin hydrochloride","vincristine sulfate",{"trials":746,"activeCount":100},[747],{"nctId":748,"briefTitle":749,"status":169,"phases":750,"completion":751,"start":752,"enrollment":753,"conditions":754,"interventions":755},"NCT00002802","Therapy Based on Stage of Disease and Risk Assessment in Treating Children With Neuroblastoma",[90],"2003-09","1990-07",500,[741],[756,757,708,758,743,759,760,761,762,744,763],"carboplatin","cisplatin","dacarbazine","etoposide","ifosfamide","melphalan","mesna","vindesine",{"trials":765,"activeCount":100},[],{"trials":767,"activeCount":100},[],{"intervention":769,"totalTrials":491,"cells":770},"Mycophenolate Mofetil",{"EARLY_PHASE1":771,"PHASE1":773,"PHASE2":784,"PHASE3":806,"PHASE4":808,"NA":810},{"trials":772,"activeCount":100},[],{"trials":774,"activeCount":100},[775],{"nctId":776,"briefTitle":777,"status":423,"phases":778,"primaryCompletion":779,"completion":779,"start":780,"enrollment":126,"conditions":781,"interventions":783},"NCT00433953","Genetic Drug Study of Mycophenolic Acid (CellCept) in Pediatric Kidney Transplant Patients",[88],"2010-02","2007-02",[782],"Kidney Transplant",[769],{"trials":785,"activeCount":217,"soonestReadout":790},[786,796],{"nctId":787,"briefTitle":788,"status":112,"phases":789,"primaryCompletion":790,"completion":695,"start":791,"enrollment":792,"conditions":793,"interventions":795},"NCT05538208","The Pediatric Lupus Nephritis Mycophenolate Mofetil (PLUMM) Study",[89],"2026-07","2024-06-07",105,[794],"Lupus Nephritis",[769,769],{"nctId":797,"briefTitle":798,"status":799,"phases":800,"primaryCompletion":801,"completion":802,"start":803,"enrollment":100,"conditions":804,"interventions":805},"NCT05101447","Pharmacokinetically-driven Dosing of Mycophenolate Mofetil for the Treatment of Pediatric Proliferative Lupus Nephritis","WITHDRAWN",[89],"2024-01","2024-07","2023-07",[794],[769],{"trials":807,"activeCount":100},[],{"trials":809,"activeCount":100},[],{"trials":811,"activeCount":100},[],{"intervention":813,"totalTrials":491,"cells":814},"Viral Specific T-cells",{"EARLY_PHASE1":815,"PHASE1":817,"PHASE2":819,"PHASE3":850,"PHASE4":852,"NA":854},{"trials":816,"activeCount":100},[],{"trials":818,"activeCount":100},[],{"trials":820,"activeCount":217,"soonestReadout":835},[821,831,841],{"nctId":822,"briefTitle":823,"status":169,"phases":824,"primaryCompletion":825,"completion":826,"start":827,"enrollment":828,"conditions":829,"interventions":830},"NCT03883906","Donor-Derived Viral Specific T-cells (VSTs) for Prophylaxis Against Viral Infections After Allogeneic Stem Cell Transplant",[89],"2020-10-31","2021-10-01","2019-03-16",30,[698,687],[813],{"nctId":832,"briefTitle":833,"status":144,"phases":834,"primaryCompletion":835,"completion":836,"start":837,"enrollment":427,"conditions":838,"interventions":840},"NCT04331275","Viral Specific T-cells for Treatment of Viral Infections After Solid Organ Transplant",[89],"2026-09","2028-09","2020-08-18",[839,687],"Solid Organ Transplant",[813],{"nctId":842,"briefTitle":843,"status":799,"phases":844,"primaryCompletion":845,"completion":846,"start":847,"enrollment":100,"conditions":848,"interventions":849},"NCT04406064","Viral Specific T-cells for Treatment of COVID-19",[89],"2024-06","2025-06","2021-01",[687],[813],{"trials":851,"activeCount":100},[],{"trials":853,"activeCount":100},[],{"trials":855,"activeCount":100},[],{"intervention":857,"totalTrials":96,"cells":858},"Losartan",{"EARLY_PHASE1":859,"PHASE1":861,"PHASE2":863,"PHASE3":884,"PHASE4":886,"NA":888},{"trials":860,"activeCount":100},[],{"trials":862,"activeCount":100},[],{"trials":864,"activeCount":217,"soonestReadout":146},[865,874],{"nctId":866,"briefTitle":867,"status":112,"phases":868,"primaryCompletion":146,"completion":548,"start":869,"enrollment":870,"conditions":871,"interventions":873},"NCT05012631","Losartan for Diffuse Myocardial Fibrosis in Sickle Cell Disease",[89],"2021-09-01",24,[29,872],"Diffuse Myocardial Fibrosis",[857],{"nctId":875,"briefTitle":876,"status":169,"phases":877,"primaryCompletion":600,"completion":878,"start":879,"enrollment":880,"conditions":881,"interventions":883},"NCT01479439","Losartan to Reverse Sickle Nephropathy",[89],"2015-12","2012-02",36,[882,573],"Nephropathy",[857],{"trials":885,"activeCount":100},[],{"trials":887,"activeCount":100},[],{"trials":889,"activeCount":100},[],{"intervention":891,"totalTrials":96,"cells":892},"2'-Fucosyllactose",{"EARLY_PHASE1":893,"PHASE1":895,"PHASE2":897,"PHASE3":920,"PHASE4":922,"NA":924},{"trials":894,"activeCount":100},[],{"trials":896,"activeCount":100},[],{"trials":898,"activeCount":217,"soonestReadout":903},[899,910],{"nctId":900,"briefTitle":901,"status":112,"phases":902,"primaryCompletion":903,"completion":903,"start":904,"enrollment":905,"conditions":906,"interventions":909},"NCT03847467","Pilot and Feasibility Study of 2'-FL as a Dietary Supplement in IBD Patients Receiving Stable Maintenance Anti-TNF Therapy",[88,89],"2027-06-30","2019-09-20",116,[907,509,908],"Inflammatory Bowel Diseases","Ulcerative Colitis",[891],{"nctId":911,"briefTitle":912,"status":169,"phases":913,"primaryCompletion":914,"completion":914,"start":915,"enrollment":721,"conditions":916,"interventions":918},"NCT04263597","Oral Supplementation of 2'-Fucosyllactose in Allogeneic Bone Marrow Transplant Recipients",[88,89],"2025-05-23","2020-08-26",[917],"Hematopoietic Stem Cell Transplant",[919],"2'-fucosyllactose",{"trials":921,"activeCount":100},[],{"trials":923,"activeCount":100},[],{"trials":925,"activeCount":100},[],{"intervention":61,"totalTrials":96,"cells":927},{"EARLY_PHASE1":928,"PHASE1":942,"PHASE2":944,"PHASE3":955,"PHASE4":957,"NA":959},{"trials":929,"activeCount":100},[930],{"nctId":931,"briefTitle":932,"status":169,"phases":933,"primaryCompletion":934,"completion":934,"start":935,"enrollment":9,"conditions":936,"interventions":938},"NCT02998151","Neurophysiological and Acute Pharmacological Studies in FXS Patients",[87],"2020-11","2016-01",[937],"Fragile X Syndrome",[939,940,941,61],"Acamprosate","Lovastatin","Minocycline",{"trials":943,"activeCount":100},[],{"trials":945,"activeCount":217,"soonestReadout":60},[946],{"nctId":58,"briefTitle":59,"status":144,"phases":947,"primaryCompletion":60,"completion":948,"start":949,"enrollment":950,"conditions":951,"interventions":952},[89],"2026-03-05","2022-09-08",45,[937],[61,953,954],"Memantine","Roflumilast",{"trials":956,"activeCount":100},[],{"trials":958,"activeCount":100},[],{"trials":960,"activeCount":100},[],{"intervention":962,"totalTrials":217,"cells":963},"Alpha-proteinase inhibitor",{"EARLY_PHASE1":964,"PHASE1":966,"PHASE2":968,"PHASE3":978,"PHASE4":980,"NA":982},{"trials":965,"activeCount":100},[],{"trials":967,"activeCount":100},[],{"trials":969,"activeCount":217,"soonestReadout":974},[970],{"nctId":971,"briefTitle":972,"status":112,"phases":973,"primaryCompletion":974,"completion":695,"start":975,"enrollment":24,"conditions":976,"interventions":977},"NCT05485155","Zemaira Eosinophilic Esophagitis Pilot Study",[89],"2026-10","2025-05-15",[34],[962],{"trials":979,"activeCount":100},[],{"trials":981,"activeCount":100},[],{"trials":983,"activeCount":100},[],{"intervention":730,"totalTrials":217,"cells":985},{"EARLY_PHASE1":986,"PHASE1":988,"PHASE2":990,"PHASE3":996,"PHASE4":998,"NA":1000},{"trials":987,"activeCount":100},[],{"trials":989,"activeCount":100},[],{"trials":991,"activeCount":217,"soonestReadout":274},[992],{"nctId":717,"briefTitle":718,"status":112,"phases":993,"primaryCompletion":274,"completion":353,"start":720,"enrollment":721,"conditions":994,"interventions":995},[89],[723,724,725,726],[728,729,730,731,732,733],{"trials":997,"activeCount":100},[],{"trials":999,"activeCount":100},[],{"trials":1001,"activeCount":100},[],{"intervention":731,"totalTrials":217,"cells":1003},{"EARLY_PHASE1":1004,"PHASE1":1006,"PHASE2":1008,"PHASE3":1014,"PHASE4":1016,"NA":1018},{"trials":1005,"activeCount":100},[],{"trials":1007,"activeCount":100},[],{"trials":1009,"activeCount":217,"soonestReadout":274},[1010],{"nctId":717,"briefTitle":718,"status":112,"phases":1011,"primaryCompletion":274,"completion":353,"start":720,"enrollment":721,"conditions":1012,"interventions":1013},[89],[723,724,725,726],[728,729,730,731,732,733],{"trials":1015,"activeCount":100},[],{"trials":1017,"activeCount":100},[],{"trials":1019,"activeCount":100},[],{"intervention":732,"totalTrials":217,"cells":1021},{"EARLY_PHASE1":1022,"PHASE1":1024,"PHASE2":1026,"PHASE3":1032,"PHASE4":1034,"NA":1036},{"trials":1023,"activeCount":100},[],{"trials":1025,"activeCount":100},[],{"trials":1027,"activeCount":217,"soonestReadout":274},[1028],{"nctId":717,"briefTitle":718,"status":112,"phases":1029,"primaryCompletion":274,"completion":353,"start":720,"enrollment":721,"conditions":1030,"interventions":1031},[89],[723,724,725,726],[728,729,730,731,732,733],{"trials":1033,"activeCount":100},[],{"trials":1035,"activeCount":100},[],{"trials":1037,"activeCount":100},[],{"intervention":733,"totalTrials":217,"cells":1039},{"EARLY_PHASE1":1040,"PHASE1":1042,"PHASE2":1044,"PHASE3":1050,"PHASE4":1052,"NA":1054},{"trials":1041,"activeCount":100},[],{"trials":1043,"activeCount":100},[],{"trials":1045,"activeCount":217,"soonestReadout":274},[1046],{"nctId":717,"briefTitle":718,"status":112,"phases":1047,"primaryCompletion":274,"completion":353,"start":720,"enrollment":721,"conditions":1048,"interventions":1049},[89],[723,724,725,726],[728,729,730,731,732,733],{"trials":1051,"activeCount":100},[],{"trials":1053,"activeCount":100},[],{"trials":1055,"activeCount":100},[],{"intervention":1057,"totalTrials":217,"cells":1058},"phenoxymethyl penicillin",{"EARLY_PHASE1":1059,"PHASE1":1061,"PHASE2":1063,"PHASE3":1075,"PHASE4":1077,"NA":1079},{"trials":1060,"activeCount":100},[],{"trials":1062,"activeCount":100},[],{"trials":1064,"activeCount":217,"soonestReadout":505},[1065],{"nctId":1066,"briefTitle":1067,"status":144,"phases":1068,"primaryCompletion":505,"completion":1069,"start":1070,"enrollment":1071,"conditions":1072,"interventions":1073},"NCT05693545","GOALIE: Intramuscular vs. Enteral Penicillin Prophylaxis to Prevent Progression of Latent RHD Trial",[89],"2027-09-30","2023-09-01",1004,[483],[1057,1074],"intramuscular benzathine penicillin G (BPG) prophylaxis",{"trials":1076,"activeCount":100},[],{"trials":1078,"activeCount":100},[],{"trials":1080,"activeCount":100},[],{"intervention":1074,"totalTrials":217,"cells":1082},{"EARLY_PHASE1":1083,"PHASE1":1085,"PHASE2":1087,"PHASE3":1093,"PHASE4":1095,"NA":1097},{"trials":1084,"activeCount":100},[],{"trials":1086,"activeCount":100},[],{"trials":1088,"activeCount":217,"soonestReadout":505},[1089],{"nctId":1066,"briefTitle":1067,"status":144,"phases":1090,"primaryCompletion":505,"completion":1069,"start":1070,"enrollment":1071,"conditions":1091,"interventions":1092},[89],[483],[1057,1074],{"trials":1094,"activeCount":100},[],{"trials":1096,"activeCount":100},[],{"trials":1098,"activeCount":100},[],{"intervention":51,"totalTrials":217,"cells":1100},{"EARLY_PHASE1":1101,"PHASE1":1103,"PHASE2":1105,"PHASE3":1115,"PHASE4":1117,"NA":1119},{"trials":1102,"activeCount":100},[],{"trials":1104,"activeCount":100},[],{"trials":1106,"activeCount":217,"soonestReadout":50},[1107],{"nctId":48,"briefTitle":49,"status":144,"phases":1108,"primaryCompletion":50,"completion":1109,"start":1110,"enrollment":1111,"conditions":1112,"interventions":1114},[89],"2025-12","2020-12-15",58,[1113],"Neurofibromatosis 1",[51],{"trials":1116,"activeCount":100},[],{"trials":1118,"activeCount":100},[],{"trials":1120,"activeCount":100},[],{"intervention":1122,"totalTrials":217,"cells":1123},"Abatacept",{"EARLY_PHASE1":1124,"PHASE1":1126,"PHASE2":1128,"PHASE3":1139,"PHASE4":1141,"NA":1143},{"trials":1125,"activeCount":100},[],{"trials":1127,"activeCount":100},[],{"trials":1129,"activeCount":217,"soonestReadout":790},[1130],{"nctId":1131,"briefTitle":1132,"status":112,"phases":1133,"primaryCompletion":790,"completion":790,"start":1134,"enrollment":522,"conditions":1135,"interventions":1138},"NCT04925375","Abatacept for the Treatment of Common Variable Immunodeficiency With Interstitial Lung Disease",[89],"2021-07-14",[1136,1137],"Interstitial Lung Disease","Common Variable Immunodeficiency",[1122],{"trials":1140,"activeCount":100},[],{"trials":1142,"activeCount":100},[],{"trials":1144,"activeCount":100},[],{"intervention":1146,"totalTrials":217,"cells":1147},"Vitamin A",{"EARLY_PHASE1":1148,"PHASE1":1150,"PHASE2":1152,"PHASE3":1167,"PHASE4":1169,"NA":1171},{"trials":1149,"activeCount":100},[],{"trials":1151,"activeCount":100},[],{"trials":1153,"activeCount":217,"soonestReadout":1158},[1154],{"nctId":1155,"briefTitle":1156,"status":112,"phases":1157,"primaryCompletion":1158,"completion":1159,"start":1160,"enrollment":1161,"conditions":1162,"interventions":1166},"NCT06450925","Vitamin A Supplementation in Allogeneic Stem Cell Transplantation.",[89],"2027-08","2029-08","2025-03-25",190,[1163,1164,1165],"Graft Vs Host Disease","Vitamin A Deficiency","Vitamin D Deficiency",[1146],{"trials":1168,"activeCount":100},[],{"trials":1170,"activeCount":100},[],{"trials":1172,"activeCount":100},[],{"intervention":1174,"totalTrials":217,"cells":1175},"Viral Specific T-cells (VSTs) Scheduled",{"EARLY_PHASE1":1176,"PHASE1":1178,"PHASE2":1180,"PHASE3":1193,"PHASE4":1195,"NA":1197},{"trials":1177,"activeCount":100},[],{"trials":1179,"activeCount":100},[],{"trials":1181,"activeCount":217,"soonestReadout":1186},[1182],{"nctId":1183,"briefTitle":1184,"status":112,"phases":1185,"primaryCompletion":1186,"completion":1187,"start":1188,"enrollment":507,"conditions":1189,"interventions":1191},"NCT04230356","Trial of Scheduled Versus Treatment Administration of Donor-Derived Viral Specific T-cells for Viral Infections After Stem Cell Transplant",[89],"2028-03","2028-06","2021-01-27",[1190,687],"Allogeneic Stell Cell Transplant",[1174,1192],"Viral Specific T-cells (VSTs) Treatment",{"trials":1194,"activeCount":100},[],{"trials":1196,"activeCount":100},[],{"trials":1198,"activeCount":100},[],{"intervention":1192,"totalTrials":217,"cells":1200},{"EARLY_PHASE1":1201,"PHASE1":1203,"PHASE2":1205,"PHASE3":1211,"PHASE4":1213,"NA":1215},{"trials":1202,"activeCount":100},[],{"trials":1204,"activeCount":100},[],{"trials":1206,"activeCount":217,"soonestReadout":1186},[1207],{"nctId":1183,"briefTitle":1184,"status":112,"phases":1208,"primaryCompletion":1186,"completion":1187,"start":1188,"enrollment":507,"conditions":1209,"interventions":1210},[89],[1190,687],[1174,1192],{"trials":1212,"activeCount":100},[],{"trials":1214,"activeCount":100},[],{"trials":1216,"activeCount":100},[],{"intervention":1218,"totalTrials":217,"cells":1219},"Gene-Corrected Macrophages administered by bronchoscopic instillation",{"EARLY_PHASE1":1220,"PHASE1":1222,"PHASE2":1224,"PHASE3":1236,"PHASE4":1238,"NA":1240},{"trials":1221,"activeCount":100},[],{"trials":1223,"activeCount":100},[],{"trials":1225,"activeCount":217,"soonestReadout":1230},[1226],{"nctId":1227,"briefTitle":1228,"status":112,"phases":1229,"primaryCompletion":1230,"completion":1231,"start":1232,"enrollment":491,"conditions":1233,"interventions":1235},"NCT05761899","Safety and Efficacy of PMT Therapy of hPAP",[88,89],"2026-09-01","2038-10-01","2023-06-26",[1234],"Hereditary Pulmonary Alveolar Proteinosis",[1218],{"trials":1237,"activeCount":100},[],{"trials":1239,"activeCount":100},[],{"trials":1241,"activeCount":100},[],{"intervention":953,"totalTrials":217,"cells":1243},{"EARLY_PHASE1":1244,"PHASE1":1246,"PHASE2":1248,"PHASE3":1254,"PHASE4":1256,"NA":1258},{"trials":1245,"activeCount":100},[],{"trials":1247,"activeCount":100},[],{"trials":1249,"activeCount":217,"soonestReadout":60},[1250],{"nctId":58,"briefTitle":59,"status":144,"phases":1251,"primaryCompletion":60,"completion":948,"start":949,"enrollment":950,"conditions":1252,"interventions":1253},[89],[937],[61,953,954],{"trials":1255,"activeCount":100},[],{"trials":1257,"activeCount":100},[],{"trials":1259,"activeCount":100},[],{"intervention":954,"totalTrials":217,"cells":1261},{"EARLY_PHASE1":1262,"PHASE1":1264,"PHASE2":1266,"PHASE3":1272,"PHASE4":1274,"NA":1276},{"trials":1263,"activeCount":100},[],{"trials":1265,"activeCount":100},[],{"trials":1267,"activeCount":217,"soonestReadout":60},[1268],{"nctId":58,"briefTitle":59,"status":144,"phases":1269,"primaryCompletion":60,"completion":948,"start":949,"enrollment":950,"conditions":1270,"interventions":1271},[89],[937],[61,953,954],{"trials":1273,"activeCount":100},[],{"trials":1275,"activeCount":100},[],{"trials":1277,"activeCount":100},[],{"intervention":1279,"totalTrials":217,"cells":1280},"Semaglutide",{"EARLY_PHASE1":1281,"PHASE1":1283,"PHASE2":1285,"PHASE3":1296,"PHASE4":1298,"NA":1300},{"trials":1282,"activeCount":100},[],{"trials":1284,"activeCount":100},[],{"trials":1286,"activeCount":217,"soonestReadout":1291},[1287],{"nctId":1288,"briefTitle":1289,"status":187,"phases":1290,"primaryCompletion":1291,"completion":1292,"start":328,"enrollment":24,"conditions":1293,"interventions":1295},"NCT07430332","GLP-1 RA for Stage 1 Type 1 Diabetes",[89],"2029-06-01","2030-01-01",[1294],"Stage 1 Diabetes Mellitus, Type 1",[1279],{"trials":1297,"activeCount":100},[],{"trials":1299,"activeCount":100},[],{"trials":1301,"activeCount":100},[],{"intervention":1303,"totalTrials":217,"cells":1304},"Mirdametinib",{"EARLY_PHASE1":1305,"PHASE1":1307,"PHASE2":1309,"PHASE3":1324,"PHASE4":1326,"NA":1328},{"trials":1306,"activeCount":100},[],{"trials":1308,"activeCount":100},[],{"trials":1310,"activeCount":217,"soonestReadout":1315},[1311],{"nctId":1312,"briefTitle":1313,"status":112,"phases":1314,"primaryCompletion":1315,"completion":1316,"start":1317,"enrollment":173,"conditions":1318,"interventions":1323},"NCT06153173","Mirdametinib in Histiocytic Disorders",[89],"2030-03","2031-03","2024-02-05",[1319,1320,1321,1322],"Langerhans Cell Histiocytosis (LCH)","Juvenile Xanthogranuloma (JXG)","Rosai-Dorfman Disease (RDD)","Histiocytic Disorders",[1303],{"trials":1325,"activeCount":100},[],{"trials":1327,"activeCount":100},[],{"trials":1329,"activeCount":100},[],{"intervention":1331,"totalTrials":217,"cells":1332},"CIML-NK Cells",{"EARLY_PHASE1":1333,"PHASE1":1335,"PHASE2":1337,"PHASE3":1349,"PHASE4":1351,"NA":1353},{"trials":1334,"activeCount":100},[],{"trials":1336,"activeCount":100},[],{"trials":1338,"activeCount":217,"soonestReadout":695},[1339],{"nctId":1340,"briefTitle":1341,"status":112,"phases":1342,"primaryCompletion":695,"completion":1343,"start":1344,"enrollment":1345,"conditions":1346,"interventions":1348},"NCT05580601","Cytokine-Induced Memory-Like Natural Killer Cells (CIML-NK) for Relapsed & Refractory Acute Myeloid Leukemia (AML)",[88,89],"2027-07","2023-05-05",20,[1347],"Acute Myeloid Leukemia",[1331],{"trials":1350,"activeCount":100},[],{"trials":1352,"activeCount":100},[],{"trials":1354,"activeCount":100},[],{"intervention":1356,"totalTrials":217,"cells":1357},"Xenon-129",{"EARLY_PHASE1":1358,"PHASE1":1360,"PHASE2":1362,"PHASE3":1375,"PHASE4":1377,"NA":1379},{"trials":1359,"activeCount":100},[],{"trials":1361,"activeCount":100},[],{"trials":1363,"activeCount":217,"soonestReadout":1368},[1364],{"nctId":1365,"briefTitle":1366,"status":144,"phases":1367,"primaryCompletion":1368,"completion":1369,"start":1370,"enrollment":1371,"conditions":1372,"interventions":1374},"NCT06012500","Gas Exchange MRI to Visualize Regional Therapy Response in Interstitial Lung Disease",[88,89],"2026-12-01","2027-12-30","2022-04-14",78,[1373],"ILD",[1356],{"trials":1376,"activeCount":100},[],{"trials":1378,"activeCount":100},[],{"trials":1380,"activeCount":100},[],{"intervention":728,"totalTrials":96,"cells":1382},{"EARLY_PHASE1":1383,"PHASE1":1385,"PHASE2":1387,"PHASE3":1393,"PHASE4":1395,"NA":1397},{"trials":1384,"activeCount":100},[],{"trials":1386,"activeCount":100},[],{"trials":1388,"activeCount":217,"soonestReadout":274},[1389],{"nctId":717,"briefTitle":718,"status":112,"phases":1390,"primaryCompletion":274,"completion":353,"start":720,"enrollment":721,"conditions":1391,"interventions":1392},[89],[723,724,725,726],[728,729,730,731,732,733],{"trials":1394,"activeCount":100},[],{"trials":1396,"activeCount":100},[],{"trials":1398,"activeCount":100},[1399],{"nctId":1400,"briefTitle":1401,"status":169,"phases":1402,"primaryCompletion":1403,"completion":1403,"start":1404,"conditions":1405,"interventions":1407},"NCT00253487","Combination Chemotherapy and Radiation Therapy in Treating Younger Patients Who Are Undergoing an Autologous Stem Cell Transplant for Newly Diagnosed Gliomas",[92],"2012-08","2005-08",[1406],"Brain and Central Nervous System Tumors",[1408,1409,1410],"O6-benzylguanine","busulfan","temozolomide",{"intervention":1412,"totalTrials":96,"cells":1413},"Alemtuzumab",{"EARLY_PHASE1":1414,"PHASE1":1416,"PHASE2":1418,"PHASE3":1430,"PHASE4":1432,"NA":1434},{"trials":1415,"activeCount":100},[],{"trials":1417,"activeCount":100},[],{"trials":1419,"activeCount":217,"soonestReadout":1424},[1420],{"nctId":1421,"briefTitle":1422,"status":112,"phases":1423,"primaryCompletion":1424,"completion":1424,"start":1425,"enrollment":1426,"conditions":1427,"interventions":1429},"NCT05501756","Precision Alemtuzumab Dosing for Allogeneic Hematopoietic Cell Transplantation",[89],"2028-08-31","2023-01-11",60,[1428],"Allogeneic Hematopoietic Cell Transplantation",[1412],{"trials":1431,"activeCount":100},[],{"trials":1433,"activeCount":100},[],{"trials":1435,"activeCount":100},[1436],{"nctId":1437,"briefTitle":1438,"status":169,"phases":1439,"primaryCompletion":1440,"completion":1440,"start":1441,"enrollment":30,"conditions":1442,"interventions":1443},"NCT03302754","Precision Dosing of Alemtuzumab",[92],"2019-03-10","2017-10-05",[1428],[1412],{"intervention":1445,"totalTrials":491,"cells":1446},"Quercetin",{"EARLY_PHASE1":1447,"PHASE1":1449,"PHASE2":1469,"PHASE3":1482,"PHASE4":1484,"NA":1486},{"trials":1448,"activeCount":100},[],{"trials":1450,"activeCount":217,"soonestReadout":1455},[1451,1461],{"nctId":1452,"briefTitle":1453,"status":112,"phases":1454,"primaryCompletion":1455,"completion":1456,"start":1457,"enrollment":30,"conditions":1458,"interventions":1460},"NCT07433621","Quercetin in Patients With XIAP (X-linked Inhibitor of Apoptosis) Deficiency",[88],"2028-11","2029-06","2026-02-26",[1459],"XIAP Deficiency",[1445],{"nctId":1462,"briefTitle":1463,"status":169,"phases":1464,"primaryCompletion":1465,"completion":1465,"start":1466,"enrollment":828,"conditions":1467,"interventions":1468},"NCT01720147","Quercetin in Children With Fanconi Anemia; a Pilot Study",[88],"2021-10-26","2012-07",[723],[1445],{"trials":1470,"activeCount":100},[1471],{"nctId":1472,"briefTitle":1473,"status":169,"phases":1474,"primaryCompletion":1475,"completion":1476,"start":1477,"enrollment":1478,"conditions":1479,"interventions":1481},"NCT03476330","Quercetin Chemoprevention for Squamous Cell Carcinoma in Patients With Fanconi Anemia",[89],"2025-03-06","2026-01-09","2018-05-08",48,[723,1480],"Squamous Cell Carcinoma",[1445],{"trials":1483,"activeCount":100},[],{"trials":1485,"activeCount":100},[],{"trials":1487,"activeCount":100},[],{"intervention":1489,"totalTrials":217,"cells":1490},"Vyxeos",{"EARLY_PHASE1":1491,"PHASE1":1493,"PHASE2":1506,"PHASE3":1508,"PHASE4":1510,"NA":1512},{"trials":1492,"activeCount":100},[],{"trials":1494,"activeCount":217,"soonestReadout":695},[1495],{"nctId":1496,"briefTitle":1497,"status":112,"phases":1498,"primaryCompletion":695,"completion":1499,"start":1500,"enrollment":1501,"conditions":1502,"interventions":1504},"NCT03826992","Venetoclax Combined With Vyxeos (CPX-351) for Participants With Relapsed or Refractory Acute Leukemia",[88],"2028-01","2018-12-27",21,[1503],"Leukemia",[1489,1505],"Venetoclax",{"trials":1507,"activeCount":100},[],{"trials":1509,"activeCount":100},[],{"trials":1511,"activeCount":100},[],{"trials":1513,"activeCount":100},[],{"intervention":1505,"totalTrials":217,"cells":1515},{"EARLY_PHASE1":1516,"PHASE1":1518,"PHASE2":1524,"PHASE3":1526,"PHASE4":1528,"NA":1530},{"trials":1517,"activeCount":100},[],{"trials":1519,"activeCount":217,"soonestReadout":695},[1520],{"nctId":1496,"briefTitle":1497,"status":112,"phases":1521,"primaryCompletion":695,"completion":1499,"start":1500,"enrollment":1501,"conditions":1522,"interventions":1523},[88],[1503],[1489,1505],{"trials":1525,"activeCount":100},[],{"trials":1527,"activeCount":100},[],{"trials":1529,"activeCount":100},[],{"trials":1531,"activeCount":100},[],{"intervention":1533,"totalTrials":217,"cells":1534},"Zoledronate",{"EARLY_PHASE1":1535,"PHASE1":1537,"PHASE2":1546,"PHASE3":1548,"PHASE4":1550,"NA":1552},{"trials":1536,"activeCount":100},[],{"trials":1538,"activeCount":217,"soonestReadout":1499},[1539],{"nctId":1540,"briefTitle":1541,"status":112,"phases":1542,"primaryCompletion":1499,"completion":1455,"start":191,"enrollment":1345,"conditions":1543,"interventions":1545},"NCT07375290","Zoledronate to Prevent Bone Health Complications in Pediatric Hematopoietic Stem Cell Transplant Survivors",[88],[1544],"Hematopoietic Stem Cell Transplantation",[1533],{"trials":1547,"activeCount":100},[],{"trials":1549,"activeCount":100},[],{"trials":1551,"activeCount":100},[],{"trials":1553,"activeCount":100},[],{"intervention":1555,"totalTrials":217,"cells":1556},"Inotuzumab Ozogamicin, Venetoclax, and Dexamethasone",{"EARLY_PHASE1":1557,"PHASE1":1559,"PHASE2":1572,"PHASE3":1574,"PHASE4":1576,"NA":1578},{"trials":1558,"activeCount":100},[],{"trials":1560,"activeCount":217,"soonestReadout":1565},[1561],{"nctId":1562,"briefTitle":1563,"status":112,"phases":1564,"primaryCompletion":1565,"completion":1566,"start":1567,"enrollment":1568,"conditions":1569,"interventions":1571},"NCT06863259","Study of Inotuzumab Ozogamicin, Venetoclax, and Dexamethasone for Relapsed B-cell ALL",[88],"2028-01-01","2029-01-01","2025-05-21",28,[1570],"B-cell Acute Lymphoblastic Leukemia",[1555],{"trials":1573,"activeCount":100},[],{"trials":1575,"activeCount":100},[],{"trials":1577,"activeCount":100},[],{"trials":1579,"activeCount":100},[],{"intervention":1581,"totalTrials":217,"cells":1582},"Hyperpolarized Xe129",{"EARLY_PHASE1":1583,"PHASE1":1592,"PHASE2":1594,"PHASE3":1596,"PHASE4":1598,"NA":1600},{"trials":1584,"activeCount":217,"soonestReadout":1499},[1585],{"nctId":1586,"briefTitle":1587,"status":112,"phases":1588,"primaryCompletion":1499,"completion":1499,"start":1589,"enrollment":1426,"conditions":1590,"interventions":1591},"NCT06339593","Regional Monitoring of CF Lung Disease",[87],"2024-01-05",[20],[1581],{"trials":1593,"activeCount":100},[],{"trials":1595,"activeCount":100},[],{"trials":1597,"activeCount":100},[],{"trials":1599,"activeCount":100},[],{"trials":1601,"activeCount":100},[],{"intervention":1603,"totalTrials":217,"cells":1604},"Romiplostim",{"EARLY_PHASE1":1605,"PHASE1":1617,"PHASE2":1619,"PHASE3":1621,"PHASE4":1623,"NA":1625},{"trials":1606,"activeCount":217,"soonestReadout":1611},[1607],{"nctId":1608,"briefTitle":1609,"status":112,"phases":1610,"primaryCompletion":1611,"completion":1565,"start":1612,"enrollment":148,"conditions":1613,"interventions":1616},"NCT07048249","Single Arm Romiplostim to Prevent CIT",[87],"2027-01-01","2024-01-26",[1614,1615],"Ewings Sarcoma","Chemotherapy Induced Thrombocytopenia",[1603],{"trials":1618,"activeCount":100},[],{"trials":1620,"activeCount":100},[],{"trials":1622,"activeCount":100},[],{"trials":1624,"activeCount":100},[],{"trials":1626,"activeCount":100},[],{"intervention":1628,"totalTrials":217,"cells":1629},"Emapalumab 3 mg\u002Fkg",{"EARLY_PHASE1":1630,"PHASE1":1641,"PHASE2":1643,"PHASE3":1645,"PHASE4":1647,"NA":1649},{"trials":1631,"activeCount":217,"soonestReadout":1456},[1632],{"nctId":1633,"briefTitle":1634,"status":112,"phases":1635,"primaryCompletion":1456,"completion":1159,"start":1636,"enrollment":1345,"conditions":1637,"interventions":1639},"NCT07244419","Prevention of Graft Rejection in Hematopoietic Stem Cell Transplant (HSCT) Recipients",[87],"2026-01-07",[1544,1638],"Graft Failure",[1628,1640],"Emapalumab 10 mg\u002Fkg",{"trials":1642,"activeCount":100},[],{"trials":1644,"activeCount":100},[],{"trials":1646,"activeCount":100},[],{"trials":1648,"activeCount":100},[],{"trials":1650,"activeCount":100},[],{"intervention":1640,"totalTrials":217,"cells":1652},{"EARLY_PHASE1":1653,"PHASE1":1659,"PHASE2":1661,"PHASE3":1663,"PHASE4":1665,"NA":1667},{"trials":1654,"activeCount":217,"soonestReadout":1456},[1655],{"nctId":1633,"briefTitle":1634,"status":112,"phases":1656,"primaryCompletion":1456,"completion":1159,"start":1636,"enrollment":1345,"conditions":1657,"interventions":1658},[87],[1544,1638],[1628,1640],{"trials":1660,"activeCount":100},[],{"trials":1662,"activeCount":100},[],{"trials":1664,"activeCount":100},[],{"trials":1666,"activeCount":100},[],{"trials":1668,"activeCount":100},[],{"intervention":1670,"totalTrials":162,"cells":1671},"Amitriptyline",{"EARLY_PHASE1":1672,"PHASE1":1674,"PHASE2":1676,"PHASE3":1692,"PHASE4":1713,"NA":1715},{"trials":1673,"activeCount":100},[],{"trials":1675,"activeCount":100},[],{"trials":1677,"activeCount":100},[1678],{"nctId":1679,"briefTitle":1680,"status":169,"phases":1681,"primaryCompletion":1682,"completion":1683,"start":1684,"enrollment":1685,"conditions":1686,"interventions":1691},"NCT03472092","Mind and Body Approaches to Pain Reduction in Youth With Migraine",[89],"2025-02-24","2025-06-30","2018-10-02",132,[1687,1688,1689,1690],"Headache, Migraine","Migraine","Migraine Disorders","Headache",[1670],{"trials":1693,"activeCount":100},[1694,1704],{"nctId":1695,"briefTitle":1696,"status":423,"phases":1697,"primaryCompletion":1698,"completion":935,"start":1699,"enrollment":1700,"conditions":1701,"interventions":1702},"NCT01581281","The Childhood and Adolescent Migraine Prevention Study",[90],"2015-04","2012-06",488,[1688,1689,1690],[1670,1703],"Topiramate",{"nctId":1705,"briefTitle":1706,"status":1707,"phases":1708,"primaryCompletion":1403,"completion":1709,"start":1710,"enrollment":1685,"conditions":1711,"interventions":1712},"NCT00389038","Pediatric Chronic Headache Trial","UNKNOWN",[90],"2012-09","2006-10",[1690],[1670],{"trials":1714,"activeCount":100},[],{"trials":1716,"activeCount":217,"soonestReadout":1721},[1717],{"nctId":1718,"briefTitle":1719,"status":112,"phases":1720,"primaryCompletion":1721,"completion":548,"start":1722,"enrollment":1723,"conditions":1724,"interventions":1729},"NCT05889624","Responding With Evidence and Access for Childhood Headaches",[92],"2027-07-31","2023-08-22",400,[1690,1725,1687,1688,1689,1726,1727,1728],"Headache Disorders","Migraine With Aura","Migraine Without Aura","Chronic Migraine",[1670],{"intervention":1731,"totalTrials":217,"cells":1732},"18F-FAPI-74",{"EARLY_PHASE1":1733,"PHASE1":1735,"PHASE2":1737,"PHASE3":1739,"PHASE4":1741,"NA":1743},{"trials":1734,"activeCount":100},[],{"trials":1736,"activeCount":100},[],{"trials":1738,"activeCount":100},[],{"trials":1740,"activeCount":100},[],{"trials":1742,"activeCount":100},[],{"trials":1744,"activeCount":217,"soonestReadout":1749},[1745],{"nctId":1746,"briefTitle":1747,"status":112,"phases":1748,"primaryCompletion":1749,"completion":1750,"start":1751,"enrollment":828,"conditions":1752,"interventions":1754},"NCT07077213","18F-Fibroblast Activation Protein Inhibitor (18F-FAPI-74) in Tuberculosis Patients",[],"2027-07-01","2027-12-01","2026-03-12",[1753],"Tuberculosis, Pulmonary",[1731],{"intervention":46,"totalTrials":217,"cells":1756},{"EARLY_PHASE1":1757,"PHASE1":1759,"PHASE2":1761,"PHASE3":1763,"PHASE4":1765,"NA":1767},{"trials":1758,"activeCount":100},[],{"trials":1760,"activeCount":100},[],{"trials":1762,"activeCount":100},[],{"trials":1764,"activeCount":100},[],{"trials":1766,"activeCount":100},[],{"trials":1768,"activeCount":217,"soonestReadout":45},[1769],{"nctId":43,"briefTitle":44,"status":144,"phases":1770,"primaryCompletion":45,"completion":191,"start":1771,"enrollment":1772,"conditions":1773,"interventions":1774},[],"2020-03-06",25,[509],[46],{"intervention":66,"totalTrials":217,"cells":1776},{"EARLY_PHASE1":1777,"PHASE1":1779,"PHASE2":1781,"PHASE3":1783,"PHASE4":1785,"NA":1787},{"trials":1778,"activeCount":100},[],{"trials":1780,"activeCount":100},[],{"trials":1782,"activeCount":100},[],{"trials":1784,"activeCount":100},[],{"trials":1786,"activeCount":100},[],{"trials":1788,"activeCount":217,"soonestReadout":65},[1789],{"nctId":63,"briefTitle":64,"status":144,"phases":1790,"primaryCompletion":65,"completion":65,"start":1791,"enrollment":522,"conditions":1792,"interventions":1793},[],"2016-03",[20],[66],{"intervention":76,"totalTrials":217,"cells":1795},{"EARLY_PHASE1":1796,"PHASE1":1798,"PHASE2":1800,"PHASE3":1802,"PHASE4":1804,"NA":1806},{"trials":1797,"activeCount":100},[],{"trials":1799,"activeCount":100},[],{"trials":1801,"activeCount":100},[],{"trials":1803,"activeCount":100},[],{"trials":1805,"activeCount":100},[],{"trials":1807,"activeCount":217,"soonestReadout":75},[1808],{"nctId":73,"briefTitle":74,"status":112,"phases":1809,"primaryCompletion":75,"completion":505,"start":1810,"enrollment":377,"conditions":1811,"interventions":1813},[],"2021-02-08",[20,1812],"Non-CF Bronchiectasis",[76],{"intervention":1815,"totalTrials":217,"cells":1816},"CFTR Modulators",{"EARLY_PHASE1":1817,"PHASE1":1819,"PHASE2":1821,"PHASE3":1823,"PHASE4":1825,"NA":1827},{"trials":1818,"activeCount":100},[],{"trials":1820,"activeCount":100},[],{"trials":1822,"activeCount":100},[],{"trials":1824,"activeCount":100},[],{"trials":1826,"activeCount":100},[],{"trials":1828,"activeCount":217,"soonestReadout":659},[1829],{"nctId":1830,"briefTitle":1831,"status":112,"phases":1832,"primaryCompletion":659,"completion":1833,"start":1834,"enrollment":355,"conditions":1835,"interventions":1836},"NCT04580368","Testing Drug Efficacy in Cystic Fibrosis Through N-of-1 Trials",[92],"2030-01-31","2021-05-01",[20],[1815],{"intervention":1838,"totalTrials":217,"cells":1839},"Electronic Decision Tool",{"EARLY_PHASE1":1840,"PHASE1":1842,"PHASE2":1844,"PHASE3":1846,"PHASE4":1848,"NA":1850},{"trials":1841,"activeCount":100},[],{"trials":1843,"activeCount":100},[],{"trials":1845,"activeCount":100},[],{"trials":1847,"activeCount":100},[],{"trials":1849,"activeCount":100},[],{"trials":1851,"activeCount":217,"soonestReadout":1856},[1852],{"nctId":1853,"briefTitle":1854,"status":144,"phases":1855,"primaryCompletion":1856,"completion":1856,"start":1857,"enrollment":1858,"conditions":1859,"interventions":1866},"NCT04481061","Engaging Adolescents in Decisions About Return of Genomic Research Results",[92],"2026-11-30","2020-03-10",787,[1860,1861,1862,1863,1864,1865],"Genetic Screening","Adolescent","Genetic Change","Shared Decision Making","Knowledge, Attitudes, Practice","Genetic Testing",[1838],{"intervention":1868,"totalTrials":217,"cells":1869},"Glucagon-Like Peptide-1 receptor agonists",{"EARLY_PHASE1":1870,"PHASE1":1872,"PHASE2":1874,"PHASE3":1876,"PHASE4":1878,"NA":1880},{"trials":1871,"activeCount":100},[],{"trials":1873,"activeCount":100},[],{"trials":1875,"activeCount":100},[],{"trials":1877,"activeCount":100},[],{"trials":1879,"activeCount":100},[],{"trials":1881,"activeCount":217,"soonestReadout":790},[1882],{"nctId":1883,"briefTitle":1884,"status":272,"phases":1885,"primaryCompletion":790,"completion":790,"start":1886,"enrollment":377,"conditions":1887,"interventions":1893},"NCT06581120","GLP_1 RA Ultrasound Study",[],"2024-07-08",[1888,1889,1890,1891,1892],"Glucagon Like Peptide-1 (GLP-1","Delayed Gastric Emptying","Risk of Aspiration","Diabetes","Morbid Obesity",[1868],{"intervention":1895,"totalTrials":1896,"cells":1897},"Dexmedetomidine",6,{"EARLY_PHASE1":1898,"PHASE1":1900,"PHASE2":1948,"PHASE3":1950,"PHASE4":1952,"NA":1973},{"trials":1899,"activeCount":100},[],{"trials":1901,"activeCount":100},[1902,1916,1927,1938],{"nctId":1903,"briefTitle":1904,"status":423,"phases":1905,"primaryCompletion":1906,"completion":1907,"start":1908,"enrollment":1909,"conditions":1910,"interventions":1913},"NCT00894751","Two Anesthetic Techniques in Magnetic Resonance Imaging (MRI)",[88],"2011-01","2011-12","2009-01",98,[1911,1912],"Magnetic Resonance Imaging","Anesthesia",[1914,1915],"dexmedetomidine","propofol",{"nctId":1917,"briefTitle":1918,"status":169,"phases":1919,"primaryCompletion":1908,"completion":1908,"start":1920,"enrollment":126,"conditions":1921,"interventions":1923},"NCT00671931","Susceptibility of Motor-Evoked Potentials to Varying Targeted Blood Levels of Dexmedetomidine",[88],"2007-04",[1922],"Scoliosis",[1924,1925,1895,1926,1895],"low dexmedetomidine, low propofol","high dexmedetomidine, low propofol","Dexmedetomidin",{"nctId":1928,"briefTitle":1929,"status":169,"phases":1930,"primaryCompletion":1931,"completion":1931,"start":1932,"enrollment":1933,"conditions":1934,"interventions":1936},"NCT02250820","A Comparison of Two Sedation Techniques in Children Undergoing Transthoracic Echocardiography (TTE)",[88],"2017-12","2014-11",280,[1935],"Heart Disease",[1895,1937],"Pentobarbital",{"nctId":1939,"briefTitle":1940,"status":169,"phases":1941,"primaryCompletion":1942,"completion":1942,"start":1943,"enrollment":1944,"conditions":1945,"interventions":1946},"NCT02652507","Dexmedetomidine and Ketamine in MRI",[88],"2018-05","2016-06",22,[1911],[1895,1947],"Ketamine",{"trials":1949,"activeCount":100},[],{"trials":1951,"activeCount":100},[],{"trials":1953,"activeCount":100},[1954,1963],{"nctId":1955,"briefTitle":1956,"status":169,"phases":1957,"primaryCompletion":1958,"completion":1958,"start":201,"enrollment":1426,"conditions":1959,"interventions":1961},"NCT01344759","Dexmedetomidine and Propofol in Children With History of Obstructive Sleep Apnea",[91],"2011-11",[1960],"Sleep Apnea, Obstructive",[1895,1962],"Propofol",{"nctId":1964,"briefTitle":1965,"status":169,"phases":1966,"primaryCompletion":1967,"completion":1967,"start":1968,"enrollment":1969,"conditions":1970,"interventions":1971},"NCT02523144","Dexmedetomidine in Children Having Transthoracic Echocardiography",[91],"2017-05","2014-09",279,[1935],[1972,1895,1895],"Chloral Hydrate",{"trials":1974,"activeCount":100},[],{"intervention":1976,"totalTrials":217,"cells":1977},"Drug-eluting Stent Mometasone",{"EARLY_PHASE1":1978,"PHASE1":1980,"PHASE2":1982,"PHASE3":1984,"PHASE4":1986,"NA":1997},{"trials":1979,"activeCount":100},[],{"trials":1981,"activeCount":100},[],{"trials":1983,"activeCount":100},[],{"trials":1985,"activeCount":100},[],{"trials":1987,"activeCount":100},[1988],{"nctId":1989,"briefTitle":1990,"status":799,"phases":1991,"primaryCompletion":1992,"completion":1992,"start":1993,"enrollment":100,"conditions":1994,"interventions":1996},"NCT03605537","Use of Mometasone Eluting Stent in Choanal Atresia",[91],"2019-10-11","2018-07-03",[1995],"Choanal Atresia",[1976],{"trials":1998,"activeCount":100},[],{"intervention":2000,"totalTrials":217,"cells":2001},"Sodium chloride",{"EARLY_PHASE1":2002,"PHASE1":2004,"PHASE2":2006,"PHASE3":2008,"PHASE4":2010,"NA":2021},{"trials":2003,"activeCount":100},[],{"trials":2005,"activeCount":100},[],{"trials":2007,"activeCount":100},[],{"trials":2009,"activeCount":100},[],{"trials":2011,"activeCount":100},[2012],{"nctId":2013,"briefTitle":2014,"status":423,"phases":2015,"primaryCompletion":1906,"completion":1906,"start":2016,"enrollment":2017,"conditions":2018,"interventions":2020},"NCT01795638","Sodium Supplementation and Growth in Very Low Birth Weight Infants",[91],"2009-10",53,[2019],"Extreme Immaturity",[2000],{"trials":2022,"activeCount":100},[],{"intervention":2024,"totalTrials":217,"cells":2025},"Intravenous Ketorolac",{"EARLY_PHASE1":2026,"PHASE1":2028,"PHASE2":2030,"PHASE3":2032,"PHASE4":2034,"NA":2048},{"trials":2027,"activeCount":100},[],{"trials":2029,"activeCount":100},[],{"trials":2031,"activeCount":100},[],{"trials":2033,"activeCount":100},[],{"trials":2035,"activeCount":100},[2036],{"nctId":2037,"briefTitle":2038,"status":423,"phases":2039,"primaryCompletion":2040,"completion":2041,"start":2042,"enrollment":2043,"conditions":2044,"interventions":2046},"NCT00115336","Ketorolac Versus Ibuprofen to Treat Painful Episodes of Sickle Cell Disease",[91],"2008-08","2008-12","2005-01",10,[2045,624],"Hematologic Diseases",[2024,2047],"Ibuprofen",{"trials":2049,"activeCount":100},[],{"intervention":2047,"totalTrials":217,"cells":2051},{"EARLY_PHASE1":2052,"PHASE1":2054,"PHASE2":2056,"PHASE3":2058,"PHASE4":2060,"NA":2066},{"trials":2053,"activeCount":100},[],{"trials":2055,"activeCount":100},[],{"trials":2057,"activeCount":100},[],{"trials":2059,"activeCount":100},[],{"trials":2061,"activeCount":100},[2062],{"nctId":2037,"briefTitle":2038,"status":423,"phases":2063,"primaryCompletion":2040,"completion":2041,"start":2042,"enrollment":2043,"conditions":2064,"interventions":2065},[91],[2045,624],[2024,2047],{"trials":2067,"activeCount":100},[],{"intervention":2069,"totalTrials":217,"cells":2070},"OROS-Methylphenidate",{"EARLY_PHASE1":2071,"PHASE1":2073,"PHASE2":2075,"PHASE3":2077,"PHASE4":2079,"NA":2091},{"trials":2072,"activeCount":100},[],{"trials":2074,"activeCount":100},[],{"trials":2076,"activeCount":100},[],{"trials":2078,"activeCount":100},[],{"trials":2080,"activeCount":100},[2081],{"nctId":2082,"briefTitle":2083,"status":169,"phases":2084,"primaryCompletion":2085,"completion":2086,"start":2087,"enrollment":2088,"conditions":2089,"interventions":2090},"NCT02293655","The Effects of ADHD Medication (TEAM) Study",[91],"2020-06-30","2021-06-30","2015-01-12",204,[215],[2069],{"trials":2092,"activeCount":100},[],{"intervention":2094,"totalTrials":217,"cells":2095},"2011-2012 seasonal flu vaccine Subcutaneous",{"EARLY_PHASE1":2096,"PHASE1":2098,"PHASE2":2100,"PHASE3":2102,"PHASE4":2104,"NA":2116},{"trials":2097,"activeCount":100},[],{"trials":2099,"activeCount":100},[],{"trials":2101,"activeCount":100},[],{"trials":2103,"activeCount":100},[],{"trials":2105,"activeCount":100},[2106],{"nctId":2107,"briefTitle":2108,"status":169,"phases":2109,"primaryCompletion":1907,"completion":610,"start":601,"enrollment":1944,"conditions":2110,"interventions":2114},"NCT01422200","Flu Vaccine Study in Neuromuscular Patients 2011",[91],[2111,2112,2113],"Duchenne Muscular Dystrophy","Spinal Muscular Atrophy","Congenital Muscular Dystrophy",[2094,2115],"2011-2012 seasonal flu vaccine Intramuscular",{"trials":2117,"activeCount":100},[],{"intervention":2115,"totalTrials":217,"cells":2119},{"EARLY_PHASE1":2120,"PHASE1":2122,"PHASE2":2124,"PHASE3":2126,"PHASE4":2128,"NA":2134},{"trials":2121,"activeCount":100},[],{"trials":2123,"activeCount":100},[],{"trials":2125,"activeCount":100},[],{"trials":2127,"activeCount":100},[],{"trials":2129,"activeCount":100},[2130],{"nctId":2107,"briefTitle":2108,"status":169,"phases":2131,"primaryCompletion":1907,"completion":610,"start":601,"enrollment":1944,"conditions":2132,"interventions":2133},[91],[2111,2112,2113],[2094,2115],{"trials":2135,"activeCount":100},[],{"intervention":2137,"totalTrials":217,"cells":2138},"Probenecid",{"EARLY_PHASE1":2139,"PHASE1":2141,"PHASE2":2143,"PHASE3":2145,"PHASE4":2147,"NA":2159},{"trials":2140,"activeCount":100},[],{"trials":2142,"activeCount":100},[],{"trials":2144,"activeCount":100},[],{"trials":2146,"activeCount":100},[],{"trials":2148,"activeCount":100},[2149],{"nctId":2150,"briefTitle":2151,"status":169,"phases":2152,"primaryCompletion":2085,"completion":2153,"start":2154,"enrollment":2155,"conditions":2156,"interventions":2158},"NCT03965351","TRPV2 Agonists in the Fontan Circulation",[91],"2020-12-31","2017-03-21",8,[2157],"Fontan",[2137],{"trials":2160,"activeCount":100},[],{"intervention":2162,"totalTrials":217,"cells":2163},"OROS-Methylphenidate and placebo for inattentive type pts",{"EARLY_PHASE1":2164,"PHASE1":2166,"PHASE2":2168,"PHASE3":2170,"PHASE4":2172,"NA":2186},{"trials":2165,"activeCount":100},[],{"trials":2167,"activeCount":100},[],{"trials":2169,"activeCount":100},[],{"trials":2171,"activeCount":100},[],{"trials":2173,"activeCount":100},[2174],{"nctId":2175,"briefTitle":2176,"status":169,"phases":2177,"primaryCompletion":2178,"completion":2179,"start":202,"enrollment":2180,"conditions":2181,"interventions":2184},"NCT01727414","Attention Deficit Disorder Medication Response Study",[91],"2013-07","2014-07",171,[2182,2183],"ADHD - Inattentive Type","ADHD - Combined Type",[2162,2185],"OROS-Methylphenidate and placebo for combined type pts",{"trials":2187,"activeCount":100},[],{"intervention":2185,"totalTrials":217,"cells":2189},{"EARLY_PHASE1":2190,"PHASE1":2192,"PHASE2":2194,"PHASE3":2196,"PHASE4":2198,"NA":2204},{"trials":2191,"activeCount":100},[],{"trials":2193,"activeCount":100},[],{"trials":2195,"activeCount":100},[],{"trials":2197,"activeCount":100},[],{"trials":2199,"activeCount":100},[2200],{"nctId":2175,"briefTitle":2176,"status":169,"phases":2201,"primaryCompletion":2178,"completion":2179,"start":202,"enrollment":2180,"conditions":2202,"interventions":2203},[91],[2182,2183],[2162,2185],{"trials":2205,"activeCount":100},[],{"intervention":2207,"totalTrials":217,"cells":2208},"Rotarix®,",{"EARLY_PHASE1":2209,"PHASE1":2211,"PHASE2":2213,"PHASE3":2215,"PHASE4":2217,"NA":2231},{"trials":2210,"activeCount":100},[],{"trials":2212,"activeCount":100},[],{"trials":2214,"activeCount":100},[],{"trials":2216,"activeCount":100},[],{"trials":2218,"activeCount":100},[2219],{"nctId":2220,"briefTitle":2221,"status":169,"phases":2222,"primaryCompletion":1967,"completion":1967,"start":600,"enrollment":2223,"conditions":2224,"interventions":2227},"NCT02542462","Potential Mechanisms for Intussusception After Rotavirus Vaccine-Pilot Study",[91],144,[2225,2226],"Intussusception","Rotavirus Infections",[2207,2228,2229,2230],"Rotarix®, with other routine vaccines","RotaTeq®,","RotaTeq®, with other routine vaccines",{"trials":2232,"activeCount":100},[],{"intervention":2228,"totalTrials":217,"cells":2234},{"EARLY_PHASE1":2235,"PHASE1":2237,"PHASE2":2239,"PHASE3":2241,"PHASE4":2243,"NA":2249},{"trials":2236,"activeCount":100},[],{"trials":2238,"activeCount":100},[],{"trials":2240,"activeCount":100},[],{"trials":2242,"activeCount":100},[],{"trials":2244,"activeCount":100},[2245],{"nctId":2220,"briefTitle":2221,"status":169,"phases":2246,"primaryCompletion":1967,"completion":1967,"start":600,"enrollment":2223,"conditions":2247,"interventions":2248},[91],[2225,2226],[2207,2228,2229,2230],{"trials":2250,"activeCount":100},[],{"intervention":2229,"totalTrials":217,"cells":2252},{"EARLY_PHASE1":2253,"PHASE1":2255,"PHASE2":2257,"PHASE3":2259,"PHASE4":2261,"NA":2267},{"trials":2254,"activeCount":100},[],{"trials":2256,"activeCount":100},[],{"trials":2258,"activeCount":100},[],{"trials":2260,"activeCount":100},[],{"trials":2262,"activeCount":100},[2263],{"nctId":2220,"briefTitle":2221,"status":169,"phases":2264,"primaryCompletion":1967,"completion":1967,"start":600,"enrollment":2223,"conditions":2265,"interventions":2266},[91],[2225,2226],[2207,2228,2229,2230],{"trials":2268,"activeCount":100},[],{"intervention":2230,"totalTrials":217,"cells":2270},{"EARLY_PHASE1":2271,"PHASE1":2273,"PHASE2":2275,"PHASE3":2277,"PHASE4":2279,"NA":2285},{"trials":2272,"activeCount":100},[],{"trials":2274,"activeCount":100},[],{"trials":2276,"activeCount":100},[],{"trials":2278,"activeCount":100},[],{"trials":2280,"activeCount":100},[2281],{"nctId":2220,"briefTitle":2221,"status":169,"phases":2282,"primaryCompletion":1967,"completion":1967,"start":600,"enrollment":2223,"conditions":2283,"interventions":2284},[91],[2225,2226],[2207,2228,2229,2230],{"trials":2286,"activeCount":100},[],{"intervention":1972,"totalTrials":217,"cells":2288},{"EARLY_PHASE1":2289,"PHASE1":2291,"PHASE2":2293,"PHASE3":2295,"PHASE4":2297,"NA":2303},{"trials":2290,"activeCount":100},[],{"trials":2292,"activeCount":100},[],{"trials":2294,"activeCount":100},[],{"trials":2296,"activeCount":100},[],{"trials":2298,"activeCount":100},[2299],{"nctId":1964,"briefTitle":1965,"status":169,"phases":2300,"primaryCompletion":1967,"completion":1967,"start":1968,"enrollment":1969,"conditions":2301,"interventions":2302},[91],[1935],[1972,1895,1895],{"trials":2304,"activeCount":100},[],{"intervention":2306,"totalTrials":491,"cells":2307},"Dexamethasone",{"EARLY_PHASE1":2308,"PHASE1":2310,"PHASE2":2328,"PHASE3":2344,"PHASE4":2355,"NA":2357},{"trials":2309,"activeCount":100},[],{"trials":2311,"activeCount":100},[2312],{"nctId":2313,"briefTitle":2314,"status":169,"phases":2315,"primaryCompletion":2316,"completion":2317,"start":2318,"enrollment":1478,"conditions":2319,"interventions":2322},"NCT03668860","India Dexamethasone and Betamethasone",[88],"2019-02-28","2019-12-31","2018-09-20",[2320,2321],"Preterm Birth","Antenatal Corticosteroids",[2323,2324,2325,2326,2327],"Dexamethasone 4 mg\u002Fml","Betamethasone 4 mg\u002Fml","Celestone Soluspan 6Mg\u002FMl Suspension for","Dexamethasone Oral","Betamethasone Oral",{"trials":2329,"activeCount":100},[2330],{"nctId":2331,"briefTitle":2332,"status":169,"phases":2333,"primaryCompletion":600,"completion":2334,"start":2335,"enrollment":2336,"conditions":2337,"interventions":2339},"NCT01104025","Hybrid Immunotherapy for Hemophagocytic LymphoHistiocytosis",[89],"2016-04","2010-04",31,[2338],"Hemophagocytic Lymphohistiocytosis",[2340,2341,2342,2343,2306],"ATG, rabbit","Etoposide","Methotrexate","hydrocortisone",{"trials":2345,"activeCount":100},[2346],{"nctId":2347,"briefTitle":2348,"status":423,"phases":2349,"primaryCompletion":2350,"completion":2351,"start":2352,"enrollment":30,"conditions":2353,"interventions":2354},"NCT00530270","Dexamethasone to Treat Acute Chest Syndrome in People With Sickle Cell Disease",[90],"2008-06","2008-11","2006-12",[624],[2306],{"trials":2356,"activeCount":100},[],{"trials":2358,"activeCount":100},[],{"intervention":2360,"totalTrials":491,"cells":2361},"Cholecalciferol",{"EARLY_PHASE1":2362,"PHASE1":2364,"PHASE2":2366,"PHASE3":2396,"PHASE4":2409,"NA":2411},{"trials":2363,"activeCount":100},[],{"trials":2365,"activeCount":100},[],{"trials":2367,"activeCount":100},[2368,2382],{"nctId":2369,"briefTitle":2370,"status":169,"phases":2371,"primaryCompletion":2372,"completion":2372,"start":2373,"enrollment":1501,"conditions":2374,"interventions":2376},"NCT04179461","Personalized Treatment Algorithms for Difficult-to-treat Asthma",[89],"2019-10-03","2018-03-16",[2375],"Asthma in Children",[2360,2377,2378,2379,2380,2381],"antihistamine","Azithromycin","emollient cream","Fluticasone Propionate","Asthma Controller Medication",{"nctId":2383,"briefTitle":2384,"status":169,"phases":2385,"completion":2386,"start":2387,"enrollment":2388,"conditions":2389,"interventions":2392},"NCT00004488","Phase II Randomized Study of Alendronate Sodium for Osteopenia in Patients With Gaucher's Disease",[89],"2002-09","1998-10",82,[2390,2391],"Gaucher's Disease","Osteopenia",[2393,2394,2395],"alendronate sodium","calcium carbonate","cholecalciferol",{"trials":2397,"activeCount":100},[2398],{"nctId":2399,"briefTitle":2400,"status":169,"phases":2401,"primaryCompletion":2402,"completion":2403,"start":2404,"enrollment":2405,"conditions":2406,"interventions":2407},"NCT00610688","Controlled Trial of Prenatal Vitamin D3 Supplementation to Prevent Vitamin D Deficiency in Mothers and Their Infants",[90],"2011-06","2012-04","2008-01",192,[1165],[2408,2360,2360],"Prenatal Vitamin",{"trials":2410,"activeCount":100},[],{"trials":2412,"activeCount":100},[],{"intervention":1947,"totalTrials":491,"cells":2414},{"EARLY_PHASE1":2415,"PHASE1":2417,"PHASE2":2431,"PHASE3":2433,"PHASE4":2446,"NA":2448},{"trials":2416,"activeCount":100},[],{"trials":2418,"activeCount":100},[2419,2423],{"nctId":1939,"briefTitle":1940,"status":169,"phases":2420,"primaryCompletion":1942,"completion":1942,"start":1943,"enrollment":1944,"conditions":2421,"interventions":2422},[88],[1911],[1895,1947],{"nctId":2424,"briefTitle":2425,"status":169,"phases":2426,"primaryCompletion":2427,"completion":2427,"start":2428,"enrollment":1501,"conditions":2429,"interventions":2430},"NCT02611921","Study of Intranasal Ketamine for Social Impairment in Autism Spectrum Disorder",[88],"2018-05-07","2015-12-22",[15],[1947],{"trials":2432,"activeCount":100},[],{"trials":2434,"activeCount":100},[2435],{"nctId":2436,"briefTitle":2437,"status":169,"phases":2438,"primaryCompletion":2439,"completion":2154,"start":2440,"enrollment":2441,"conditions":2442,"interventions":2444},"NCT02778880","Pain Reduction With Intranasal Medications for Extremity Injuries",[90],"2017-02-22","2016-03-31",90,[23,2443],"Traumatic Limb Injury",[1947,2445],"Fentanyl",{"trials":2447,"activeCount":100},[],{"trials":2449,"activeCount":100},[],{"intervention":2342,"totalTrials":96,"cells":2451},{"EARLY_PHASE1":2452,"PHASE1":2454,"PHASE2":2456,"PHASE3":2462,"PHASE4":2475,"NA":2477},{"trials":2453,"activeCount":100},[],{"trials":2455,"activeCount":100},[],{"trials":2457,"activeCount":100},[2458],{"nctId":2331,"briefTitle":2332,"status":169,"phases":2459,"primaryCompletion":600,"completion":2334,"start":2335,"enrollment":2336,"conditions":2460,"interventions":2461},[89],[2338],[2340,2341,2342,2343,2306],{"trials":2463,"activeCount":100},[2464],{"nctId":2465,"briefTitle":2466,"status":423,"phases":2467,"primaryCompletion":2468,"completion":2468,"start":2468,"enrollment":2469,"conditions":2470,"interventions":2472},"NCT00035958","Understanding the Pathogenesis and Treatment of Childhood Onset Dermatomyositis",[89,90],"2002-08",75,[2471],"Dermatomyositis",[2473,2342,2474],"Prednisone","Etanercept",{"trials":2476,"activeCount":100},[],{"trials":2478,"activeCount":100},[],{"intervention":2474,"totalTrials":96,"cells":2480},{"EARLY_PHASE1":2481,"PHASE1":2491,"PHASE2":2493,"PHASE3":2495,"PHASE4":2501,"NA":2503},{"trials":2482,"activeCount":100},[2483],{"nctId":2484,"briefTitle":2485,"status":169,"phases":2486,"primaryCompletion":2487,"completion":2487,"start":2488,"enrollment":491,"conditions":2489,"interventions":2490},"NCT00965666","Pilot Study of Etanercept (Enbrel) in Children With Fanconi Anemia",[87],"2010-10","2005-10",[723],[2474],{"trials":2492,"activeCount":100},[],{"trials":2494,"activeCount":100},[],{"trials":2496,"activeCount":100},[2497],{"nctId":2465,"briefTitle":2466,"status":423,"phases":2498,"primaryCompletion":2468,"completion":2468,"start":2468,"enrollment":2469,"conditions":2499,"interventions":2500},[89,90],[2471],[2473,2342,2474],{"trials":2502,"activeCount":100},[],{"trials":2504,"activeCount":100},[],{"intervention":2341,"totalTrials":96,"cells":2506},{"EARLY_PHASE1":2507,"PHASE1":2509,"PHASE2":2511,"PHASE3":2517,"PHASE4":2523,"NA":2525},{"trials":2508,"activeCount":100},[],{"trials":2510,"activeCount":100},[],{"trials":2512,"activeCount":100},[2513],{"nctId":2331,"briefTitle":2332,"status":169,"phases":2514,"primaryCompletion":600,"completion":2334,"start":2335,"enrollment":2336,"conditions":2515,"interventions":2516},[89],[2338],[2340,2341,2342,2343,2306],{"trials":2518,"activeCount":100},[2519],{"nctId":748,"briefTitle":749,"status":169,"phases":2520,"completion":751,"start":752,"enrollment":753,"conditions":2521,"interventions":2522},[90],[741],[756,757,708,758,743,759,760,761,762,744,763],{"trials":2524,"activeCount":100},[],{"trials":2526,"activeCount":100},[],{"intervention":2528,"totalTrials":96,"cells":2529},"Montelukast",{"EARLY_PHASE1":2530,"PHASE1":2532,"PHASE2":2542,"PHASE3":2544,"PHASE4":2554,"NA":2556},{"trials":2531,"activeCount":100},[],{"trials":2533,"activeCount":100},[2534],{"nctId":2535,"briefTitle":2536,"status":169,"phases":2537,"primaryCompletion":2402,"completion":2402,"start":2538,"enrollment":540,"conditions":2539,"interventions":2541},"NCT00492102","Montelukast in Very Low Birthweight Infants",[88],"2007-03",[2540],"Bronchopulmonary Dysplasia",[2528],{"trials":2543,"activeCount":100},[],{"trials":2545,"activeCount":100},[2546],{"nctId":2547,"briefTitle":2548,"status":169,"phases":2549,"primaryCompletion":2550,"completion":2550,"start":2551,"enrollment":905,"conditions":2552,"interventions":2553},"NCT02793375","Does Montelukast Decrease Post Adenotonsillectomy Pain in Children",[90],"2024-11-19","2018-08-02",[23],[2528],{"trials":2555,"activeCount":100},[],{"trials":2557,"activeCount":100},[],{"intervention":743,"totalTrials":96,"cells":2559},{"EARLY_PHASE1":2560,"PHASE1":2562,"PHASE2":2564,"PHASE3":2570,"PHASE4":2576,"NA":2578},{"trials":2561,"activeCount":100},[],{"trials":2563,"activeCount":100},[],{"trials":2565,"activeCount":100},[2566],{"nctId":735,"briefTitle":736,"status":169,"phases":2567,"completion":738,"start":739,"enrollment":126,"conditions":2568,"interventions":2569},[89],[741],[708,743,744],{"trials":2571,"activeCount":100},[2572],{"nctId":748,"briefTitle":749,"status":169,"phases":2573,"completion":751,"start":752,"enrollment":753,"conditions":2574,"interventions":2575},[90],[741],[756,757,708,758,743,759,760,761,762,744,763],{"trials":2577,"activeCount":100},[],{"trials":2579,"activeCount":100},[],{"intervention":744,"totalTrials":96,"cells":2581},{"EARLY_PHASE1":2582,"PHASE1":2584,"PHASE2":2586,"PHASE3":2592,"PHASE4":2598,"NA":2600},{"trials":2583,"activeCount":100},[],{"trials":2585,"activeCount":100},[],{"trials":2587,"activeCount":100},[2588],{"nctId":735,"briefTitle":736,"status":169,"phases":2589,"completion":738,"start":739,"enrollment":126,"conditions":2590,"interventions":2591},[89],[741],[708,743,744],{"trials":2593,"activeCount":100},[2594],{"nctId":748,"briefTitle":749,"status":169,"phases":2595,"completion":751,"start":752,"enrollment":753,"conditions":2596,"interventions":2597},[90],[741],[756,757,708,758,743,759,760,761,762,744,763],{"trials":2599,"activeCount":100},[],{"trials":2601,"activeCount":100},[],{"intervention":2603,"totalTrials":96,"cells":2604},"Melphalan",{"EARLY_PHASE1":2605,"PHASE1":2607,"PHASE2":2619,"PHASE3":2621,"PHASE4":2627,"NA":2629},{"trials":2606,"activeCount":100},[],{"trials":2608,"activeCount":100},[2609],{"nctId":2610,"briefTitle":2611,"status":169,"phases":2612,"primaryCompletion":2613,"completion":2614,"start":2615,"enrollment":2616,"conditions":2617,"interventions":2618},"NCT02390544","A Pharmacokinetic Study of Melphalan in Children",[88],"2018-09-22","2018-09-23","2015-05-08",34,[1544],[2603],{"trials":2620,"activeCount":100},[],{"trials":2622,"activeCount":100},[2623],{"nctId":748,"briefTitle":749,"status":169,"phases":2624,"completion":751,"start":752,"enrollment":753,"conditions":2625,"interventions":2626},[90],[741],[756,757,708,758,743,759,760,761,762,744,763],{"trials":2628,"activeCount":100},[],{"trials":2630,"activeCount":100},[],{"intervention":2473,"totalTrials":217,"cells":2632},{"EARLY_PHASE1":2633,"PHASE1":2635,"PHASE2":2637,"PHASE3":2639,"PHASE4":2645,"NA":2647},{"trials":2634,"activeCount":100},[],{"trials":2636,"activeCount":100},[],{"trials":2638,"activeCount":100},[],{"trials":2640,"activeCount":100},[2641],{"nctId":2465,"briefTitle":2466,"status":423,"phases":2642,"primaryCompletion":2468,"completion":2468,"start":2468,"enrollment":2469,"conditions":2643,"interventions":2644},[89,90],[2471],[2473,2342,2474],{"trials":2646,"activeCount":100},[],{"trials":2648,"activeCount":100},[],{"intervention":2650,"totalTrials":217,"cells":2651},"Ethosuximide",{"EARLY_PHASE1":2652,"PHASE1":2654,"PHASE2":2656,"PHASE3":2658,"PHASE4":2676,"NA":2678},{"trials":2653,"activeCount":100},[],{"trials":2655,"activeCount":100},[],{"trials":2657,"activeCount":100},[],{"trials":2659,"activeCount":100},[2660],{"nctId":2661,"briefTitle":2662,"status":169,"phases":2663,"primaryCompletion":2664,"completion":2665,"start":2666,"enrollment":2667,"conditions":2668,"interventions":2673},"NCT00088452","Childhood Absence Epilepsy Rx PK-PD-Pharmacogenetics Study",[90],"2013-01","2016-08-31","2004-07",453,[2669,2670,2671,2672],"Childhood Absence Epilepsy","Petit Mal Epilepsy","Epilepsy","Seizures",[2650,2674,2675],"Lamotrigine","Valproic acid",{"trials":2677,"activeCount":100},[],{"trials":2679,"activeCount":100},[],{"intervention":2674,"totalTrials":217,"cells":2681},{"EARLY_PHASE1":2682,"PHASE1":2684,"PHASE2":2686,"PHASE3":2688,"PHASE4":2694,"NA":2696},{"trials":2683,"activeCount":100},[],{"trials":2685,"activeCount":100},[],{"trials":2687,"activeCount":100},[],{"trials":2689,"activeCount":100},[2690],{"nctId":2661,"briefTitle":2662,"status":169,"phases":2691,"primaryCompletion":2664,"completion":2665,"start":2666,"enrollment":2667,"conditions":2692,"interventions":2693},[90],[2669,2670,2671,2672],[2650,2674,2675],{"trials":2695,"activeCount":100},[],{"trials":2697,"activeCount":100},[],{"intervention":2675,"totalTrials":217,"cells":2699},{"EARLY_PHASE1":2700,"PHASE1":2702,"PHASE2":2704,"PHASE3":2706,"PHASE4":2712,"NA":2714},{"trials":2701,"activeCount":100},[],{"trials":2703,"activeCount":100},[],{"trials":2705,"activeCount":100},[],{"trials":2707,"activeCount":100},[2708],{"nctId":2661,"briefTitle":2662,"status":169,"phases":2709,"primaryCompletion":2664,"completion":2665,"start":2666,"enrollment":2667,"conditions":2710,"interventions":2711},[90],[2669,2670,2671,2672],[2650,2674,2675],{"trials":2713,"activeCount":100},[],{"trials":2715,"activeCount":100},[],{"intervention":1703,"totalTrials":217,"cells":2717},{"EARLY_PHASE1":2718,"PHASE1":2720,"PHASE2":2722,"PHASE3":2724,"PHASE4":2730,"NA":2732},{"trials":2719,"activeCount":100},[],{"trials":2721,"activeCount":100},[],{"trials":2723,"activeCount":100},[],{"trials":2725,"activeCount":100},[2726],{"nctId":1695,"briefTitle":1696,"status":423,"phases":2727,"primaryCompletion":1698,"completion":935,"start":1699,"enrollment":1700,"conditions":2728,"interventions":2729},[90],[1688,1689,1690],[1670,1703],{"trials":2731,"activeCount":100},[],{"trials":2733,"activeCount":100},[],{"intervention":2735,"totalTrials":217,"cells":2736},"influenza vaccine",{"EARLY_PHASE1":2737,"PHASE1":2739,"PHASE2":2741,"PHASE3":2743,"PHASE4":2757,"NA":2759},{"trials":2738,"activeCount":100},[],{"trials":2740,"activeCount":100},[],{"trials":2742,"activeCount":100},[],{"trials":2744,"activeCount":100},[2745],{"nctId":2746,"briefTitle":2747,"status":169,"phases":2748,"primaryCompletion":2749,"completion":2750,"start":2751,"enrollment":2752,"conditions":2753,"interventions":2755},"NCT01034254","Field Trial of Maternal Influenza Immunization in Asia",[90],"2014-05","2017-10","2010-11",3693,[2754],"Influenza Human",[2735,2756],"saline placebo",{"trials":2758,"activeCount":100},[],{"trials":2760,"activeCount":100},[],{"intervention":2756,"totalTrials":217,"cells":2762},{"EARLY_PHASE1":2763,"PHASE1":2765,"PHASE2":2767,"PHASE3":2769,"PHASE4":2775,"NA":2777},{"trials":2764,"activeCount":100},[],{"trials":2766,"activeCount":100},[],{"trials":2768,"activeCount":100},[],{"trials":2770,"activeCount":100},[2771],{"nctId":2746,"briefTitle":2747,"status":169,"phases":2772,"primaryCompletion":2749,"completion":2750,"start":2751,"enrollment":2752,"conditions":2773,"interventions":2774},[90],[2754],[2735,2756],{"trials":2776,"activeCount":100},[],{"trials":2778,"activeCount":100},[],{"intervention":2780,"totalTrials":217,"cells":2781},"Lithium",{"EARLY_PHASE1":2782,"PHASE1":2784,"PHASE2":2786,"PHASE3":2788,"PHASE4":2801,"NA":2803},{"trials":2783,"activeCount":100},[],{"trials":2785,"activeCount":100},[],{"trials":2787,"activeCount":100},[],{"trials":2789,"activeCount":100},[2790],{"nctId":2791,"briefTitle":2792,"status":169,"phases":2793,"primaryCompletion":2794,"completion":651,"start":2795,"enrollment":2796,"conditions":2797,"interventions":2799},"NCT00221429","Lithium Versus Divalproex for Treating Pediatric Bipolar Disorder",[90],"2006-08","2001-03",153,[2798],"Bipolar Disorder",[2780,2800],"sodium divalproex",{"trials":2802,"activeCount":100},[],{"trials":2804,"activeCount":100},[],{"intervention":2800,"totalTrials":217,"cells":2806},{"EARLY_PHASE1":2807,"PHASE1":2809,"PHASE2":2811,"PHASE3":2813,"PHASE4":2819,"NA":2821},{"trials":2808,"activeCount":100},[],{"trials":2810,"activeCount":100},[],{"trials":2812,"activeCount":100},[],{"trials":2814,"activeCount":100},[2815],{"nctId":2791,"briefTitle":2792,"status":169,"phases":2816,"primaryCompletion":2794,"completion":651,"start":2795,"enrollment":2796,"conditions":2817,"interventions":2818},[90],[2798],[2780,2800],{"trials":2820,"activeCount":100},[],{"trials":2822,"activeCount":100},[],{"intervention":2824,"totalTrials":217,"cells":2825},"Nebulized Magnesium Sulfate",{"EARLY_PHASE1":2826,"PHASE1":2828,"PHASE2":2830,"PHASE3":2832,"PHASE4":2843,"NA":2845},{"trials":2827,"activeCount":100},[],{"trials":2829,"activeCount":100},[],{"trials":2831,"activeCount":100},[],{"trials":2833,"activeCount":100},[2834],{"nctId":2835,"briefTitle":2836,"status":799,"phases":2837,"primaryCompletion":2838,"completion":2838,"start":2839,"enrollment":100,"conditions":2840,"interventions":2842},"NCT00522444","Nebulized Magnesium Sulfate in Pediatric Asthma",[90],"2013-09","2007-09",[2841],"Asthma",[2824],{"trials":2844,"activeCount":100},[],{"trials":2846,"activeCount":100},[],{"intervention":2848,"totalTrials":217,"cells":2849},"gases Nitric Oxide",{"EARLY_PHASE1":2850,"PHASE1":2852,"PHASE2":2854,"PHASE3":2856,"PHASE4":2866,"NA":2868},{"trials":2851,"activeCount":100},[],{"trials":2853,"activeCount":100},[],{"trials":2855,"activeCount":100},[],{"trials":2857,"activeCount":100},[2858],{"nctId":2859,"briefTitle":2860,"status":799,"phases":2861,"primaryCompletion":2862,"completion":2862,"start":2862,"enrollment":100,"conditions":2863,"interventions":2865},"NCT04259684","Nitric Oxide During Cardiopulmonary Bypass in Neonates to Reduce Risk of Acute Kidney Injury",[89,90],"2019-10-20",[26,2864],"Congenital Heart Disease",[2848],{"trials":2867,"activeCount":100},[],{"trials":2869,"activeCount":100},[],{"intervention":2445,"totalTrials":217,"cells":2871},{"EARLY_PHASE1":2872,"PHASE1":2874,"PHASE2":2876,"PHASE3":2878,"PHASE4":2884,"NA":2886},{"trials":2873,"activeCount":100},[],{"trials":2875,"activeCount":100},[],{"trials":2877,"activeCount":100},[],{"trials":2879,"activeCount":100},[2880],{"nctId":2436,"briefTitle":2437,"status":169,"phases":2881,"primaryCompletion":2439,"completion":2154,"start":2440,"enrollment":2441,"conditions":2882,"interventions":2883},[90],[23,2443],[1947,2445],{"trials":2885,"activeCount":100},[],{"trials":2887,"activeCount":100},[],{"intervention":2889,"totalTrials":217,"cells":2890},"Glycocholic Acid",{"EARLY_PHASE1":2891,"PHASE1":2893,"PHASE2":2895,"PHASE3":2897,"PHASE4":2911,"NA":2913},{"trials":2892,"activeCount":100},[],{"trials":2894,"activeCount":100},[],{"trials":2896,"activeCount":100},[],{"trials":2898,"activeCount":100},[2899],{"nctId":2900,"briefTitle":2901,"status":169,"phases":2902,"primaryCompletion":2903,"completion":2903,"start":2904,"enrollment":2905,"conditions":2906,"interventions":2910},"NCT01589523","GlycoCholic Acid Treatment for Patients With Inborn Errors in Bile Acid Synthesis",[90],"2019-01-22","2006-02",5,[2907,2908,2909],"Bile Acid Synthesis Defect","Inborn Error of Bile Acid Metabolism","Inborn Error of Bile Acid Conjugation",[2889],{"trials":2912,"activeCount":100},[],{"trials":2914,"activeCount":100},[],{"intervention":2916,"totalTrials":217,"cells":2917},"Risperidone oral solution",{"EARLY_PHASE1":2918,"PHASE1":2920,"PHASE2":2922,"PHASE3":2924,"PHASE4":2936,"NA":2938},{"trials":2919,"activeCount":100},[],{"trials":2921,"activeCount":100},[],{"trials":2923,"activeCount":100},[],{"trials":2925,"activeCount":100},[2926],{"nctId":2927,"briefTitle":2928,"status":169,"phases":2929,"primaryCompletion":2930,"completion":2930,"start":2931,"enrollment":2932,"conditions":2933,"interventions":2934},"NCT00221403","Placebo Controlled Trial of Valproate and Risperidone in Young Children With Bipolar Disorders",[90],"2011-05","2004-09",46,[2798],[2916,2935],"Valproate Oral Solution",{"trials":2937,"activeCount":100},[],{"trials":2939,"activeCount":100},[],{"intervention":2935,"totalTrials":217,"cells":2941},{"EARLY_PHASE1":2942,"PHASE1":2944,"PHASE2":2946,"PHASE3":2948,"PHASE4":2954,"NA":2956},{"trials":2943,"activeCount":100},[],{"trials":2945,"activeCount":100},[],{"trials":2947,"activeCount":100},[],{"trials":2949,"activeCount":100},[2950],{"nctId":2927,"briefTitle":2928,"status":169,"phases":2951,"primaryCompletion":2930,"completion":2930,"start":2931,"enrollment":2932,"conditions":2952,"interventions":2953},[90],[2798],[2916,2935],{"trials":2955,"activeCount":100},[],{"trials":2957,"activeCount":100},[],{"intervention":2959,"totalTrials":217,"cells":2960},"Transdermal Estrogen",{"EARLY_PHASE1":2961,"PHASE1":2963,"PHASE2":2965,"PHASE3":2967,"PHASE4":2979,"NA":2981},{"trials":2962,"activeCount":100},[],{"trials":2964,"activeCount":100},[],{"trials":2966,"activeCount":100},[],{"trials":2968,"activeCount":100},[2969],{"nctId":2970,"briefTitle":2971,"status":169,"phases":2972,"primaryCompletion":2973,"completion":2973,"start":2974,"enrollment":2975,"conditions":2976,"interventions":2978},"NCT03568708","Primary Ovarian Insufficiency: Phenotype and Optimal Treatment",[90],"2023-01-05","2018-11-01",19,[2977],"Primary Ovarian Insufficiency",[2959],{"trials":2980,"activeCount":100},[],{"trials":2982,"activeCount":100},[],{"intervention":2984,"totalTrials":217,"cells":2985},"Fluticasone Propionate, 880 mcg twice daily",{"EARLY_PHASE1":2986,"PHASE1":2988,"PHASE2":2990,"PHASE3":2992,"PHASE4":3006,"NA":3008},{"trials":2987,"activeCount":100},[],{"trials":2989,"activeCount":100},[],{"trials":2991,"activeCount":100},[],{"trials":2993,"activeCount":100},[2994],{"nctId":2995,"briefTitle":2996,"status":169,"phases":2997,"primaryCompletion":2998,"completion":2999,"start":3000,"enrollment":3001,"conditions":3002,"interventions":3005},"NCT02778867","SOFEED: Six Food vs. One Food Eosinophilic Esophagitis Diet Study",[89,90],"2019-04-17","2019-05-29","2016-05-20",129,[3003,3004],"Eosinophilic Gastrointestinal Disorders (EGIDs)","Eosinophilic Esophagitis (EoE)",[2984],{"trials":3007,"activeCount":100},[],{"trials":3009,"activeCount":100},[],{"intervention":3011,"totalTrials":217,"cells":3012},"Infliximab precision dosing",{"EARLY_PHASE1":3013,"PHASE1":3015,"PHASE2":3017,"PHASE3":3019,"PHASE4":3028,"NA":3030},{"trials":3014,"activeCount":100},[],{"trials":3016,"activeCount":100},[],{"trials":3018,"activeCount":100},[],{"trials":3020,"activeCount":100},[3021],{"nctId":3022,"briefTitle":3023,"status":423,"phases":3024,"primaryCompletion":3025,"completion":3025,"start":826,"enrollment":1896,"conditions":3026,"interventions":3027},"NCT04974099","Personalized Infliximab Induction Strategy With Model-informed Dosing in Patients With Crohn's Disease",[89,90],"2024-08-01",[509],[3011],{"trials":3029,"activeCount":100},[],{"trials":3031,"activeCount":100},[],{"intervention":3033,"totalTrials":217,"cells":3034},"Benralizumab",{"EARLY_PHASE1":3035,"PHASE1":3037,"PHASE2":3039,"PHASE3":3041,"PHASE4":3053,"NA":3055},{"trials":3036,"activeCount":100},[],{"trials":3038,"activeCount":100},[],{"trials":3040,"activeCount":100},[],{"trials":3042,"activeCount":100},[3043],{"nctId":3044,"briefTitle":3045,"status":169,"phases":3046,"primaryCompletion":3047,"completion":3048,"start":3049,"enrollment":148,"conditions":3050,"interventions":3052},"NCT03473977","Benralizumab for Eosinophilic Gastritis (BEGS)",[89,90],"2020-06-22","2022-01-12","2018-04-23",[3051],"Eosinophilic Gastritis or Gastroenteritis",[3033],{"trials":3054,"activeCount":100},[],{"trials":3056,"activeCount":100},[],{"intervention":3058,"totalTrials":217,"cells":3059},"Fluticasone Propionate, 800 mcg twice daily",{"EARLY_PHASE1":3060,"PHASE1":3062,"PHASE2":3064,"PHASE3":3066,"PHASE4":3077,"NA":3079},{"trials":3061,"activeCount":100},[],{"trials":3063,"activeCount":100},[],{"trials":3065,"activeCount":100},[],{"trials":3067,"activeCount":100},[3068],{"nctId":3069,"briefTitle":3070,"status":169,"phases":3071,"primaryCompletion":3072,"completion":3072,"start":3073,"enrollment":3074,"conditions":3075,"interventions":3076},"NCT02610816","Eosinophilic Esophagitis Intervention Trial-1 Food vs. 4 Food Elimination Diet Followed by Swallowed Glucocorticoids",[89,90],"2018-05-16","2016-03-21",67,[34,3003],[3058],{"trials":3078,"activeCount":100},[],{"trials":3080,"activeCount":100},[],{"intervention":2408,"totalTrials":217,"cells":3082},{"EARLY_PHASE1":3083,"PHASE1":3085,"PHASE2":3087,"PHASE3":3089,"PHASE4":3095,"NA":3097},{"trials":3084,"activeCount":100},[],{"trials":3086,"activeCount":100},[],{"trials":3088,"activeCount":100},[],{"trials":3090,"activeCount":100},[3091],{"nctId":2399,"briefTitle":2400,"status":169,"phases":3092,"primaryCompletion":2402,"completion":2403,"start":2404,"enrollment":2405,"conditions":3093,"interventions":3094},[90],[1165],[2408,2360,2360],{"trials":3096,"activeCount":100},[],{"trials":3098,"activeCount":100},[],{"intervention":756,"totalTrials":217,"cells":3100},{"EARLY_PHASE1":3101,"PHASE1":3103,"PHASE2":3105,"PHASE3":3107,"PHASE4":3113,"NA":3115},{"trials":3102,"activeCount":100},[],{"trials":3104,"activeCount":100},[],{"trials":3106,"activeCount":100},[],{"trials":3108,"activeCount":100},[3109],{"nctId":748,"briefTitle":749,"status":169,"phases":3110,"completion":751,"start":752,"enrollment":753,"conditions":3111,"interventions":3112},[90],[741],[756,757,708,758,743,759,760,761,762,744,763],{"trials":3114,"activeCount":100},[],{"trials":3116,"activeCount":100},[],{"intervention":757,"totalTrials":217,"cells":3118},{"EARLY_PHASE1":3119,"PHASE1":3121,"PHASE2":3123,"PHASE3":3125,"PHASE4":3131,"NA":3133},{"trials":3120,"activeCount":100},[],{"trials":3122,"activeCount":100},[],{"trials":3124,"activeCount":100},[],{"trials":3126,"activeCount":100},[3127],{"nctId":748,"briefTitle":749,"status":169,"phases":3128,"completion":751,"start":752,"enrollment":753,"conditions":3129,"interventions":3130},[90],[741],[756,757,708,758,743,759,760,761,762,744,763],{"trials":3132,"activeCount":100},[],{"trials":3134,"activeCount":100},[],{"intervention":758,"totalTrials":217,"cells":3136},{"EARLY_PHASE1":3137,"PHASE1":3139,"PHASE2":3141,"PHASE3":3143,"PHASE4":3149,"NA":3151},{"trials":3138,"activeCount":100},[],{"trials":3140,"activeCount":100},[],{"trials":3142,"activeCount":100},[],{"trials":3144,"activeCount":100},[3145],{"nctId":748,"briefTitle":749,"status":169,"phases":3146,"completion":751,"start":752,"enrollment":753,"conditions":3147,"interventions":3148},[90],[741],[756,757,708,758,743,759,760,761,762,744,763],{"trials":3150,"activeCount":100},[],{"trials":3152,"activeCount":100},[],{"intervention":760,"totalTrials":217,"cells":3154},{"EARLY_PHASE1":3155,"PHASE1":3157,"PHASE2":3159,"PHASE3":3161,"PHASE4":3167,"NA":3169},{"trials":3156,"activeCount":100},[],{"trials":3158,"activeCount":100},[],{"trials":3160,"activeCount":100},[],{"trials":3162,"activeCount":100},[3163],{"nctId":748,"briefTitle":749,"status":169,"phases":3164,"completion":751,"start":752,"enrollment":753,"conditions":3165,"interventions":3166},[90],[741],[756,757,708,758,743,759,760,761,762,744,763],{"trials":3168,"activeCount":100},[],{"trials":3170,"activeCount":100},[],{"intervention":762,"totalTrials":217,"cells":3172},{"EARLY_PHASE1":3173,"PHASE1":3175,"PHASE2":3177,"PHASE3":3179,"PHASE4":3185,"NA":3187},{"trials":3174,"activeCount":100},[],{"trials":3176,"activeCount":100},[],{"trials":3178,"activeCount":100},[],{"trials":3180,"activeCount":100},[3181],{"nctId":748,"briefTitle":749,"status":169,"phases":3182,"completion":751,"start":752,"enrollment":753,"conditions":3183,"interventions":3184},[90],[741],[756,757,708,758,743,759,760,761,762,744,763],{"trials":3186,"activeCount":100},[],{"trials":3188,"activeCount":100},[],{"intervention":763,"totalTrials":217,"cells":3190},{"EARLY_PHASE1":3191,"PHASE1":3193,"PHASE2":3195,"PHASE3":3197,"PHASE4":3203,"NA":3205},{"trials":3192,"activeCount":100},[],{"trials":3194,"activeCount":100},[],{"trials":3196,"activeCount":100},[],{"trials":3198,"activeCount":100},[3199],{"nctId":748,"briefTitle":749,"status":169,"phases":3200,"completion":751,"start":752,"enrollment":753,"conditions":3201,"interventions":3202},[90],[741],[756,757,708,758,743,759,760,761,762,744,763],{"trials":3204,"activeCount":100},[],{"trials":3206,"activeCount":100},[],{"intervention":3208,"totalTrials":162,"cells":3209},"Everolimus",{"EARLY_PHASE1":3210,"PHASE1":3212,"PHASE2":3231,"PHASE3":3258,"PHASE4":3260,"NA":3262},{"trials":3211,"activeCount":100},[],{"trials":3213,"activeCount":100},[3214],{"nctId":3215,"briefTitle":3216,"status":169,"phases":3217,"primaryCompletion":3218,"completion":3219,"start":3220,"enrollment":2975,"conditions":3221,"interventions":3229},"NCT03355794","A Study of Ribociclib and Everolimus Following Radiation Therapy in Children With Newly Diagnosed Non-biopsied Diffuse Pontine Gliomas (DIPG) and RB+ Biopsied DIPG and High Grade Gliomas (HGG)",[88],"2020-07-31","2022-07-31","2017-11-14",[3222,3223,3224,3225,3226,3227,3228],"Diffuse Intrinsic Pontine Glioma","Malignant Glioma of Brain","High Grade Glioma","Bithalamic High Grade Glioma","Brainstem Glioma","Glioblastoma","Anaplastic Astrocytoma",[3230,3208],"ribociclib",{"trials":3232,"activeCount":100},[3233,3242,3250],{"nctId":3234,"briefTitle":3235,"status":169,"phases":3236,"primaryCompletion":2838,"completion":2838,"start":2041,"enrollment":1345,"conditions":3237,"interventions":3240},"NCT00792766","Long Term Follow Up for RAD001 Therapy of Angiomyolipomata in Patients With Tuberous Sclerosis (TSC) and Sporadic Lymphangioleiomyomatosis (LAM)",[88,89],[3238,3239],"Tuberous Sclerosis","Angiolipoma",[3241],"everolimus",{"nctId":3243,"briefTitle":3244,"status":169,"phases":3245,"primaryCompletion":2334,"completion":2334,"start":3246,"enrollment":1345,"conditions":3247,"interventions":3249},"NCT01070316","Everolimus (RAD001) Therapy for Epilepsy in Patients With Tuberous Sclerosis Complex (TSC)",[88,89],"2010-01",[2671,3248],"Tuberous Sclerosis Complex",[3208],{"nctId":3251,"briefTitle":3252,"status":169,"phases":3253,"primaryCompletion":609,"completion":609,"start":3254,"enrollment":1568,"conditions":3255,"interventions":3257},"NCT00411619","Everolimus (RAD001) Therapy of Giant Cell Astrocytoma in Patients With Tuberous Sclerosis Complex",[88,89],"2007-01",[3238,3256],"Subependymal Giant Cell Astrocytoma",[3208],{"trials":3259,"activeCount":100},[],{"trials":3261,"activeCount":100},[],{"trials":3263,"activeCount":100},[],{"intervention":3265,"totalTrials":491,"cells":3266},"Ruxolitinib",{"EARLY_PHASE1":3267,"PHASE1":3269,"PHASE2":3291,"PHASE3":3305,"PHASE4":3307,"NA":3309},{"trials":3268,"activeCount":100},[],{"trials":3270,"activeCount":100},[3271,3281],{"nctId":3272,"briefTitle":3273,"status":169,"phases":3274,"primaryCompletion":3275,"completion":3275,"start":3276,"enrollment":27,"conditions":3277,"interventions":3280},"NCT05121142","Study of Ruxolitinib for Acute and Chronic Graft Versus Host Disease",[88],"2023-05-13","2021-10-27",[3278,3279,839],"Acute-graft-versus-host Disease","Chronic Graft-versus-host-disease",[3265],{"nctId":3282,"briefTitle":3283,"status":423,"phases":3284,"primaryCompletion":3285,"completion":3286,"start":3287,"enrollment":217,"conditions":3288,"interventions":3290},"NCT06695507","Upfront Ruxolitinib for Chronic Graft-vs-host Disease",[88],"2025-08-20","2025-09-18","2025-02-19",[3289],"Chronic Graft Versus Host Disease",[3265],{"trials":3292,"activeCount":100},[3293],{"nctId":3294,"briefTitle":3295,"status":423,"phases":3296,"primaryCompletion":3297,"completion":3298,"start":3299,"enrollment":3300,"conditions":3301,"interventions":3304},"NCT04908735","Ruxolitinib for Early Lung Dysfunction After Hematopoietic Stem Cell Transplant",[89],"2025-09-17","2025-11-16","2021-11-12",7,[3302,3303],"Hematopoietic Stem Cell Transplant (HSCT)","Bronchiolitis Obliterans (BO)",[3265],{"trials":3306,"activeCount":100},[],{"trials":3308,"activeCount":100},[],{"trials":3310,"activeCount":100},[],{"intervention":3230,"totalTrials":96,"cells":3312},{"EARLY_PHASE1":3313,"PHASE1":3315,"PHASE2":3321,"PHASE3":3331,"PHASE4":3333,"NA":3335},{"trials":3314,"activeCount":100},[],{"trials":3316,"activeCount":100},[3317],{"nctId":3215,"briefTitle":3216,"status":169,"phases":3318,"primaryCompletion":3218,"completion":3219,"start":3220,"enrollment":2975,"conditions":3319,"interventions":3320},[88],[3222,3223,3224,3225,3226,3227,3228],[3230,3208],{"trials":3322,"activeCount":100},[3323],{"nctId":3324,"briefTitle":3325,"status":423,"phases":3326,"primaryCompletion":1942,"completion":3327,"start":2334,"enrollment":35,"conditions":3328,"interventions":3329},"NCT02607124","A Phase I\u002FII Study of Ribociclib,a CDK4\u002F6 Inhibitor, Following Radiation Therapy",[88,89],"2018-08",[3224,3222,3225],[3330],"Ribociclib",{"trials":3332,"activeCount":100},[],{"trials":3334,"activeCount":100},[],{"trials":3336,"activeCount":100},[],{"intervention":3338,"totalTrials":96,"cells":3339},"Melatonin",{"EARLY_PHASE1":3340,"PHASE1":3342,"PHASE2":3344,"PHASE3":3360,"PHASE4":3362,"NA":3364},{"trials":3341,"activeCount":100},[],{"trials":3343,"activeCount":100},[],{"trials":3345,"activeCount":100},[3346,3353],{"nctId":3347,"briefTitle":3348,"status":169,"phases":3349,"primaryCompletion":2402,"completion":3350,"start":3246,"enrollment":2155,"conditions":3351,"interventions":3352},"NCT00867451","Improving Sleep and Daytime Functioning Among Children Diagnosed With Attention Deficit Hyperactivity Disorder (ADHD)",[88,89],"2011-07",[18],[3338],{"nctId":3354,"briefTitle":3355,"status":169,"phases":3356,"primaryCompletion":578,"completion":570,"start":2402,"enrollment":35,"conditions":3357,"interventions":3358},"NCT00965575","Pilot Study of Melatonin and Epilepsy",[89],[2671],[3338,3359],"Placebos",{"trials":3361,"activeCount":100},[],{"trials":3363,"activeCount":100},[],{"trials":3365,"activeCount":100},[],{"intervention":3367,"totalTrials":96,"cells":3368},"Losartan Potassium",{"EARLY_PHASE1":3369,"PHASE1":3371,"PHASE2":3373,"PHASE3":3394,"PHASE4":3396,"NA":3398},{"trials":3370,"activeCount":100},[],{"trials":3372,"activeCount":100},[],{"trials":3374,"activeCount":100},[3375,3384],{"nctId":3376,"briefTitle":3377,"status":169,"phases":3378,"primaryCompletion":3379,"completion":3380,"start":3381,"enrollment":24,"conditions":3382,"interventions":3383},"NCT03029091","An Open-Label Trial of Losartan Potassium in Participants With Eosinophilic Esophagitis (EoE)",[89],"2019-07-22","2019-08-22","2017-05-23",[34],[3367],{"nctId":3385,"briefTitle":3386,"status":169,"phases":3387,"primaryCompletion":3388,"completion":3389,"start":3390,"enrollment":1896,"conditions":3391,"interventions":3393},"NCT01808196","Testing Effectiveness of Losartan in Patients With EoE With or Without a CTD",[89],"2015-01-13","2015-02-13","2013-10-10",[34,3392],"Connective Tissue Disorders",[3367],{"trials":3395,"activeCount":100},[],{"trials":3397,"activeCount":100},[],{"trials":3399,"activeCount":100},[],{"intervention":3401,"totalTrials":96,"cells":3402},"Lidocaine",{"EARLY_PHASE1":3403,"PHASE1":3405,"PHASE2":3416,"PHASE3":3427,"PHASE4":3429,"NA":3431},{"trials":3404,"activeCount":100},[],{"trials":3406,"activeCount":100},[3407],{"nctId":3408,"briefTitle":3409,"status":423,"phases":3410,"primaryCompletion":3411,"completion":3411,"start":3412,"enrollment":96,"conditions":3413,"interventions":3415},"NCT02241096","PK Intravenous Lidocaine Infusion",[88],"2015-09","2015-01",[3414],"Colorectal Surgery",[3401],{"trials":3417,"activeCount":100},[3418],{"nctId":3419,"briefTitle":3420,"status":799,"phases":3421,"primaryCompletion":3422,"completion":3423,"start":3412,"enrollment":100,"conditions":3424,"interventions":3426},"NCT01836614","Intravenous Lidocaine Infusion in the Management of Post-operative Pain in Colorectal Patients",[88,89],"2018-03","2018-04",[3425],"Colorectal Disorders",[3401],{"trials":3428,"activeCount":100},[],{"trials":3430,"activeCount":100},[],{"trials":3432,"activeCount":100},[],{"intervention":2394,"totalTrials":96,"cells":3434},{"EARLY_PHASE1":3435,"PHASE1":3437,"PHASE2":3439,"PHASE3":3455,"PHASE4":3457,"NA":3459},{"trials":3436,"activeCount":100},[],{"trials":3438,"activeCount":100},[],{"trials":3440,"activeCount":100},[3441,3445],{"nctId":2383,"briefTitle":2384,"status":169,"phases":3442,"completion":2386,"start":2387,"enrollment":2388,"conditions":3443,"interventions":3444},[89],[2390,2391],[2393,2394,2395],{"nctId":3446,"briefTitle":3447,"status":169,"phases":3448,"completion":3449,"start":3450,"enrollment":2405,"conditions":3451,"interventions":3453},"NCT00000429","Calcium Supplements for Bone Health in Juvenile Rheumatoid Arthritis",[89],"2001-05","1996-06",[3452],"Juvenile Rheumatoid Arthritis",[3454],"Calcium carbonate",{"trials":3456,"activeCount":100},[],{"trials":3458,"activeCount":100},[],{"trials":3460,"activeCount":100},[],{"intervention":3359,"totalTrials":96,"cells":3462},{"EARLY_PHASE1":3463,"PHASE1":3465,"PHASE2":3476,"PHASE3":3482,"PHASE4":3484,"NA":3486},{"trials":3464,"activeCount":100},[],{"trials":3466,"activeCount":100},[3467],{"nctId":3468,"briefTitle":3469,"status":169,"phases":3470,"primaryCompletion":3471,"completion":3471,"start":3472,"enrollment":2017,"conditions":3473,"interventions":3475},"NCT04031755","A Proof-of-Concept Study of Minocycline in Autism",[88],"2020-10-30","2019-04-19",[15,3474],"Autism",[941,3359],{"trials":3477,"activeCount":100},[3478],{"nctId":3354,"briefTitle":3355,"status":169,"phases":3479,"primaryCompletion":578,"completion":570,"start":2402,"enrollment":35,"conditions":3480,"interventions":3481},[89],[2671],[3338,3359],{"trials":3483,"activeCount":100},[],{"trials":3485,"activeCount":100},[],{"trials":3487,"activeCount":100},[],{"intervention":3489,"totalTrials":96,"cells":3490},"Risperidone",{"EARLY_PHASE1":3491,"PHASE1":3493,"PHASE2":3504,"PHASE3":3514,"PHASE4":3516,"NA":3518},{"trials":3492,"activeCount":100},[],{"trials":3494,"activeCount":100},[3495],{"nctId":3496,"briefTitle":3497,"status":169,"phases":3498,"completion":3499,"start":3500,"enrollment":377,"conditions":3501,"interventions":3503},"NCT00147394","Risperidone Pharmacokinetics in Children With Pervasive Developmental Disorder (PDD)",[88],"2004-06","2001-12",[3502],"Child Development Disorders, Pervasive",[3489],{"trials":3505,"activeCount":100},[3506],{"nctId":3507,"briefTitle":3508,"status":169,"phases":3509,"completion":3510,"start":3511,"enrollment":377,"conditions":3512,"interventions":3513},"NCT00166595","Pharmacogenetics of Risperidone in Children With Pervasive Developmental Disorder (PDD)",[88,89],"2005-03","2003-02",[3502],[3489],{"trials":3515,"activeCount":100},[],{"trials":3517,"activeCount":100},[],{"trials":3519,"activeCount":100},[],{"intervention":3521,"totalTrials":217,"cells":3522},"Lactobacillus GG",{"EARLY_PHASE1":3523,"PHASE1":3525,"PHASE2":3527,"PHASE3":3538,"PHASE4":3540,"NA":3542},{"trials":3524,"activeCount":100},[],{"trials":3526,"activeCount":100},[],{"trials":3528,"activeCount":100},[3529],{"nctId":3530,"briefTitle":3531,"status":799,"phases":3532,"primaryCompletion":3533,"completion":3534,"start":3535,"enrollment":100,"conditions":3536,"interventions":3537},"NCT00895336","Lactobacillus GG in Pediatric Ulcerative Colitis (UC)",[89],"2012-03","2012-10","2011-03",[908],[3521],{"trials":3539,"activeCount":100},[],{"trials":3541,"activeCount":100},[],{"trials":3543,"activeCount":100},[],{"intervention":3545,"totalTrials":217,"cells":3546},"Maraviroc",{"EARLY_PHASE1":3547,"PHASE1":3549,"PHASE2":3551,"PHASE3":3562,"PHASE4":3564,"NA":3566},{"trials":3548,"activeCount":100},[],{"trials":3550,"activeCount":100},[],{"trials":3552,"activeCount":100},[3553],{"nctId":3554,"briefTitle":3555,"status":423,"phases":3556,"primaryCompletion":3557,"completion":3557,"start":2179,"enrollment":2336,"conditions":3558,"interventions":3561},"NCT02167451","Maraviroc as GVHD Prophylaxis in Transplant Recipients",[88,89],"2018-09",[3559,3560],"Diagnoses That Require Stem Cell Transplant","Graft Versus Host Disease (GVHD)",[3545],{"trials":3563,"activeCount":100},[],{"trials":3565,"activeCount":100},[],{"trials":3567,"activeCount":100},[],{"intervention":3569,"totalTrials":217,"cells":3570},"Xylitol",{"EARLY_PHASE1":3571,"PHASE1":3573,"PHASE2":3575,"PHASE3":3585,"PHASE4":3587,"NA":3589},{"trials":3572,"activeCount":100},[],{"trials":3574,"activeCount":100},[],{"trials":3576,"activeCount":100},[3577],{"nctId":3578,"briefTitle":3579,"status":423,"phases":3580,"primaryCompletion":3581,"completion":3581,"start":3582,"enrollment":2932,"conditions":3583,"interventions":3584},"NCT04117477","Xylitol - Healthcare Associated Infection Reduction in Stem Cell Transplant Patients",[89],"2021-03-20","2019-09-27",[1428],[3569],{"trials":3586,"activeCount":100},[],{"trials":3588,"activeCount":100},[],{"trials":3590,"activeCount":100},[],{"intervention":2340,"totalTrials":217,"cells":3592},{"EARLY_PHASE1":3593,"PHASE1":3595,"PHASE2":3597,"PHASE3":3603,"PHASE4":3605,"NA":3607},{"trials":3594,"activeCount":100},[],{"trials":3596,"activeCount":100},[],{"trials":3598,"activeCount":100},[3599],{"nctId":2331,"briefTitle":2332,"status":169,"phases":3600,"primaryCompletion":600,"completion":2334,"start":2335,"enrollment":2336,"conditions":3601,"interventions":3602},[89],[2338],[2340,2341,2342,2343,2306],{"trials":3604,"activeCount":100},[],{"trials":3606,"activeCount":100},[],{"trials":3608,"activeCount":100},[],{"intervention":2343,"totalTrials":217,"cells":3610},{"EARLY_PHASE1":3611,"PHASE1":3613,"PHASE2":3615,"PHASE3":3621,"PHASE4":3623,"NA":3625},{"trials":3612,"activeCount":100},[],{"trials":3614,"activeCount":100},[],{"trials":3616,"activeCount":100},[3617],{"nctId":2331,"briefTitle":2332,"status":169,"phases":3618,"primaryCompletion":600,"completion":2334,"start":2335,"enrollment":2336,"conditions":3619,"interventions":3620},[89],[2338],[2340,2341,2342,2343,2306],{"trials":3622,"activeCount":100},[],{"trials":3624,"activeCount":100},[],{"trials":3626,"activeCount":100},[],{"intervention":3628,"totalTrials":217,"cells":3629},"N-acetylcysteine",{"EARLY_PHASE1":3630,"PHASE1":3632,"PHASE2":3634,"PHASE3":3645,"PHASE4":3647,"NA":3649},{"trials":3631,"activeCount":100},[],{"trials":3633,"activeCount":100},[],{"trials":3635,"activeCount":100},[3636],{"nctId":3637,"briefTitle":3638,"status":169,"phases":3639,"primaryCompletion":3640,"completion":3641,"start":3642,"enrollment":2905,"conditions":3643,"interventions":3644},"NCT04481035","Antioxidant Therapy With N-acetylcysteine for Learning and Motor Behavior in Children With Neurofibromatosis Type 1",[89],"2020-06-14","2021-12-16","2019-01-15",[1113],[3628],{"trials":3646,"activeCount":100},[],{"trials":3648,"activeCount":100},[],{"trials":3650,"activeCount":100},[],{"intervention":431,"totalTrials":217,"cells":3652},{"EARLY_PHASE1":3653,"PHASE1":3655,"PHASE2":3657,"PHASE3":3663,"PHASE4":3665,"NA":3667},{"trials":3654,"activeCount":100},[],{"trials":3656,"activeCount":100},[],{"trials":3658,"activeCount":100},[3659],{"nctId":421,"briefTitle":422,"status":423,"phases":3660,"primaryCompletion":425,"completion":425,"start":426,"enrollment":427,"conditions":3661,"interventions":3662},[89],[429],[431,412],{"trials":3664,"activeCount":100},[],{"trials":3666,"activeCount":100},[],{"trials":3668,"activeCount":100},[],{"intervention":2377,"totalTrials":217,"cells":3670},{"EARLY_PHASE1":3671,"PHASE1":3673,"PHASE2":3675,"PHASE3":3681,"PHASE4":3683,"NA":3685},{"trials":3672,"activeCount":100},[],{"trials":3674,"activeCount":100},[],{"trials":3676,"activeCount":100},[3677],{"nctId":2369,"briefTitle":2370,"status":169,"phases":3678,"primaryCompletion":2372,"completion":2372,"start":2373,"enrollment":1501,"conditions":3679,"interventions":3680},[89],[2375],[2360,2377,2378,2379,2380,2381],{"trials":3682,"activeCount":100},[],{"trials":3684,"activeCount":100},[],{"trials":3686,"activeCount":100},[],{"intervention":2378,"totalTrials":217,"cells":3688},{"EARLY_PHASE1":3689,"PHASE1":3691,"PHASE2":3693,"PHASE3":3699,"PHASE4":3701,"NA":3703},{"trials":3690,"activeCount":100},[],{"trials":3692,"activeCount":100},[],{"trials":3694,"activeCount":100},[3695],{"nctId":2369,"briefTitle":2370,"status":169,"phases":3696,"primaryCompletion":2372,"completion":2372,"start":2373,"enrollment":1501,"conditions":3697,"interventions":3698},[89],[2375],[2360,2377,2378,2379,2380,2381],{"trials":3700,"activeCount":100},[],{"trials":3702,"activeCount":100},[],{"trials":3704,"activeCount":100},[],{"intervention":2379,"totalTrials":217,"cells":3706},{"EARLY_PHASE1":3707,"PHASE1":3709,"PHASE2":3711,"PHASE3":3717,"PHASE4":3719,"NA":3721},{"trials":3708,"activeCount":100},[],{"trials":3710,"activeCount":100},[],{"trials":3712,"activeCount":100},[3713],{"nctId":2369,"briefTitle":2370,"status":169,"phases":3714,"primaryCompletion":2372,"completion":2372,"start":2373,"enrollment":1501,"conditions":3715,"interventions":3716},[89],[2375],[2360,2377,2378,2379,2380,2381],{"trials":3718,"activeCount":100},[],{"trials":3720,"activeCount":100},[],{"trials":3722,"activeCount":100},[],{"intervention":2380,"totalTrials":217,"cells":3724},{"EARLY_PHASE1":3725,"PHASE1":3727,"PHASE2":3729,"PHASE3":3735,"PHASE4":3737,"NA":3739},{"trials":3726,"activeCount":100},[],{"trials":3728,"activeCount":100},[],{"trials":3730,"activeCount":100},[3731],{"nctId":2369,"briefTitle":2370,"status":169,"phases":3732,"primaryCompletion":2372,"completion":2372,"start":2373,"enrollment":1501,"conditions":3733,"interventions":3734},[89],[2375],[2360,2377,2378,2379,2380,2381],{"trials":3736,"activeCount":100},[],{"trials":3738,"activeCount":100},[],{"trials":3740,"activeCount":100},[],{"intervention":2381,"totalTrials":217,"cells":3742},{"EARLY_PHASE1":3743,"PHASE1":3745,"PHASE2":3747,"PHASE3":3753,"PHASE4":3755,"NA":3757},{"trials":3744,"activeCount":100},[],{"trials":3746,"activeCount":100},[],{"trials":3748,"activeCount":100},[3749],{"nctId":2369,"briefTitle":2370,"status":169,"phases":3750,"primaryCompletion":2372,"completion":2372,"start":2373,"enrollment":1501,"conditions":3751,"interventions":3752},[89],[2375],[2360,2377,2378,2379,2380,2381],{"trials":3754,"activeCount":100},[],{"trials":3756,"activeCount":100},[],{"trials":3758,"activeCount":100},[],{"intervention":3760,"totalTrials":217,"cells":3761},"Tofacitinib",{"EARLY_PHASE1":3762,"PHASE1":3764,"PHASE2":3766,"PHASE3":3779,"PHASE4":3781,"NA":3783},{"trials":3763,"activeCount":100},[],{"trials":3765,"activeCount":100},[],{"trials":3767,"activeCount":100},[3768],{"nctId":3769,"briefTitle":3770,"status":169,"phases":3771,"primaryCompletion":3772,"completion":3773,"start":3774,"enrollment":27,"conditions":3775,"interventions":3778},"NCT03288324","Open-label Study of Tofacitinib for Moderate to Severe Skin Involvement in Young Adults With Lupus",[88,89],"2022-11-01","2023-12-01","2017-08-23",[3776,3777],"Cutaneous Lupus","Systemic Lupus Erythematosus",[3760],{"trials":3780,"activeCount":100},[],{"trials":3782,"activeCount":100},[],{"trials":3784,"activeCount":100},[],{"intervention":3786,"totalTrials":217,"cells":3787},"liraglutide",{"EARLY_PHASE1":3788,"PHASE1":3790,"PHASE2":3792,"PHASE3":3803,"PHASE4":3805,"NA":3807},{"trials":3789,"activeCount":100},[],{"trials":3791,"activeCount":100},[],{"trials":3793,"activeCount":100},[3794],{"nctId":3795,"briefTitle":3796,"status":169,"phases":3797,"primaryCompletion":878,"completion":878,"start":3798,"enrollment":2616,"conditions":3799,"interventions":3802},"NCT01832532","A Pilot Study of the Effects on Sleep Disordered Breathing (SDB) When Using the Drug Liraglutide for 4 Weeks",[88,89],"2013-04",[3800,3801],"Sleep Apnea","Sleep Disordered Breathing",[3786],{"trials":3804,"activeCount":100},[],{"trials":3806,"activeCount":100},[],{"trials":3808,"activeCount":100},[],{"intervention":3810,"totalTrials":217,"cells":3811},"TAVT-18",{"EARLY_PHASE1":3812,"PHASE1":3814,"PHASE2":3816,"PHASE3":3826,"PHASE4":3828,"NA":3830},{"trials":3813,"activeCount":100},[],{"trials":3815,"activeCount":100},[],{"trials":3817,"activeCount":100},[3818],{"nctId":3819,"briefTitle":3820,"status":169,"phases":3821,"primaryCompletion":3822,"completion":3822,"start":3823,"enrollment":2905,"conditions":3824,"interventions":3825},"NCT04595513","Stopping TSC Onset and Progression 2: Epilepsy Prevention in TSC Infants",[88,89],"2022-12-15","2020-09-08",[3248,2671],[3810],{"trials":3827,"activeCount":100},[],{"trials":3829,"activeCount":100},[],{"trials":3831,"activeCount":100},[],{"intervention":3833,"totalTrials":217,"cells":3834},"Amifostine",{"EARLY_PHASE1":3835,"PHASE1":3837,"PHASE2":3839,"PHASE3":3852,"PHASE4":3854,"NA":3856},{"trials":3836,"activeCount":100},[],{"trials":3838,"activeCount":100},[],{"trials":3840,"activeCount":100},[3841],{"nctId":3842,"briefTitle":3843,"status":423,"phases":3844,"primaryCompletion":3845,"completion":3846,"start":3847,"enrollment":96,"conditions":3848,"interventions":3851},"NCT05167370","High Dose Chemotherapy With Amifostine and Autologous Stem Cell Transplantation for High Risk Relapsed Pediatric Solid Tumors and Brain Tumors",[89],"2011-04-29","2012-04-24","2010-12-13",[3849,3850],"Solid Tumors","Brain Tumors",[3833],{"trials":3853,"activeCount":100},[],{"trials":3855,"activeCount":100},[],{"trials":3857,"activeCount":100},[],{"intervention":3859,"totalTrials":217,"cells":3860},"Eculizumab",{"EARLY_PHASE1":3861,"PHASE1":3863,"PHASE2":3865,"PHASE3":3880,"PHASE4":3882,"NA":3884},{"trials":3862,"activeCount":100},[],{"trials":3864,"activeCount":100},[],{"trials":3866,"activeCount":100},[3867],{"nctId":3868,"briefTitle":3869,"status":169,"phases":3870,"primaryCompletion":3871,"completion":3872,"start":3873,"enrollment":3874,"conditions":3875,"interventions":3879},"NCT03518203","Eculizumab to Treat Thrombotic Microangiopathy\u002FAtypical Hemolytic Uremic Syndrome -Associated Multiple Organ Dysfunction Syndrome in Hematopoietic Stem Cell Transplant Recipients",[89],"2022-04-04","2022-06-01","2018-08-03",23,[3876,3877,3878],"Thrombotic Microangiopathies","Atypical Hemolytic Uremic Syndrome","Multiple Organ Dysfunction Syndrome",[3859],{"trials":3881,"activeCount":100},[],{"trials":3883,"activeCount":100},[],{"trials":3885,"activeCount":100},[],{"intervention":2393,"totalTrials":217,"cells":3887},{"EARLY_PHASE1":3888,"PHASE1":3890,"PHASE2":3892,"PHASE3":3898,"PHASE4":3900,"NA":3902},{"trials":3889,"activeCount":100},[],{"trials":3891,"activeCount":100},[],{"trials":3893,"activeCount":100},[3894],{"nctId":2383,"briefTitle":2384,"status":169,"phases":3895,"completion":2386,"start":2387,"enrollment":2388,"conditions":3896,"interventions":3897},[89],[2390,2391],[2393,2394,2395],{"trials":3899,"activeCount":100},[],{"trials":3901,"activeCount":100},[],{"trials":3903,"activeCount":100},[],{"intervention":3905,"totalTrials":217,"cells":3906},"Metformin",{"EARLY_PHASE1":3907,"PHASE1":3909,"PHASE2":3911,"PHASE3":3924,"PHASE4":3926,"NA":3928},{"trials":3908,"activeCount":100},[],{"trials":3910,"activeCount":100},[],{"trials":3912,"activeCount":100},[3913],{"nctId":3914,"briefTitle":3915,"status":169,"phases":3916,"primaryCompletion":3917,"completion":3917,"start":578,"enrollment":24,"conditions":3918,"interventions":3923},"NCT02179788","Metformin to Augment Low Milk Supply (MALMS) Study",[88,89],"2016-07",[3919,3920,3921,3922],"Low Milk Supply","Pre-diabetes","Insulin Resistance","Suppressed Lactation",[3905],{"trials":3925,"activeCount":100},[],{"trials":3927,"activeCount":100},[],{"trials":3929,"activeCount":100},[],{"intervention":3931,"totalTrials":217,"cells":3932},"Bortezomib",{"EARLY_PHASE1":3933,"PHASE1":3935,"PHASE2":3937,"PHASE3":3947,"PHASE4":3949,"NA":3951},{"trials":3934,"activeCount":100},[],{"trials":3936,"activeCount":100},[],{"trials":3938,"activeCount":100},[3939],{"nctId":3940,"briefTitle":3941,"status":169,"phases":3942,"primaryCompletion":2749,"completion":2749,"start":1466,"enrollment":162,"conditions":3943,"interventions":3946},"NCT01929980","Bortezomib to Treat Significant Complication of HSCT",[89],[3944,3945],"Allogeneic Stem Cell Transplantation","Refractory Autoimmune Cytopenia(s)",[3931],{"trials":3948,"activeCount":100},[],{"trials":3950,"activeCount":100},[],{"trials":3952,"activeCount":100},[],{"intervention":3954,"totalTrials":217,"cells":3955},"Mepolizumab",{"EARLY_PHASE1":3956,"PHASE1":3958,"PHASE2":3960,"PHASE3":3972,"PHASE4":3974,"NA":3976},{"trials":3957,"activeCount":100},[],{"trials":3959,"activeCount":100},[],{"trials":3961,"activeCount":100},[3962],{"nctId":3963,"briefTitle":3964,"status":169,"phases":3965,"primaryCompletion":3966,"completion":3966,"start":3500,"enrollment":870,"conditions":3967,"interventions":3971},"NCT00266565","Anti-Interleukin-5 (IL-5) Study for Hypereosinophilic Syndrome",[88,89],"2005-04",[3968,3969,3970,34],"Hypereosinophilic Syndromes","Eosinophilic Gastroenteritis","Churg-Strauss Syndrome",[3954],{"trials":3973,"activeCount":100},[],{"trials":3975,"activeCount":100},[],{"trials":3977,"activeCount":100},[],{"intervention":3979,"totalTrials":217,"cells":3980},"Norditropin",{"EARLY_PHASE1":3981,"PHASE1":3983,"PHASE2":3985,"PHASE3":3997,"PHASE4":3999,"NA":4001},{"trials":3982,"activeCount":100},[],{"trials":3984,"activeCount":100},[],{"trials":3986,"activeCount":100},[3987],{"nctId":3988,"briefTitle":3989,"status":169,"phases":3990,"primaryCompletion":3991,"completion":3992,"start":3993,"enrollment":1944,"conditions":3994,"interventions":3996},"NCT03288103","Growth Hormone Treatment in Patients With Aggrecan (ACAN) Deficiency",[88,89],"2023-03-31","2023-08-31","2018-02-01",[3995],"Short Stature",[3979],{"trials":3998,"activeCount":100},[],{"trials":4000,"activeCount":100},[],{"trials":4002,"activeCount":100},[],{"intervention":4004,"totalTrials":217,"cells":4005},"oral dipyridamole, oral magnesium, or a combination of both",{"EARLY_PHASE1":4006,"PHASE1":4008,"PHASE2":4010,"PHASE3":4019,"PHASE4":4021,"NA":4023},{"trials":4007,"activeCount":100},[],{"trials":4009,"activeCount":100},[],{"trials":4011,"activeCount":100},[4012],{"nctId":4013,"briefTitle":4014,"status":799,"phases":4015,"start":4016,"enrollment":100,"conditions":4017,"interventions":4018},"NCT00276146","Dipyridamole\u002FMagnesium To Improve Sickle Cell Hydration",[89],"2005-05",[624],[4004],{"trials":4020,"activeCount":100},[],{"trials":4022,"activeCount":100},[],{"trials":4024,"activeCount":100},[],{"intervention":4026,"totalTrials":217,"cells":4027},"Sildenafil",{"EARLY_PHASE1":4028,"PHASE1":4030,"PHASE2":4032,"PHASE3":4045,"PHASE4":4047,"NA":4049},{"trials":4029,"activeCount":100},[],{"trials":4031,"activeCount":100},[],{"trials":4033,"activeCount":100},[4034],{"nctId":4035,"briefTitle":4036,"status":799,"phases":4037,"primaryCompletion":4038,"completion":4038,"start":1403,"enrollment":100,"conditions":4039,"interventions":4044},"NCT01194232","Sildenafil Trial in Children and Young Adults With CF",[88,89],"2012-12",[4040,4041,4042,4043],"Cystic Fibrosis With Mild to Moderate Lung Disease","CMRI of Lung Perfusion","Lung Perfusion","Lung Vascularization",[4026],{"trials":4046,"activeCount":100},[],{"trials":4048,"activeCount":100},[],{"trials":4050,"activeCount":100},[],{"intervention":4052,"totalTrials":217,"cells":4053},"RAD001",{"EARLY_PHASE1":4054,"PHASE1":4056,"PHASE2":4058,"PHASE3":4067,"PHASE4":4069,"NA":4071},{"trials":4055,"activeCount":100},[],{"trials":4057,"activeCount":100},[],{"trials":4059,"activeCount":100},[4060],{"nctId":4061,"briefTitle":4062,"status":169,"phases":4063,"primaryCompletion":2178,"completion":2178,"start":1404,"enrollment":880,"conditions":4064,"interventions":4066},"NCT00457964","RAD001 Therapy of Angiomyolipomata in Patients With TS Complex and Sporadic LAM",[88,89],[3238,4065],"Lymphangioleiomyomatosis",[4052],{"trials":4068,"activeCount":100},[],{"trials":4070,"activeCount":100},[],{"trials":4072,"activeCount":100},[],{"intervention":4074,"totalTrials":217,"cells":4075},"Treprostinil",{"EARLY_PHASE1":4076,"PHASE1":4078,"PHASE2":4080,"PHASE3":4090,"PHASE4":4092,"NA":4094},{"trials":4077,"activeCount":100},[],{"trials":4079,"activeCount":100},[],{"trials":4081,"activeCount":100},[4082],{"nctId":4083,"briefTitle":4084,"status":423,"phases":4085,"primaryCompletion":4086,"completion":4086,"start":4087,"enrollment":24,"conditions":4088,"interventions":4089},"NCT02769624","Acute Effects of Inhaled Treprostinil in Fontan Patients",[89],"2018-09-21","2017-02-21",[2864],[4074],{"trials":4091,"activeCount":100},[],{"trials":4093,"activeCount":100},[],{"trials":4095,"activeCount":100},[],{"intervention":4097,"totalTrials":217,"cells":4098},"Hp 129Xenon",{"EARLY_PHASE1":4099,"PHASE1":4101,"PHASE2":4103,"PHASE3":4114,"PHASE4":4116,"NA":4118},{"trials":4100,"activeCount":100},[],{"trials":4102,"activeCount":100},[],{"trials":4104,"activeCount":100},[4105],{"nctId":4106,"briefTitle":4107,"status":169,"phases":4108,"primaryCompletion":4109,"completion":4109,"start":4110,"enrollment":491,"conditions":4111,"interventions":4113},"NCT03603899","Hp129 Xenon Imaging and BOS in Lung Transplantation",[88,89],"2024-05-28","2020-09-09",[4112],"Bronchiolitis Obliterans",[4097],{"trials":4115,"activeCount":100},[],{"trials":4117,"activeCount":100},[],{"trials":4119,"activeCount":100},[],{"intervention":4121,"totalTrials":217,"cells":4122},"IGF-1",{"EARLY_PHASE1":4123,"PHASE1":4125,"PHASE2":4127,"PHASE3":4136,"PHASE4":4138,"NA":4140},{"trials":4124,"activeCount":100},[],{"trials":4126,"activeCount":100},[],{"trials":4128,"activeCount":100},[4129],{"nctId":4130,"briefTitle":4131,"status":169,"phases":4132,"primaryCompletion":3534,"completion":4133,"start":2751,"enrollment":126,"conditions":4134,"interventions":4135},"NCT01207908","Safety and Efficacy Study of IGF-1 in Duchenne Muscular Dystrophy",[88,89],"2013-06",[2111],[4121],{"trials":4137,"activeCount":100},[],{"trials":4139,"activeCount":100},[],{"trials":4141,"activeCount":100},[],{"intervention":4143,"totalTrials":217,"cells":4144},"Increlex",{"EARLY_PHASE1":4145,"PHASE1":4147,"PHASE2":4149,"PHASE3":4160,"PHASE4":4162,"NA":4164},{"trials":4146,"activeCount":100},[],{"trials":4148,"activeCount":100},[],{"trials":4150,"activeCount":100},[4151],{"nctId":4152,"briefTitle":4153,"status":169,"phases":4154,"primaryCompletion":4155,"completion":4156,"start":4157,"enrollment":3300,"conditions":4158,"interventions":4159},"NCT02636270","IGF-1 Treatment for Individuals With Short Stature Due to PAPP-A2 Deficiency",[88,89],"2022-10-14","2022-12-01","2015-12-21",[3995],[4143],{"trials":4161,"activeCount":100},[],{"trials":4163,"activeCount":100},[],{"trials":4165,"activeCount":100},[],{"intervention":4167,"totalTrials":217,"cells":4168},"AMD3100",{"EARLY_PHASE1":4169,"PHASE1":4171,"PHASE2":4173,"PHASE3":4183,"PHASE4":4185,"NA":4187},{"trials":4170,"activeCount":100},[],{"trials":4172,"activeCount":100},[],{"trials":4174,"activeCount":100},[4175],{"nctId":4176,"briefTitle":4177,"status":169,"phases":4178,"primaryCompletion":4179,"completion":4179,"start":4180,"enrollment":217,"conditions":4181,"interventions":4182},"NCT00479115","Mobilization and Collection of Peripheral Blood Stem Cells in Patients With Fanconi Anemia Using G-CSF and AMD3100",[88,89],"2010-12","2007-05",[723],[4167],{"trials":4184,"activeCount":100},[],{"trials":4186,"activeCount":100},[],{"trials":4188,"activeCount":100},[],{"intervention":4190,"totalTrials":217,"cells":4191},"growth hormone",{"EARLY_PHASE1":4192,"PHASE1":4194,"PHASE2":4196,"PHASE3":4207,"PHASE4":4209,"NA":4211},{"trials":4193,"activeCount":100},[],{"trials":4195,"activeCount":100},[],{"trials":4197,"activeCount":100},[4198],{"nctId":4199,"briefTitle":4200,"status":169,"phases":4201,"primaryCompletion":4202,"completion":4203,"start":3966,"enrollment":1944,"conditions":4204,"interventions":4205},"NCT00109473","Trial of Growth Hormone Therapy in Pediatric Crohn's Disease",[89],"2009-07","2009-08",[535],[4190,4206],"cortecosteroid",{"trials":4208,"activeCount":100},[],{"trials":4210,"activeCount":100},[],{"trials":4212,"activeCount":100},[],{"intervention":4206,"totalTrials":217,"cells":4214},{"EARLY_PHASE1":4215,"PHASE1":4217,"PHASE2":4219,"PHASE3":4225,"PHASE4":4227,"NA":4229},{"trials":4216,"activeCount":100},[],{"trials":4218,"activeCount":100},[],{"trials":4220,"activeCount":100},[4221],{"nctId":4199,"briefTitle":4200,"status":169,"phases":4222,"primaryCompletion":4202,"completion":4203,"start":3966,"enrollment":1944,"conditions":4223,"interventions":4224},[89],[535],[4190,4206],{"trials":4226,"activeCount":100},[],{"trials":4228,"activeCount":100},[],{"trials":4230,"activeCount":100},[],{"intervention":4232,"totalTrials":217,"cells":4233},"Dupilumab",{"EARLY_PHASE1":4234,"PHASE1":4236,"PHASE2":4238,"PHASE3":4251,"PHASE4":4253,"NA":4255},{"trials":4235,"activeCount":100},[],{"trials":4237,"activeCount":100},[],{"trials":4239,"activeCount":100},[4240],{"nctId":4241,"briefTitle":4242,"status":169,"phases":4243,"primaryCompletion":4244,"completion":4245,"start":4246,"enrollment":4247,"conditions":4248,"interventions":4250},"NCT03678545","Dupilumab in Eosinophilic Gastritis",[89],"2024-03-04","2024-11-13","2021-05-15",41,[4249,3969],"Eosinophilic Gastritis",[4232],{"trials":4252,"activeCount":100},[],{"trials":4254,"activeCount":100},[],{"trials":4256,"activeCount":100},[],{"intervention":4258,"totalTrials":217,"cells":4259},"Intravenous acetaminophen",{"EARLY_PHASE1":4260,"PHASE1":4262,"PHASE2":4264,"PHASE3":4277,"PHASE4":4279,"NA":4281},{"trials":4261,"activeCount":100},[],{"trials":4263,"activeCount":100},[],{"trials":4265,"activeCount":100},[4266],{"nctId":4267,"briefTitle":4268,"status":799,"phases":4269,"primaryCompletion":4270,"completion":4271,"start":4272,"enrollment":100,"conditions":4273,"interventions":4276},"NCT03883893","IV Acetaminophen and Post-Tonsillectomy Pain",[89],"2022-10","2023-04","2021-12",[4274,4275],"Tonsillectomy","Adenoidectomy",[4258],{"trials":4278,"activeCount":100},[],{"trials":4280,"activeCount":100},[],{"trials":4282,"activeCount":100},[],{"intervention":4284,"totalTrials":217,"cells":4285},"ARU-1801",{"EARLY_PHASE1":4286,"PHASE1":4288,"PHASE2":4290,"PHASE3":4299,"PHASE4":4301,"NA":4303},{"trials":4287,"activeCount":100},[],{"trials":4289,"activeCount":100},[],{"trials":4291,"activeCount":100},[4292],{"nctId":4293,"briefTitle":4294,"status":423,"phases":4295,"primaryCompletion":4296,"completion":4296,"start":2179,"enrollment":3300,"conditions":4297,"interventions":4298},"NCT02186418","Gene Transfer for Patients With Sickle Cell Disease",[88,89],"2022-10-31",[624],[4284],{"trials":4300,"activeCount":100},[],{"trials":4302,"activeCount":100},[],{"trials":4304,"activeCount":100},[],{"intervention":4306,"totalTrials":217,"cells":4307},"Pioglitazone hydrochloride",{"EARLY_PHASE1":4308,"PHASE1":4310,"PHASE2":4312,"PHASE3":4324,"PHASE4":4326,"NA":4328},{"trials":4309,"activeCount":100},[],{"trials":4311,"activeCount":100},[],{"trials":4313,"activeCount":100},[4314],{"nctId":4315,"briefTitle":4316,"status":169,"phases":4317,"primaryCompletion":521,"completion":4318,"start":4319,"enrollment":30,"conditions":4320,"interventions":4323},"NCT01352182","Pharmacokinetic and Biomarker Study of Pioglitazone in Adolescents With Severe Sepsis and Septic Shock",[88,89],"2017-01","2011-10",[4321,4322],"Severe Sepsis","Septic Shock",[4306],{"trials":4325,"activeCount":100},[],{"trials":4327,"activeCount":100},[],{"trials":4329,"activeCount":100},[],{"intervention":4331,"totalTrials":217,"cells":4332},"Isosorbide Dinitrate",{"EARLY_PHASE1":4333,"PHASE1":4335,"PHASE2":4337,"PHASE3":4347,"PHASE4":4349,"NA":4351},{"trials":4334,"activeCount":100},[],{"trials":4336,"activeCount":100},[],{"trials":4338,"activeCount":100},[4339],{"nctId":4340,"briefTitle":4341,"status":169,"phases":4342,"primaryCompletion":2085,"completion":4343,"start":4344,"enrollment":1345,"conditions":4345,"interventions":4346},"NCT04297241","Nitrate Effect on Exercise Capacitance",[89],"2021-05-03","2019-12-12",[2157],[4331],{"trials":4348,"activeCount":100},[],{"trials":4350,"activeCount":100},[],{"trials":4352,"activeCount":100},[],{"intervention":4354,"totalTrials":217,"cells":4355},"Leukine",{"EARLY_PHASE1":4356,"PHASE1":4358,"PHASE2":4360,"PHASE3":4368,"PHASE4":4370,"NA":4372},{"trials":4357,"activeCount":100},[],{"trials":4359,"activeCount":100},[],{"trials":4361,"activeCount":100},[4362],{"nctId":4363,"briefTitle":4364,"status":169,"phases":4365,"primaryCompletion":2178,"completion":2179,"start":1403,"enrollment":96,"conditions":4366,"interventions":4367},"NCT01511068","Inhaled Granulocyte-Macrophage Colony Stimulating Factor (GM-CSF) in Hereditary Pulmonary Alveolar Proteinosis (PAP)",[89],[1234],[4354],{"trials":4369,"activeCount":100},[],{"trials":4371,"activeCount":100},[],{"trials":4373,"activeCount":100},[],{"intervention":4375,"totalTrials":217,"cells":4376},"Selumetinib",{"EARLY_PHASE1":4377,"PHASE1":4379,"PHASE2":4381,"PHASE3":4396,"PHASE4":4398,"NA":4400},{"trials":4378,"activeCount":100},[],{"trials":4380,"activeCount":100},[],{"trials":4382,"activeCount":100},[4383],{"nctId":4384,"briefTitle":4385,"status":423,"phases":4386,"primaryCompletion":4387,"completion":4387,"start":4388,"enrollment":2043,"conditions":4389,"interventions":4395},"NCT03095248","Trial of Selumetinib in Patients With Neurofibromatosis Type II Related Tumors",[89],"2024-05-21","2017-05-08",[4390,4391,4392,4393,4394],"Neurofibromatosis 2","Vestibular Schwannoma","Meningioma","Ependymoma","Glioma",[4375],{"trials":4397,"activeCount":100},[],{"trials":4399,"activeCount":100},[],{"trials":4401,"activeCount":100},[],{"intervention":4403,"totalTrials":217,"cells":4404},"CD34+",{"EARLY_PHASE1":4405,"PHASE1":4407,"PHASE2":4409,"PHASE3":4422,"PHASE4":4424,"NA":4426},{"trials":4406,"activeCount":100},[],{"trials":4408,"activeCount":100},[],{"trials":4410,"activeCount":100},[4411],{"nctId":4412,"briefTitle":4413,"status":423,"phases":4414,"primaryCompletion":4415,"completion":4415,"start":2487,"enrollment":3874,"conditions":4416,"interventions":4421},"NCT01856582","CD34+ Stem Cell Infusion to Augment Graft Function",[89],"2018-08-15",[4417,4418,4419,4420],"Waning Donor Chimerism","Waning Immune Function","Primary Immunodeficiency Disease(s)","Bone Marrow Failure",[4403],{"trials":4423,"activeCount":100},[],{"trials":4425,"activeCount":100},[],{"trials":4427,"activeCount":100},[],{"intervention":4429,"totalTrials":217,"cells":4430},"Triptorelin pamoate",{"EARLY_PHASE1":4431,"PHASE1":4433,"PHASE2":4435,"PHASE3":4446,"PHASE4":4448,"NA":4450},{"trials":4432,"activeCount":100},[],{"trials":4434,"activeCount":100},[],{"trials":4436,"activeCount":100},[4437],{"nctId":4438,"briefTitle":4439,"status":169,"phases":4440,"primaryCompletion":4441,"completion":4441,"start":4442,"enrollment":2336,"conditions":4443,"interventions":4444},"NCT00124514","Triptorelin for Ovary Protection in Childhood Onset Lupus",[89],"2014-03","2003-06",[3777],[4429,4445,4445,4445],"Triptorelin Pamoate",{"trials":4447,"activeCount":100},[],{"trials":4449,"activeCount":100},[],{"trials":4451,"activeCount":100},[],{"intervention":4453,"totalTrials":217,"cells":4454},"Expecta 200 mg",{"EARLY_PHASE1":4455,"PHASE1":4457,"PHASE2":4459,"PHASE3":4472,"PHASE4":4474,"NA":4476},{"trials":4456,"activeCount":100},[],{"trials":4458,"activeCount":100},[],{"trials":4460,"activeCount":100},[4461],{"nctId":4462,"briefTitle":4463,"status":169,"phases":4464,"primaryCompletion":4465,"completion":4465,"start":4466,"enrollment":4467,"conditions":4468,"interventions":4470},"NCT01732874","DHA Supplementation for Lactating Mothers",[88,89],"2018-07-16","2013-05",27,[4469],"Docosohexaenoic Acid Supplementation of Mothers to",[4453,4471],"Expecta 1 gram",{"trials":4473,"activeCount":100},[],{"trials":4475,"activeCount":100},[],{"trials":4477,"activeCount":100},[],{"intervention":4471,"totalTrials":217,"cells":4479},{"EARLY_PHASE1":4480,"PHASE1":4482,"PHASE2":4484,"PHASE3":4490,"PHASE4":4492,"NA":4494},{"trials":4481,"activeCount":100},[],{"trials":4483,"activeCount":100},[],{"trials":4485,"activeCount":100},[4486],{"nctId":4462,"briefTitle":4463,"status":169,"phases":4487,"primaryCompletion":4465,"completion":4465,"start":4466,"enrollment":4467,"conditions":4488,"interventions":4489},[88,89],[4469],[4453,4471],{"trials":4491,"activeCount":100},[],{"trials":4493,"activeCount":100},[],{"trials":4495,"activeCount":100},[],{"intervention":4497,"totalTrials":217,"cells":4498},"Rapamycin, sirolimus",{"EARLY_PHASE1":4499,"PHASE1":4501,"PHASE2":4503,"PHASE3":4513,"PHASE4":4515,"NA":4517},{"trials":4500,"activeCount":100},[],{"trials":4502,"activeCount":100},[],{"trials":4504,"activeCount":100},[4505],{"nctId":4506,"briefTitle":4507,"status":169,"phases":4508,"completion":4509,"start":4510,"enrollment":1772,"conditions":4511,"interventions":4512},"NCT00457808","Rapamycin Therapy for Patients With Tuberous Sclerosis Complex and Sporadic LAM",[89],"2006-03","2002-12",[3238,4065],[4497],{"trials":4514,"activeCount":100},[],{"trials":4516,"activeCount":100},[],{"trials":4518,"activeCount":100},[],{"intervention":4520,"totalTrials":217,"cells":4521},"TCRαβ+\u002FCD19+ depleted allogeneic hematopoietic stem cell transplant",{"EARLY_PHASE1":4522,"PHASE1":4524,"PHASE2":4526,"PHASE3":4537,"PHASE4":4539,"NA":4541},{"trials":4523,"activeCount":100},[],{"trials":4525,"activeCount":100},[],{"trials":4527,"activeCount":100},[4528],{"nctId":4529,"briefTitle":4530,"status":423,"phases":4531,"primaryCompletion":4532,"completion":4533,"start":4534,"enrollment":24,"conditions":4535,"interventions":4536},"NCT04088760","TCRαβ+\u002FCD19+ Depleted Allogeneic Hematopoietic Stem Cell Transplantation for Malignant and Non-malignant Disorders",[89],"2021-05-14","2021-09-03","2019-09-16",[1428],[4520],{"trials":4538,"activeCount":100},[],{"trials":4540,"activeCount":100},[],{"trials":4542,"activeCount":100},[],{"intervention":939,"totalTrials":491,"cells":4544},{"EARLY_PHASE1":4545,"PHASE1":4551,"PHASE2":4571,"PHASE3":4573,"PHASE4":4575,"NA":4577},{"trials":4546,"activeCount":100},[4547],{"nctId":931,"briefTitle":932,"status":169,"phases":4548,"primaryCompletion":934,"completion":934,"start":935,"enrollment":9,"conditions":4549,"interventions":4550},[87],[937],[939,940,941,61],{"trials":4552,"activeCount":100},[4553,4562],{"nctId":4554,"briefTitle":4555,"status":169,"phases":4556,"primaryCompletion":4557,"completion":4557,"start":4558,"enrollment":880,"conditions":4559,"interventions":4561},"NCT01813318","Study of Acamprosate in Autism",[88],"2017-09-07","2013-07-02",[4560],"Autistic Disorder",[939],{"nctId":4563,"briefTitle":4564,"status":169,"phases":4565,"primaryCompletion":4566,"completion":4566,"start":4567,"enrollment":2932,"conditions":4568,"interventions":4569},"NCT01911455","Study of Acamprosate in Fragile x Syndrome",[88],"2018-11-08","2013-08-27",[937],[4570],"acamprosate",{"trials":4572,"activeCount":100},[],{"trials":4574,"activeCount":100},[],{"trials":4576,"activeCount":100},[],{"trials":4578,"activeCount":100},[],{"intervention":4580,"totalTrials":96,"cells":4581},"Pembrolizumab",{"EARLY_PHASE1":4582,"PHASE1":4599,"PHASE2":4613,"PHASE3":4615,"PHASE4":4617,"NA":4619},{"trials":4583,"activeCount":100},[4584],{"nctId":4585,"briefTitle":4586,"status":169,"phases":4587,"primaryCompletion":4588,"completion":4588,"start":4589,"enrollment":1944,"conditions":4590,"interventions":4597},"NCT03445858","Pembrolizumab in Combination With Decitabine and Hypofractionated Index Lesion Radiation in Pediatrics and Young Adults",[87],"2023-11-07","2018-02-12",[4591,4592,4593,4594,4595,4596],"Childhood Solid Tumor","Childhood Lymphoma","Relapsed Cancer","Refractory Cancer","Adult Solid Tumor","Adult Lymphoma",[4580,4598],"Decitabine",{"trials":4600,"activeCount":100},[4601],{"nctId":4602,"briefTitle":4603,"status":799,"phases":4604,"primaryCompletion":4605,"completion":4606,"start":4607,"enrollment":100,"conditions":4608,"interventions":4611},"NCT03605589","Pembro + Blina Combination in Pediatric and Young Adult Patients With Relapsed\u002FRefractory Acute Leukemia or Lymphoma",[88],"2021-08","2022-01","2018-09-27",[4609,4610],"Leukemia, B-cell","Lymphoma, B-Cell",[4612,4580],"Blinatumomab",{"trials":4614,"activeCount":100},[],{"trials":4616,"activeCount":100},[],{"trials":4618,"activeCount":100},[],{"trials":4620,"activeCount":100},[],{"intervention":4622,"totalTrials":96,"cells":4623},"Bevacizumab",{"EARLY_PHASE1":4624,"PHASE1":4636,"PHASE2":4649,"PHASE3":4651,"PHASE4":4653,"NA":4655},{"trials":4625,"activeCount":100},[4626],{"nctId":4627,"briefTitle":4628,"status":169,"phases":4629,"primaryCompletion":621,"completion":1931,"start":4630,"enrollment":4467,"conditions":4631,"interventions":4633},"NCT00890786","A Study of Bevacizumab Therapy in Patients With Newly Diagnosed High-Grade Gliomas and Diffuse Intrinsic Pontine Gliomas",[87],"2009-05",[4632,3222],"Newly Diagnosed High-Grade Gliomas",[4634,4622,4635],"Temozolomide","Irinotecan",{"trials":4637,"activeCount":100},[4638],{"nctId":4639,"briefTitle":4640,"status":169,"phases":4641,"primaryCompletion":4642,"completion":4642,"start":4643,"enrollment":27,"conditions":4644,"interventions":4646},"NCT00786669","A Pilot Study of the Addition of Bevacizumab to VOIT Regimen for Relapsed\u002FRefractory Pediatric Solid Tumors",[88],"2012-11","2008-10",[4645],"Solid Tumor",[4622,4634,4647,4635,4648],"Vincristine","Cefixime",{"trials":4650,"activeCount":100},[],{"trials":4652,"activeCount":100},[],{"trials":4654,"activeCount":100},[],{"trials":4656,"activeCount":100},[],{"intervention":4635,"totalTrials":96,"cells":4658},{"EARLY_PHASE1":4659,"PHASE1":4665,"PHASE2":4671,"PHASE3":4673,"PHASE4":4675,"NA":4677},{"trials":4660,"activeCount":100},[4661],{"nctId":4627,"briefTitle":4628,"status":169,"phases":4662,"primaryCompletion":621,"completion":1931,"start":4630,"enrollment":4467,"conditions":4663,"interventions":4664},[87],[4632,3222],[4634,4622,4635],{"trials":4666,"activeCount":100},[4667],{"nctId":4639,"briefTitle":4640,"status":169,"phases":4668,"primaryCompletion":4642,"completion":4642,"start":4643,"enrollment":27,"conditions":4669,"interventions":4670},[88],[4645],[4622,4634,4647,4635,4648],{"trials":4672,"activeCount":100},[],{"trials":4674,"activeCount":100},[],{"trials":4676,"activeCount":100},[],{"trials":4678,"activeCount":100},[],{"intervention":4680,"totalTrials":96,"cells":4681},"Micafungin",{"EARLY_PHASE1":4682,"PHASE1":4684,"PHASE2":4704,"PHASE3":4706,"PHASE4":4708,"NA":4710},{"trials":4683,"activeCount":100},[],{"trials":4685,"activeCount":100},[4686,4695],{"nctId":4687,"briefTitle":4688,"status":169,"phases":4689,"primaryCompletion":4690,"completion":4690,"start":4691,"enrollment":24,"conditions":4692,"interventions":4694},"NCT00842504","Alternate Day Micafungin: A PK Study in Pediatric Patients",[88],"2009-12","2007-07",[4693],"Fungal Infection",[4680],{"nctId":4696,"briefTitle":4697,"status":423,"phases":4698,"primaryCompletion":1932,"completion":1932,"start":609,"enrollment":540,"conditions":4699,"interventions":4703},"NCT02057289","A Pharmacokinetic Study of Pediatric Micafungin Prophylaxis",[88],[4700,4701,4702],"Immunocompromised","Bone Marrow Transplant","Cancer",[4680],{"trials":4705,"activeCount":100},[],{"trials":4707,"activeCount":100},[],{"trials":4709,"activeCount":100},[],{"trials":4711,"activeCount":100},[],{"intervention":941,"totalTrials":96,"cells":4713},{"EARLY_PHASE1":4714,"PHASE1":4720,"PHASE2":4726,"PHASE3":4728,"PHASE4":4730,"NA":4732},{"trials":4715,"activeCount":100},[4716],{"nctId":931,"briefTitle":932,"status":169,"phases":4717,"primaryCompletion":934,"completion":934,"start":935,"enrollment":9,"conditions":4718,"interventions":4719},[87],[937],[939,940,941,61],{"trials":4721,"activeCount":100},[4722],{"nctId":3468,"briefTitle":3469,"status":169,"phases":4723,"primaryCompletion":3471,"completion":3471,"start":3472,"enrollment":2017,"conditions":4724,"interventions":4725},[88],[15,3474],[941,3359],{"trials":4727,"activeCount":100},[],{"trials":4729,"activeCount":100},[],{"trials":4731,"activeCount":100},[],{"trials":4733,"activeCount":100},[],{"intervention":4612,"totalTrials":217,"cells":4735},{"EARLY_PHASE1":4736,"PHASE1":4738,"PHASE2":4744,"PHASE3":4746,"PHASE4":4748,"NA":4750},{"trials":4737,"activeCount":100},[],{"trials":4739,"activeCount":100},[4740],{"nctId":4602,"briefTitle":4603,"status":799,"phases":4741,"primaryCompletion":4605,"completion":4606,"start":4607,"enrollment":100,"conditions":4742,"interventions":4743},[88],[4609,4610],[4612,4580],{"trials":4745,"activeCount":100},[],{"trials":4747,"activeCount":100},[],{"trials":4749,"activeCount":100},[],{"trials":4751,"activeCount":100},[],{"intervention":4753,"totalTrials":217,"cells":4754},"Oxandrolone",{"EARLY_PHASE1":4755,"PHASE1":4757,"PHASE2":4765,"PHASE3":4767,"PHASE4":4769,"NA":4771},{"trials":4756,"activeCount":100},[],{"trials":4758,"activeCount":100},[4759],{"nctId":4760,"briefTitle":4761,"status":169,"phases":4762,"primaryCompletion":4690,"completion":3246,"start":2666,"enrollment":2043,"conditions":4763,"interventions":4764},"NCT00243399","Oxandrolone for the Treatment of Bone Marrow Aplasia in Fanconi Anemia",[88],[723],[4753],{"trials":4766,"activeCount":100},[],{"trials":4768,"activeCount":100},[],{"trials":4770,"activeCount":100},[],{"trials":4772,"activeCount":100},[],{"intervention":4774,"totalTrials":217,"cells":4775},"Pioglitazone",{"EARLY_PHASE1":4776,"PHASE1":4778,"PHASE2":4789,"PHASE3":4791,"PHASE4":4793,"NA":4795},{"trials":4777,"activeCount":100},[],{"trials":4779,"activeCount":100},[4780],{"nctId":4781,"briefTitle":4782,"status":169,"phases":4783,"primaryCompletion":4784,"completion":4784,"start":4785,"enrollment":491,"conditions":4786,"interventions":4788},"NCT03231033","Pioglitazone Therapy of Autoimmune Pulmonary Alveolar Proteinosis Autoimmune Pulmonary Alveolar Proteinosis",[88],"2019-04-02","2017-08-17",[4787],"Autoimmune Pulmonary Alveolar Proteinosis",[4774],{"trials":4790,"activeCount":100},[],{"trials":4792,"activeCount":100},[],{"trials":4794,"activeCount":100},[],{"trials":4796,"activeCount":100},[],{"intervention":4798,"totalTrials":217,"cells":4799},"Norovirus challenge pool",{"EARLY_PHASE1":4800,"PHASE1":4802,"PHASE2":4811,"PHASE3":4813,"PHASE4":4815,"NA":4817},{"trials":4801,"activeCount":100},[],{"trials":4803,"activeCount":100},[4804],{"nctId":4805,"briefTitle":4806,"status":169,"phases":4807,"primaryCompletion":2403,"completion":4642,"start":601,"enrollment":1426,"conditions":4808,"interventions":4810},"NCT01435811","Dose Range Evaluation of Norovirus Challenge Pool (GII.4, CIN-1)",[88],[4809],"Norovirus Infections",[4798],{"trials":4812,"activeCount":100},[],{"trials":4814,"activeCount":100},[],{"trials":4816,"activeCount":100},[],{"trials":4818,"activeCount":100},[],{"intervention":1924,"totalTrials":217,"cells":4820},{"EARLY_PHASE1":4821,"PHASE1":4823,"PHASE2":4829,"PHASE3":4831,"PHASE4":4833,"NA":4835},{"trials":4822,"activeCount":100},[],{"trials":4824,"activeCount":100},[4825],{"nctId":1917,"briefTitle":1918,"status":169,"phases":4826,"primaryCompletion":1908,"completion":1908,"start":1920,"enrollment":126,"conditions":4827,"interventions":4828},[88],[1922],[1924,1925,1895,1926,1895],{"trials":4830,"activeCount":100},[],{"trials":4832,"activeCount":100},[],{"trials":4834,"activeCount":100},[],{"trials":4836,"activeCount":100},[],{"intervention":1925,"totalTrials":217,"cells":4838},{"EARLY_PHASE1":4839,"PHASE1":4841,"PHASE2":4847,"PHASE3":4849,"PHASE4":4851,"NA":4853},{"trials":4840,"activeCount":100},[],{"trials":4842,"activeCount":100},[4843],{"nctId":1917,"briefTitle":1918,"status":169,"phases":4844,"primaryCompletion":1908,"completion":1908,"start":1920,"enrollment":126,"conditions":4845,"interventions":4846},[88],[1922],[1924,1925,1895,1926,1895],{"trials":4848,"activeCount":100},[],{"trials":4850,"activeCount":100},[],{"trials":4852,"activeCount":100},[],{"trials":4854,"activeCount":100},[],{"intervention":1926,"totalTrials":217,"cells":4856},{"EARLY_PHASE1":4857,"PHASE1":4859,"PHASE2":4865,"PHASE3":4867,"PHASE4":4869,"NA":4871},{"trials":4858,"activeCount":100},[],{"trials":4860,"activeCount":100},[4861],{"nctId":1917,"briefTitle":1918,"status":169,"phases":4862,"primaryCompletion":1908,"completion":1908,"start":1920,"enrollment":126,"conditions":4863,"interventions":4864},[88],[1922],[1924,1925,1895,1926,1895],{"trials":4866,"activeCount":100},[],{"trials":4868,"activeCount":100},[],{"trials":4870,"activeCount":100},[],{"trials":4872,"activeCount":100},[],{"intervention":4874,"totalTrials":217,"cells":4875},"Cysteamine Bitartrate",{"EARLY_PHASE1":4876,"PHASE1":4878,"PHASE2":4888,"PHASE3":4890,"PHASE4":4892,"NA":4894},{"trials":4877,"activeCount":100},[],{"trials":4879,"activeCount":100},[4880],{"nctId":4881,"briefTitle":4882,"status":169,"phases":4883,"primaryCompletion":4884,"completion":4884,"start":4885,"enrollment":1426,"conditions":4886,"interventions":4887},"NCT03883984","Cysteamine for Asthma",[88],"2021-02-10","2019-06-18",[2841],[4874],{"trials":4889,"activeCount":100},[],{"trials":4891,"activeCount":100},[],{"trials":4893,"activeCount":100},[],{"trials":4895,"activeCount":100},[],{"intervention":4897,"totalTrials":217,"cells":4898},"Tacrolimus",{"EARLY_PHASE1":4899,"PHASE1":4901,"PHASE2":4913,"PHASE3":4915,"PHASE4":4917,"NA":4919},{"trials":4900,"activeCount":100},[],{"trials":4902,"activeCount":100},[4903],{"nctId":4904,"briefTitle":4905,"status":169,"phases":4906,"primaryCompletion":4907,"completion":4908,"start":4909,"enrollment":3300,"conditions":4910,"interventions":4912},"NCT06638879","Tacrolimus Toothpaste for Management of Oral Chronic Graft vs. Host Disease (cGVHD)",[88],"2025-09-16","2026-02-18","2024-09-17",[4911],"Chronic Graft Versus Host Disease Oral",[4897],{"trials":4914,"activeCount":100},[],{"trials":4916,"activeCount":100},[],{"trials":4918,"activeCount":100},[],{"trials":4920,"activeCount":100},[],{"intervention":4922,"totalTrials":217,"cells":4923},"Sargramostim",{"EARLY_PHASE1":4924,"PHASE1":4926,"PHASE2":4936,"PHASE3":4938,"PHASE4":4940,"NA":4942},{"trials":4925,"activeCount":100},[],{"trials":4927,"activeCount":100},[4928],{"nctId":4929,"briefTitle":4930,"status":169,"phases":4931,"primaryCompletion":4932,"completion":4932,"start":4933,"enrollment":2043,"conditions":4934,"interventions":4935},"NCT03006146","Evaluation of a Single Dose of Inhaled Sargramostim in Patients With Autoimmune Pulmonary Alveolar Proteinosis",[88],"2021-06-07","2017-07-13",[4787],[4922],{"trials":4937,"activeCount":100},[],{"trials":4939,"activeCount":100},[],{"trials":4941,"activeCount":100},[],{"trials":4943,"activeCount":100},[],{"intervention":4945,"totalTrials":217,"cells":4946},"06Benzylguanine",{"EARLY_PHASE1":4947,"PHASE1":4949,"PHASE2":4961,"PHASE3":4963,"PHASE4":4965,"NA":4967},{"trials":4948,"activeCount":100},[],{"trials":4950,"activeCount":100},[4951],{"nctId":4952,"briefTitle":4953,"status":423,"phases":4954,"primaryCompletion":2041,"completion":1403,"start":4955,"enrollment":217,"conditions":4956,"interventions":4959},"NCT00272870","Treatment of Newly Diagnosed Brain Tumors With Chemotherapy and Radiation Using Cells Modified for Chemoprotection and an Experimental Drug to Decrease the Tumor Cell Resistance to Chemotherapy",[88],"2005-12",[4957,4958],"Glioblastoma Multiforme (WHO Grade IV)","Anaplastic Astrocytoma (WHO Grade III)",[4945,4960],"MGMT P140K",{"trials":4962,"activeCount":100},[],{"trials":4964,"activeCount":100},[],{"trials":4966,"activeCount":100},[],{"trials":4968,"activeCount":100},[],{"intervention":4960,"totalTrials":217,"cells":4970},{"EARLY_PHASE1":4971,"PHASE1":4973,"PHASE2":4979,"PHASE3":4981,"PHASE4":4983,"NA":4985},{"trials":4972,"activeCount":100},[],{"trials":4974,"activeCount":100},[4975],{"nctId":4952,"briefTitle":4953,"status":423,"phases":4976,"primaryCompletion":2041,"completion":1403,"start":4955,"enrollment":217,"conditions":4977,"interventions":4978},[88],[4957,4958],[4945,4960],{"trials":4980,"activeCount":100},[],{"trials":4982,"activeCount":100},[],{"trials":4984,"activeCount":100},[],{"trials":4986,"activeCount":100},[],{"intervention":4988,"totalTrials":217,"cells":4989},"Antithrombin III",{"EARLY_PHASE1":4990,"PHASE1":4992,"PHASE2":5004,"PHASE3":5006,"PHASE4":5008,"NA":5010},{"trials":4991,"activeCount":100},[],{"trials":4993,"activeCount":100},[4994],{"nctId":4995,"briefTitle":4996,"status":169,"phases":4997,"primaryCompletion":4998,"completion":4998,"start":4999,"enrollment":4467,"conditions":5000,"interventions":5003},"NCT02631174","Evaluation Of The Pharmacokinetics Of Antithrombin III In Neonates And Infants Undergoing CPB And ECMO Support",[88],"2018-06","2015-06",[5001,5002],"Extracorporeal Membrane Oxygenation Complication","Cardiopulmonary Bypass",[4988],{"trials":5005,"activeCount":100},[],{"trials":5007,"activeCount":100},[],{"trials":5009,"activeCount":100},[],{"trials":5011,"activeCount":100},[],{"intervention":5013,"totalTrials":217,"cells":5014},"Pravastatin",{"EARLY_PHASE1":5015,"PHASE1":5017,"PHASE2":5029,"PHASE3":5031,"PHASE4":5033,"NA":5035},{"trials":5016,"activeCount":100},[],{"trials":5018,"activeCount":100},[5019],{"nctId":5020,"briefTitle":5021,"status":169,"phases":5022,"primaryCompletion":5023,"completion":5024,"start":5025,"enrollment":1772,"conditions":5026,"interventions":5028},"NCT05524246","Pravastatin as a Prophylactic to Reduce Endothelial Injury in Pediatric Patients With Elevated Body Mass Index",[88],"2024-12-31","2025-03-05","2023-01-27",[3302,5027],"Endothelial Injury",[5013],{"trials":5030,"activeCount":100},[],{"trials":5032,"activeCount":100},[],{"trials":5034,"activeCount":100},[],{"trials":5036,"activeCount":100},[],{"intervention":2323,"totalTrials":217,"cells":5038},{"EARLY_PHASE1":5039,"PHASE1":5041,"PHASE2":5047,"PHASE3":5049,"PHASE4":5051,"NA":5053},{"trials":5040,"activeCount":100},[],{"trials":5042,"activeCount":100},[5043],{"nctId":2313,"briefTitle":2314,"status":169,"phases":5044,"primaryCompletion":2316,"completion":2317,"start":2318,"enrollment":1478,"conditions":5045,"interventions":5046},[88],[2320,2321],[2323,2324,2325,2326,2327],{"trials":5048,"activeCount":100},[],{"trials":5050,"activeCount":100},[],{"trials":5052,"activeCount":100},[],{"trials":5054,"activeCount":100},[],{"intervention":2324,"totalTrials":217,"cells":5056},{"EARLY_PHASE1":5057,"PHASE1":5059,"PHASE2":5065,"PHASE3":5067,"PHASE4":5069,"NA":5071},{"trials":5058,"activeCount":100},[],{"trials":5060,"activeCount":100},[5061],{"nctId":2313,"briefTitle":2314,"status":169,"phases":5062,"primaryCompletion":2316,"completion":2317,"start":2318,"enrollment":1478,"conditions":5063,"interventions":5064},[88],[2320,2321],[2323,2324,2325,2326,2327],{"trials":5066,"activeCount":100},[],{"trials":5068,"activeCount":100},[],{"trials":5070,"activeCount":100},[],{"trials":5072,"activeCount":100},[],{"intervention":2325,"totalTrials":217,"cells":5074},{"EARLY_PHASE1":5075,"PHASE1":5077,"PHASE2":5083,"PHASE3":5085,"PHASE4":5087,"NA":5089},{"trials":5076,"activeCount":100},[],{"trials":5078,"activeCount":100},[5079],{"nctId":2313,"briefTitle":2314,"status":169,"phases":5080,"primaryCompletion":2316,"completion":2317,"start":2318,"enrollment":1478,"conditions":5081,"interventions":5082},[88],[2320,2321],[2323,2324,2325,2326,2327],{"trials":5084,"activeCount":100},[],{"trials":5086,"activeCount":100},[],{"trials":5088,"activeCount":100},[],{"trials":5090,"activeCount":100},[],{"intervention":2327,"totalTrials":217,"cells":5092},{"EARLY_PHASE1":5093,"PHASE1":5095,"PHASE2":5101,"PHASE3":5103,"PHASE4":5105,"NA":5107},{"trials":5094,"activeCount":100},[],{"trials":5096,"activeCount":100},[5097],{"nctId":2313,"briefTitle":2314,"status":169,"phases":5098,"primaryCompletion":2316,"completion":2317,"start":2318,"enrollment":1478,"conditions":5099,"interventions":5100},[88],[2320,2321],[2323,2324,2325,2326,2327],{"trials":5102,"activeCount":100},[],{"trials":5104,"activeCount":100},[],{"trials":5106,"activeCount":100},[],{"trials":5108,"activeCount":100},[],{"intervention":5110,"totalTrials":217,"cells":5111},"Dexmedetomidine 1mcg\u002Fkg Intranasal",{"EARLY_PHASE1":5112,"PHASE1":5114,"PHASE2":5124,"PHASE3":5126,"PHASE4":5128,"NA":5130},{"trials":5113,"activeCount":100},[],{"trials":5115,"activeCount":100},[5116],{"nctId":5117,"briefTitle":5118,"status":169,"phases":5119,"primaryCompletion":1931,"completion":3423,"start":935,"enrollment":16,"conditions":5120,"interventions":5121},"NCT02836431","Pharmacokinetic Study of Dexmedetomidine After Intra-nasal Dosing in Children",[88],[1935],[5110,5122,5123],"Dexmedetomidine 2mcg\u002Fkg Intranasal","Dexmedetomidine 1mcg Intravenous",{"trials":5125,"activeCount":100},[],{"trials":5127,"activeCount":100},[],{"trials":5129,"activeCount":100},[],{"trials":5131,"activeCount":100},[],{"intervention":5122,"totalTrials":217,"cells":5133},{"EARLY_PHASE1":5134,"PHASE1":5136,"PHASE2":5142,"PHASE3":5144,"PHASE4":5146,"NA":5148},{"trials":5135,"activeCount":100},[],{"trials":5137,"activeCount":100},[5138],{"nctId":5117,"briefTitle":5118,"status":169,"phases":5139,"primaryCompletion":1931,"completion":3423,"start":935,"enrollment":16,"conditions":5140,"interventions":5141},[88],[1935],[5110,5122,5123],{"trials":5143,"activeCount":100},[],{"trials":5145,"activeCount":100},[],{"trials":5147,"activeCount":100},[],{"trials":5149,"activeCount":100},[],{"intervention":5123,"totalTrials":217,"cells":5151},{"EARLY_PHASE1":5152,"PHASE1":5154,"PHASE2":5160,"PHASE3":5162,"PHASE4":5164,"NA":5166},{"trials":5153,"activeCount":100},[],{"trials":5155,"activeCount":100},[5156],{"nctId":5117,"briefTitle":5118,"status":169,"phases":5157,"primaryCompletion":1931,"completion":3423,"start":935,"enrollment":16,"conditions":5158,"interventions":5159},[88],[1935],[5110,5122,5123],{"trials":5161,"activeCount":100},[],{"trials":5163,"activeCount":100},[],{"trials":5165,"activeCount":100},[],{"trials":5167,"activeCount":100},[],{"intervention":5169,"totalTrials":217,"cells":5170},"Norovirus",{"EARLY_PHASE1":5171,"PHASE1":5173,"PHASE2":5183,"PHASE3":5185,"PHASE4":5187,"NA":5189},{"trials":5172,"activeCount":100},[],{"trials":5174,"activeCount":100},[5175],{"nctId":5176,"briefTitle":5177,"status":169,"phases":5178,"primaryCompletion":5179,"completion":3535,"start":2487,"enrollment":173,"conditions":5180,"interventions":5182},"NCT01322503","Susceptibility of Human Volunteers With Different Histo-Blood With Different Histo-Blood Group Antigens to Norovirus",[88],"2011-02",[5181],"Healthy Adults",[5169],{"trials":5184,"activeCount":100},[],{"trials":5186,"activeCount":100},[],{"trials":5188,"activeCount":100},[],{"trials":5190,"activeCount":100},[],{"intervention":1937,"totalTrials":217,"cells":5192},{"EARLY_PHASE1":5193,"PHASE1":5195,"PHASE2":5201,"PHASE3":5203,"PHASE4":5205,"NA":5207},{"trials":5194,"activeCount":100},[],{"trials":5196,"activeCount":100},[5197],{"nctId":1928,"briefTitle":1929,"status":169,"phases":5198,"primaryCompletion":1931,"completion":1931,"start":1932,"enrollment":1933,"conditions":5199,"interventions":5200},[88],[1935],[1895,1937],{"trials":5202,"activeCount":100},[],{"trials":5204,"activeCount":100},[],{"trials":5206,"activeCount":100},[],{"trials":5208,"activeCount":100},[],{"intervention":5210,"totalTrials":217,"cells":5211},"Zileuton",{"EARLY_PHASE1":5212,"PHASE1":5214,"PHASE2":5223,"PHASE3":5225,"PHASE4":5227,"NA":5229},{"trials":5213,"activeCount":100},[],{"trials":5215,"activeCount":100},[5216],{"nctId":5217,"briefTitle":5218,"status":169,"phases":5219,"primaryCompletion":3798,"completion":3798,"start":5220,"enrollment":540,"conditions":5221,"interventions":5222},"NCT01136941","Trial of Zileuton CR in Children and Adults With Sickle Cell Disease",[88],"2010-09",[29],[5210],{"trials":5224,"activeCount":100},[],{"trials":5226,"activeCount":100},[],{"trials":5228,"activeCount":100},[],{"trials":5230,"activeCount":100},[],{"intervention":5232,"totalTrials":217,"cells":5233},"Dexmedetomidine buccal",{"EARLY_PHASE1":5234,"PHASE1":5236,"PHASE2":5248,"PHASE3":5250,"PHASE4":5252,"NA":5254},{"trials":5235,"activeCount":100},[],{"trials":5237,"activeCount":100},[5238],{"nctId":5239,"briefTitle":5240,"status":169,"phases":5241,"primaryCompletion":5242,"completion":5242,"start":5243,"enrollment":16,"conditions":5244,"interventions":5246},"NCT03668951","Pharmacokinetic Study of Dexmedetomidine After Intra-Nasal and Buccal Dosing in Children",[88],"2022-05-03","2018-08-20",[5245],"Heart Diseases",[5232,5247,5247],"Dexmedetomidine Intranasal",{"trials":5249,"activeCount":100},[],{"trials":5251,"activeCount":100},[],{"trials":5253,"activeCount":100},[],{"trials":5255,"activeCount":100},[],{"intervention":5247,"totalTrials":217,"cells":5257},{"EARLY_PHASE1":5258,"PHASE1":5260,"PHASE2":5266,"PHASE3":5268,"PHASE4":5270,"NA":5272},{"trials":5259,"activeCount":100},[],{"trials":5261,"activeCount":100},[5262],{"nctId":5239,"briefTitle":5240,"status":169,"phases":5263,"primaryCompletion":5242,"completion":5242,"start":5243,"enrollment":16,"conditions":5264,"interventions":5265},[88],[5245],[5232,5247,5247],{"trials":5267,"activeCount":100},[],{"trials":5269,"activeCount":100},[],{"trials":5271,"activeCount":100},[],{"trials":5273,"activeCount":100},[],{"intervention":5275,"totalTrials":217,"cells":5276},"CPX-351",{"EARLY_PHASE1":5277,"PHASE1":5279,"PHASE2":5296,"PHASE3":5298,"PHASE4":5300,"NA":5302},{"trials":5278,"activeCount":100},[],{"trials":5280,"activeCount":100},[5281],{"nctId":5282,"briefTitle":5283,"status":169,"phases":5284,"primaryCompletion":5285,"completion":5286,"start":2838,"enrollment":4467,"conditions":5287,"interventions":5295},"NCT01943682","Safety Study of CPX-351 in Children With Relapsed Leukemia or Lymphoma",[88],"2019-03","2019-04",[1347,5288,5289,5290,5291,5292,5293,5294],"Acute Lymphoblastic Leukemia","Burkitt Lymphoma","Diffuse Large Cell Lymphoma","Gray Zone Lymphoma","Lymphoblastic Lymphoma","Anaplastic Large Cell Lymphoma","Hodgkin Lymphoma",[5275],{"trials":5297,"activeCount":100},[],{"trials":5299,"activeCount":100},[],{"trials":5301,"activeCount":100},[],{"trials":5303,"activeCount":100},[],{"intervention":4648,"totalTrials":217,"cells":5305},{"EARLY_PHASE1":5306,"PHASE1":5308,"PHASE2":5314,"PHASE3":5316,"PHASE4":5318,"NA":5320},{"trials":5307,"activeCount":100},[],{"trials":5309,"activeCount":100},[5310],{"nctId":4639,"briefTitle":4640,"status":169,"phases":5311,"primaryCompletion":4642,"completion":4642,"start":4643,"enrollment":27,"conditions":5312,"interventions":5313},[88],[4645],[4622,4634,4647,4635,4648],{"trials":5315,"activeCount":100},[],{"trials":5317,"activeCount":100},[],{"trials":5319,"activeCount":100},[],{"trials":5321,"activeCount":100},[],{"intervention":5323,"totalTrials":217,"cells":5324},"AZD7325",{"EARLY_PHASE1":5325,"PHASE1":5327,"PHASE2":5337,"PHASE3":5339,"PHASE4":5341,"NA":5343},{"trials":5326,"activeCount":100},[],{"trials":5328,"activeCount":100},[5329],{"nctId":5330,"briefTitle":5331,"status":169,"phases":5332,"primaryCompletion":5333,"completion":5333,"start":5334,"enrollment":24,"conditions":5335,"interventions":5336},"NCT03140813","An Initial Study of AZD7325 in Adults With Fragile X Syndrome",[88],"2020-06-18","2018-01-16",[937],[5323,5323],{"trials":5338,"activeCount":100},[],{"trials":5340,"activeCount":100},[],{"trials":5342,"activeCount":100},[],{"trials":5344,"activeCount":100},[],{"intervention":4598,"totalTrials":217,"cells":5346},{"EARLY_PHASE1":5347,"PHASE1":5353,"PHASE2":5355,"PHASE3":5357,"PHASE4":5359,"NA":5361},{"trials":5348,"activeCount":100},[5349],{"nctId":4585,"briefTitle":4586,"status":169,"phases":5350,"primaryCompletion":4588,"completion":4588,"start":4589,"enrollment":1944,"conditions":5351,"interventions":5352},[87],[4591,4592,4593,4594,4595,4596],[4580,4598],{"trials":5354,"activeCount":100},[],{"trials":5356,"activeCount":100},[],{"trials":5358,"activeCount":100},[],{"trials":5360,"activeCount":100},[],{"trials":5362,"activeCount":100},[],{"intervention":5364,"totalTrials":217,"cells":5365},"Sirolimus",{"EARLY_PHASE1":5366,"PHASE1":5378,"PHASE2":5380,"PHASE3":5382,"PHASE4":5384,"NA":5386},{"trials":5367,"activeCount":100},[5368],{"nctId":5369,"briefTitle":5370,"status":423,"phases":5371,"primaryCompletion":4318,"completion":4318,"start":1403,"enrollment":491,"conditions":5372,"interventions":5377},"NCT01658007","Pilot Study Of Sirolimus Plus Multiagent Chemotherapy For Relapsed\u002FRefractory Acute Lymphoblastic Leukemia\u002FLymphoma",[87],[5373,5374,5375,5376],"Relapsed Lymphoblastic Leukemia","Recurrent Adult Lymphoblastic Lymphoma","Refractory Acute Lymphoblastic Leukemia","Refractory Lymphoblastic Lymphoma",[5364],{"trials":5379,"activeCount":100},[],{"trials":5381,"activeCount":100},[],{"trials":5383,"activeCount":100},[],{"trials":5385,"activeCount":100},[],{"trials":5387,"activeCount":100},[],{"intervention":5389,"totalTrials":217,"cells":5390},"Sodium Thiosulfate",{"EARLY_PHASE1":5391,"PHASE1":5403,"PHASE2":5405,"PHASE3":5407,"PHASE4":5409,"NA":5411},{"trials":5392,"activeCount":100},[5393],{"nctId":5394,"briefTitle":5395,"status":5396,"phases":5397,"primaryCompletion":695,"completion":695,"start":5398,"enrollment":5399,"conditions":5400,"interventions":5402},"NCT05756660","Sodium Thiosulfate Otoprotection During Salvage Cisplatin Therapy","SUSPENDED",[87],"2023-03-01",33,[5401],"Ototoxicity, Drug-Induced",[5389],{"trials":5404,"activeCount":100},[],{"trials":5406,"activeCount":100},[],{"trials":5408,"activeCount":100},[],{"trials":5410,"activeCount":100},[],{"trials":5412,"activeCount":100},[],{"intervention":5414,"totalTrials":217,"cells":5415},"lidocaine cream",{"EARLY_PHASE1":5416,"PHASE1":5425,"PHASE2":5427,"PHASE3":5429,"PHASE4":5431,"NA":5433},{"trials":5417,"activeCount":100},[5418],{"nctId":5419,"briefTitle":5420,"status":799,"phases":5421,"primaryCompletion":5422,"completion":5422,"start":201,"enrollment":100,"conditions":5423,"interventions":5424},"NCT00924963","J-Tip® Jet Injection of 1% Buffered Lidocaine or Saline Versus 4% Lidocaine Cream Before Venipuncture or IV Insertion",[87],"2010-06",[23],[5414],{"trials":5426,"activeCount":100},[],{"trials":5428,"activeCount":100},[],{"trials":5430,"activeCount":100},[],{"trials":5432,"activeCount":100},[],{"trials":5434,"activeCount":100},[],{"intervention":5436,"totalTrials":217,"cells":5437},"Riluzole",{"EARLY_PHASE1":5438,"PHASE1":5449,"PHASE2":5451,"PHASE3":5453,"PHASE4":5455,"NA":5457},{"trials":5439,"activeCount":100},[5440],{"nctId":5441,"briefTitle":5442,"status":169,"phases":5443,"primaryCompletion":1698,"completion":5444,"start":5445,"enrollment":2155,"conditions":5446,"interventions":5448},"NCT02081027","Pilot Study of Riluzole for Drug-Refractory Irritability in Autism Spectrum Disorders",[87],"2015-05","2013-09-19",[5447],"Autism Spectrum Disorders",[5436],{"trials":5450,"activeCount":100},[],{"trials":5452,"activeCount":100},[],{"trials":5454,"activeCount":100},[],{"trials":5456,"activeCount":100},[],{"trials":5458,"activeCount":100},[],{"intervention":940,"totalTrials":217,"cells":5460},{"EARLY_PHASE1":5461,"PHASE1":5467,"PHASE2":5469,"PHASE3":5471,"PHASE4":5473,"NA":5475},{"trials":5462,"activeCount":100},[5463],{"nctId":931,"briefTitle":932,"status":169,"phases":5464,"primaryCompletion":934,"completion":934,"start":935,"enrollment":9,"conditions":5465,"interventions":5466},[87],[937],[939,940,941,61],{"trials":5468,"activeCount":100},[],{"trials":5470,"activeCount":100},[],{"trials":5472,"activeCount":100},[],{"trials":5474,"activeCount":100},[],{"trials":5476,"activeCount":100},[],{"intervention":5478,"totalTrials":217,"cells":5479},"olestra",{"EARLY_PHASE1":5480,"PHASE1":5489,"PHASE2":5491,"PHASE3":5493,"PHASE4":5495,"NA":5497},{"trials":5481,"activeCount":100},[5482],{"nctId":5483,"briefTitle":5484,"status":169,"phases":5485,"primaryCompletion":2403,"completion":3534,"start":4179,"enrollment":1568,"conditions":5486,"interventions":5488},"NCT01261338","Intervention to Reduce Body Burdens of PCBs in Residents of Anniston, Alabama",[87],[5487],"Toxic Effect of Other Corrosive Organic Compounds",[5478],{"trials":5490,"activeCount":100},[],{"trials":5492,"activeCount":100},[],{"trials":5494,"activeCount":100},[],{"trials":5496,"activeCount":100},[],{"trials":5498,"activeCount":100},[],{"intervention":5500,"totalTrials":217,"cells":5501},"Intra-Ophthalmic Artery Topotecan",{"EARLY_PHASE1":5502,"PHASE1":5512,"PHASE2":5514,"PHASE3":5516,"PHASE4":5518,"NA":5520},{"trials":5503,"activeCount":100},[5504],{"nctId":5505,"briefTitle":5506,"status":423,"phases":5507,"primaryCompletion":5508,"completion":5508,"start":4319,"enrollment":880,"conditions":5509,"interventions":5511},"NCT01466855","A Study of Intra-Ophthalmic Artery Topotecan Infusion for the Treatment of Retinoblastoma",[87],"2015-10",[5510],"Retinoblastoma",[5500],{"trials":5513,"activeCount":100},[],{"trials":5515,"activeCount":100},[],{"trials":5517,"activeCount":100},[],{"trials":5519,"activeCount":100},[],{"trials":5521,"activeCount":100},[],{"intervention":1962,"totalTrials":491,"cells":5523},{"EARLY_PHASE1":5524,"PHASE1":5526,"PHASE2":5532,"PHASE3":5534,"PHASE4":5536,"NA":5542},{"trials":5525,"activeCount":100},[],{"trials":5527,"activeCount":100},[5528],{"nctId":1903,"briefTitle":1904,"status":423,"phases":5529,"primaryCompletion":1906,"completion":1907,"start":1908,"enrollment":1909,"conditions":5530,"interventions":5531},[88],[1911,1912],[1914,1915],{"trials":5533,"activeCount":100},[],{"trials":5535,"activeCount":100},[],{"trials":5537,"activeCount":100},[5538],{"nctId":1955,"briefTitle":1956,"status":169,"phases":5539,"primaryCompletion":1958,"completion":1958,"start":201,"enrollment":1426,"conditions":5540,"interventions":5541},[91],[1960],[1895,1962],{"trials":5543,"activeCount":100},[5544],{"nctId":5545,"briefTitle":5546,"status":169,"phases":5547,"primaryCompletion":211,"completion":211,"start":4690,"enrollment":5548,"conditions":5549,"interventions":5550},"NCT02038894","Comparing Anesthetic Techniques in Children Having Esophagogastroduodenoscopies",[92],179,[34],[5551,5552,5553,1962],"Intubated with Sevoflurane","Intubated with Propofol","Zofran - no intubation",{"intervention":4634,"totalTrials":491,"cells":5555},{"EARLY_PHASE1":5556,"PHASE1":5562,"PHASE2":5568,"PHASE3":5570,"PHASE4":5572,"NA":5574},{"trials":5557,"activeCount":100},[5558],{"nctId":4627,"briefTitle":4628,"status":169,"phases":5559,"primaryCompletion":621,"completion":1931,"start":4630,"enrollment":4467,"conditions":5560,"interventions":5561},[87],[4632,3222],[4634,4622,4635],{"trials":5563,"activeCount":100},[5564],{"nctId":4639,"briefTitle":4640,"status":169,"phases":5565,"primaryCompletion":4642,"completion":4642,"start":4643,"enrollment":27,"conditions":5566,"interventions":5567},[88],[4645],[4622,4634,4647,4635,4648],{"trials":5569,"activeCount":100},[],{"trials":5571,"activeCount":100},[],{"trials":5573,"activeCount":100},[],{"trials":5575,"activeCount":100},[5576],{"nctId":1400,"briefTitle":1401,"status":169,"phases":5577,"primaryCompletion":1403,"completion":1403,"start":1404,"conditions":5578,"interventions":5579},[92],[1406],[1408,1409,1410],{"intervention":5581,"totalTrials":491,"cells":5582},"levetiracetam",{"EARLY_PHASE1":5583,"PHASE1":5585,"PHASE2":5598,"PHASE3":5606,"PHASE4":5608,"NA":5610},{"trials":5584,"activeCount":100},[],{"trials":5586,"activeCount":100},[5587],{"nctId":5588,"briefTitle":5589,"status":169,"phases":5590,"primaryCompletion":5591,"completion":5591,"start":5592,"enrollment":5593,"conditions":5594,"interventions":5596},"NCT01521130","Imaging the Effect of Centrotemporal Spikes and Seizures on Language in Children",[88],"2017-07","2012-01",108,[5595],"Benign Childhood Epilepsy With Centro-Temporal Spikes",[5597],"Levetiracetam",{"trials":5599,"activeCount":100},[5600],{"nctId":5601,"briefTitle":5602,"status":169,"phases":5603,"primaryCompletion":3350,"completion":3350,"start":5220,"enrollment":3300,"conditions":5604,"interventions":5605},"NCT01239212","Dosing of Levetiracetam (Keppra) in Neonates",[88,89],[2672],[5581],{"trials":5607,"activeCount":100},[],{"trials":5609,"activeCount":100},[],{"trials":5611,"activeCount":100},[5612],{"nctId":5613,"briefTitle":5614,"status":169,"phases":5615,"primaryCompletion":5616,"completion":5616,"start":4643,"enrollment":16,"conditions":5617,"interventions":5618},"NCT01261416","Pharmacokinetics of Levetiracetam (Keppra) in Neonates",[],"2010-07",[2672,2671],[5581],{"intervention":5620,"totalTrials":96,"cells":5621},"Furosemide",{"EARLY_PHASE1":5622,"PHASE1":5624,"PHASE2":5626,"PHASE3":5628,"PHASE4":5630,"NA":5641},{"trials":5623,"activeCount":100},[],{"trials":5625,"activeCount":100},[],{"trials":5627,"activeCount":100},[],{"trials":5629,"activeCount":100},[],{"trials":5631,"activeCount":100},[5632],{"nctId":5633,"briefTitle":5634,"status":169,"phases":5635,"primaryCompletion":5636,"completion":5637,"start":5638,"enrollment":2975,"conditions":5639,"interventions":5640},"NCT05898022","Pragmatic Research on Diuretic Management in Early BPD Pilot",[91],"2025-07-10","2025-12-12","2023-08-17",[2540],[5620],{"trials":5642,"activeCount":100},[5643],{"nctId":5644,"briefTitle":5645,"status":169,"phases":5646,"primaryCompletion":4999,"completion":4999,"start":4319,"enrollment":5647,"conditions":5648,"interventions":5649},"NCT01709227","Peritoneal Dialysis vs Furosemide for Acute Kidney Injury After Cardiopulmonary Bypass",[92],73,[26],[5620],{"intervention":4647,"totalTrials":96,"cells":5651},{"EARLY_PHASE1":5652,"PHASE1":5654,"PHASE2":5660,"PHASE3":5662,"PHASE4":5664,"NA":5666},{"trials":5653,"activeCount":100},[],{"trials":5655,"activeCount":100},[5656],{"nctId":4639,"briefTitle":4640,"status":169,"phases":5657,"primaryCompletion":4642,"completion":4642,"start":4643,"enrollment":27,"conditions":5658,"interventions":5659},[88],[4645],[4622,4634,4647,4635,4648],{"trials":5661,"activeCount":100},[],{"trials":5663,"activeCount":100},[],{"trials":5665,"activeCount":100},[],{"trials":5667,"activeCount":100},[5668],{"nctId":5669,"briefTitle":5670,"status":799,"phases":5671,"primaryCompletion":3533,"completion":3533,"start":5672,"enrollment":100,"conditions":5673,"interventions":5674},"NCT00980551","Pilot Study of Topotecan\u002FVincristine With Subconjunctival Carboplatin for Patients With Bilateral Retinoblastoma",[92],"2010-05",[5510],[5675,5676,4647,5677],"subtenon Carboplatin","Topotecan Hydrochloride","Filgrastim",{"intervention":5679,"totalTrials":96,"cells":5680},"tauroursodeoxycholic acid",{"EARLY_PHASE1":5681,"PHASE1":5683,"PHASE2":5685,"PHASE3":5687,"PHASE4":5689,"NA":5691},{"trials":5682,"activeCount":100},[],{"trials":5684,"activeCount":100},[],{"trials":5686,"activeCount":100},[],{"trials":5688,"activeCount":100},[],{"trials":5690,"activeCount":100},[],{"trials":5692,"activeCount":100},[5693,5703],{"nctId":5694,"briefTitle":5695,"status":169,"phases":5696,"completion":5697,"start":5698,"enrollment":5699,"conditions":5700,"interventions":5701},"NCT00004441","Study of Tauroursodeoxycholic Acid for Hepatobiliary Disease in Cystic Fibrosis",[92],"2001-09","1997-09",39,[20],[5679,5702],"ursodiol",{"nctId":5704,"briefTitle":5705,"status":169,"phases":5706,"completion":5707,"start":5708,"enrollment":355,"conditions":5709,"interventions":5711},"NCT00004410","Randomized Study of Tauroursodeoxycholic Acid in Prophylactic Therapy of Total Parenteral Nutrition Associated Cholestasis in Infants",[92],"2002-03","1998-06",[5710],"Cholestasis",[5679],{"intervention":5713,"totalTrials":217,"cells":5714},"Vorinostat",{"EARLY_PHASE1":5715,"PHASE1":5717,"PHASE2":5719,"PHASE3":5721,"PHASE4":5723,"NA":5725},{"trials":5716,"activeCount":100},[],{"trials":5718,"activeCount":100},[],{"trials":5720,"activeCount":100},[],{"trials":5722,"activeCount":100},[],{"trials":5724,"activeCount":100},[],{"trials":5726,"activeCount":100},[5727],{"nctId":5728,"briefTitle":5729,"status":5730,"phases":5731,"conditions":5732,"interventions":5735},"NCT01838187","Expanded Access Protocol Using 131I-MIBG Therapy +\u002F- Vorinostat for Refractory Neuroblastoma, Pheochromocytoma, or Paraganglioma","NO_LONGER_AVAILABLE",[],[741,5733,5734],"Pheochromocytoma","Paraganglioma",[5713],{"intervention":5737,"totalTrials":217,"cells":5738},"Penicillin G Benzathine",{"EARLY_PHASE1":5739,"PHASE1":5741,"PHASE2":5743,"PHASE3":5745,"PHASE4":5747,"NA":5749},{"trials":5740,"activeCount":100},[],{"trials":5742,"activeCount":100},[],{"trials":5744,"activeCount":100},[],{"trials":5746,"activeCount":100},[],{"trials":5748,"activeCount":100},[],{"trials":5750,"activeCount":100},[5751],{"nctId":5752,"briefTitle":5753,"status":169,"phases":5754,"primaryCompletion":5755,"completion":5756,"start":5757,"enrollment":5758,"conditions":5759,"interventions":5760},"NCT05211024","A Long-term Follow up Study for Patients Who Participated in the GOAL Trial (GOAL-Post)",[],"2024-03-30","2024-04-30","2022-01-28",1423,[483],[5737],{"intervention":5675,"totalTrials":217,"cells":5762},{"EARLY_PHASE1":5763,"PHASE1":5765,"PHASE2":5767,"PHASE3":5769,"PHASE4":5771,"NA":5773},{"trials":5764,"activeCount":100},[],{"trials":5766,"activeCount":100},[],{"trials":5768,"activeCount":100},[],{"trials":5770,"activeCount":100},[],{"trials":5772,"activeCount":100},[],{"trials":5774,"activeCount":100},[5775],{"nctId":5669,"briefTitle":5670,"status":799,"phases":5776,"primaryCompletion":3533,"completion":3533,"start":5672,"enrollment":100,"conditions":5777,"interventions":5778},[92],[5510],[5675,5676,4647,5677],{"intervention":5676,"totalTrials":217,"cells":5780},{"EARLY_PHASE1":5781,"PHASE1":5783,"PHASE2":5785,"PHASE3":5787,"PHASE4":5789,"NA":5791},{"trials":5782,"activeCount":100},[],{"trials":5784,"activeCount":100},[],{"trials":5786,"activeCount":100},[],{"trials":5788,"activeCount":100},[],{"trials":5790,"activeCount":100},[],{"trials":5792,"activeCount":100},[5793],{"nctId":5669,"briefTitle":5670,"status":799,"phases":5794,"primaryCompletion":3533,"completion":3533,"start":5672,"enrollment":100,"conditions":5795,"interventions":5796},[92],[5510],[5675,5676,4647,5677],{"intervention":5677,"totalTrials":217,"cells":5798},{"EARLY_PHASE1":5799,"PHASE1":5801,"PHASE2":5803,"PHASE3":5805,"PHASE4":5807,"NA":5809},{"trials":5800,"activeCount":100},[],{"trials":5802,"activeCount":100},[],{"trials":5804,"activeCount":100},[],{"trials":5806,"activeCount":100},[],{"trials":5808,"activeCount":100},[],{"trials":5810,"activeCount":100},[5811],{"nctId":5669,"briefTitle":5670,"status":799,"phases":5812,"primaryCompletion":3533,"completion":3533,"start":5672,"enrollment":100,"conditions":5813,"interventions":5814},[92],[5510],[5675,5676,4647,5677],{"intervention":5816,"totalTrials":217,"cells":5817},"hyperpolarized Xenon gas",{"EARLY_PHASE1":5818,"PHASE1":5820,"PHASE2":5822,"PHASE3":5824,"PHASE4":5826,"NA":5828},{"trials":5819,"activeCount":100},[],{"trials":5821,"activeCount":100},[],{"trials":5823,"activeCount":100},[],{"trials":5825,"activeCount":100},[],{"trials":5827,"activeCount":100},[],{"trials":5829,"activeCount":100},[5830],{"nctId":5831,"briefTitle":5832,"status":169,"phases":5833,"primaryCompletion":5834,"completion":5834,"start":5835,"enrollment":1345,"conditions":5836,"interventions":5837},"NCT03593434","Airway Clearance Therapy on Hyperpolarized 129Xenon and MRI",[],"2021-12-30","2018-07-30",[20],[5816],{"intervention":5839,"totalTrials":217,"cells":5840},"Docosahexaenoic acid 1000 mg",{"EARLY_PHASE1":5841,"PHASE1":5843,"PHASE2":5845,"PHASE3":5847,"PHASE4":5849,"NA":5851},{"trials":5842,"activeCount":100},[],{"trials":5844,"activeCount":100},[],{"trials":5846,"activeCount":100},[],{"trials":5848,"activeCount":100},[],{"trials":5850,"activeCount":100},[],{"trials":5852,"activeCount":100},[5853],{"nctId":5854,"briefTitle":5855,"status":799,"phases":5856,"primaryCompletion":600,"completion":2334,"start":661,"enrollment":100,"conditions":5857,"interventions":5859},"NCT02137408","Docosahexaenoic Acid Supplementation of Women With Hypertension in Pregnancy to Improve Endothelial Health",[92],[5858],"Hypertension in Pregnancy",[5839],{"intervention":538,"totalTrials":217,"cells":5861},{"EARLY_PHASE1":5862,"PHASE1":5864,"PHASE2":5866,"PHASE3":5868,"PHASE4":5870,"NA":5872},{"trials":5863,"activeCount":100},[],{"trials":5865,"activeCount":100},[],{"trials":5867,"activeCount":100},[],{"trials":5869,"activeCount":100},[],{"trials":5871,"activeCount":100},[],{"trials":5873,"activeCount":100},[5874],{"nctId":528,"briefTitle":529,"status":169,"phases":5875,"primaryCompletion":531,"completion":531,"start":532,"enrollment":533,"conditions":5876,"interventions":5877},[],[535,536],[490,538],{"intervention":5879,"totalTrials":217,"cells":5880},"Single-injection sciatic PNB",{"EARLY_PHASE1":5881,"PHASE1":5883,"PHASE2":5885,"PHASE3":5887,"PHASE4":5889,"NA":5891},{"trials":5882,"activeCount":100},[],{"trials":5884,"activeCount":100},[],{"trials":5886,"activeCount":100},[],{"trials":5888,"activeCount":100},[],{"trials":5890,"activeCount":100},[],{"trials":5892,"activeCount":100},[5893],{"nctId":5894,"briefTitle":5895,"status":169,"phases":5896,"primaryCompletion":5897,"completion":5897,"start":599,"enrollment":5898,"conditions":5899,"interventions":5901},"NCT02947633","Sciatic Technique Comparison of Nerve Blockade for Pain Control Following Hamstring Autograft Harvest in Adolescents",[92],"2024-04",141,[5900],"Anterior Cruciate Ligament (ACL) Tear",[5879,5902],"Continuous sciatic PNB",{"intervention":5902,"totalTrials":217,"cells":5904},{"EARLY_PHASE1":5905,"PHASE1":5907,"PHASE2":5909,"PHASE3":5911,"PHASE4":5913,"NA":5915},{"trials":5906,"activeCount":100},[],{"trials":5908,"activeCount":100},[],{"trials":5910,"activeCount":100},[],{"trials":5912,"activeCount":100},[],{"trials":5914,"activeCount":100},[],{"trials":5916,"activeCount":100},[5917],{"nctId":5894,"briefTitle":5895,"status":169,"phases":5918,"primaryCompletion":5897,"completion":5897,"start":599,"enrollment":5898,"conditions":5919,"interventions":5920},[92],[5900],[5879,5902],{"intervention":5702,"totalTrials":217,"cells":5922},{"EARLY_PHASE1":5923,"PHASE1":5925,"PHASE2":5927,"PHASE3":5929,"PHASE4":5931,"NA":5933},{"trials":5924,"activeCount":100},[],{"trials":5926,"activeCount":100},[],{"trials":5928,"activeCount":100},[],{"trials":5930,"activeCount":100},[],{"trials":5932,"activeCount":100},[],{"trials":5934,"activeCount":100},[5935],{"nctId":5694,"briefTitle":5695,"status":169,"phases":5936,"completion":5697,"start":5698,"enrollment":5699,"conditions":5937,"interventions":5938},[92],[20],[5679,5702],{"intervention":5940,"totalTrials":217,"cells":5941},"CellCept",{"EARLY_PHASE1":5942,"PHASE1":5944,"PHASE2":5946,"PHASE3":5948,"PHASE4":5950,"NA":5952},{"trials":5943,"activeCount":100},[],{"trials":5945,"activeCount":100},[],{"trials":5947,"activeCount":100},[],{"trials":5949,"activeCount":100},[],{"trials":5951,"activeCount":100},[],{"trials":5953,"activeCount":100},[5954],{"nctId":5955,"briefTitle":5956,"status":169,"phases":5957,"primaryCompletion":779,"completion":779,"start":5958,"enrollment":9,"conditions":5959,"interventions":5960},"NCT00281619","PK-PD Study of Mycophenolic Acid (CellCept) in Pediatric Kidney Transplant Patients",[],"2006-01",[782],[5940],{"intervention":5962,"totalTrials":217,"cells":5963},"Omegaven",{"EARLY_PHASE1":5964,"PHASE1":5966,"PHASE2":5968,"PHASE3":5970,"PHASE4":5972,"NA":5974},{"trials":5965,"activeCount":100},[],{"trials":5967,"activeCount":100},[],{"trials":5969,"activeCount":100},[],{"trials":5971,"activeCount":100},[],{"trials":5973,"activeCount":100},[],{"trials":5975,"activeCount":100},[5976],{"nctId":5977,"briefTitle":5978,"status":169,"phases":5979,"primaryCompletion":5980,"completion":5980,"start":5616,"enrollment":2043,"conditions":5981,"interventions":5982},"NCT01173159","Compassionate Use of Omegaven to Reverse Parenteral Nutrition Induced Cholestasis",[92],"2018-12",[5710],[5962],{"intervention":5984,"totalTrials":217,"cells":5985},"Methadone",{"EARLY_PHASE1":5986,"PHASE1":5988,"PHASE2":5990,"PHASE3":5992,"PHASE4":5994,"NA":5996},{"trials":5987,"activeCount":100},[],{"trials":5989,"activeCount":100},[],{"trials":5991,"activeCount":100},[],{"trials":5993,"activeCount":100},[],{"trials":5995,"activeCount":100},[],{"trials":5997,"activeCount":100},[5998],{"nctId":5999,"briefTitle":6000,"status":169,"phases":6001,"primaryCompletion":6002,"completion":6002,"start":4038,"enrollment":1345,"conditions":6003,"interventions":6005},"NCT01754324","The Pharmacokinetics of Oral Methadone in the Treatment of Neonatal Abstinence Syndrome",[],"2013-12",[6004],"Neonatal Abstinence Syndrome",[5984],{"intervention":6007,"totalTrials":217,"cells":6008},"[F-18]Fluoro-DOPA PET, a diagnostic radiopharmaceutical",{"EARLY_PHASE1":6009,"PHASE1":6011,"PHASE2":6013,"PHASE3":6015,"PHASE4":6017,"NA":6019},{"trials":6010,"activeCount":100},[],{"trials":6012,"activeCount":100},[],{"trials":6014,"activeCount":100},[],{"trials":6016,"activeCount":100},[],{"trials":6018,"activeCount":100},[],{"trials":6020,"activeCount":100},[6021],{"nctId":6022,"briefTitle":6023,"status":799,"phases":6024,"completion":6025,"start":6025,"enrollment":100,"conditions":6026,"interventions":6027},"NCT00556153","[F-18]Fluoro-DOPA PET Imaging of Brain Tumors in Children",[],"2013-02",[3850],[6007],{"intervention":6029,"totalTrials":217,"cells":6030},"Desflurane",{"EARLY_PHASE1":6031,"PHASE1":6033,"PHASE2":6035,"PHASE3":6037,"PHASE4":6039,"NA":6041},{"trials":6032,"activeCount":100},[],{"trials":6034,"activeCount":100},[],{"trials":6036,"activeCount":100},[],{"trials":6038,"activeCount":100},[],{"trials":6040,"activeCount":100},[],{"trials":6042,"activeCount":100},[6043],{"nctId":6044,"briefTitle":6045,"status":169,"phases":6046,"primaryCompletion":2334,"completion":6047,"start":6048,"enrollment":828,"conditions":6049,"interventions":6051},"NCT02199314","Anesthesia and Motor Evoked Potential (MEP) Recruitment",[92],"2017-03","2013-03",[6050],"Idiopathic Scoliosis",[6029],{"intervention":5551,"totalTrials":217,"cells":6053},{"EARLY_PHASE1":6054,"PHASE1":6056,"PHASE2":6058,"PHASE3":6060,"PHASE4":6062,"NA":6064},{"trials":6055,"activeCount":100},[],{"trials":6057,"activeCount":100},[],{"trials":6059,"activeCount":100},[],{"trials":6061,"activeCount":100},[],{"trials":6063,"activeCount":100},[],{"trials":6065,"activeCount":100},[6066],{"nctId":5545,"briefTitle":5546,"status":169,"phases":6067,"primaryCompletion":211,"completion":211,"start":4690,"enrollment":5548,"conditions":6068,"interventions":6069},[92],[34],[5551,5552,5553,1962],{"intervention":5552,"totalTrials":217,"cells":6071},{"EARLY_PHASE1":6072,"PHASE1":6074,"PHASE2":6076,"PHASE3":6078,"PHASE4":6080,"NA":6082},{"trials":6073,"activeCount":100},[],{"trials":6075,"activeCount":100},[],{"trials":6077,"activeCount":100},[],{"trials":6079,"activeCount":100},[],{"trials":6081,"activeCount":100},[],{"trials":6083,"activeCount":100},[6084],{"nctId":5545,"briefTitle":5546,"status":169,"phases":6085,"primaryCompletion":211,"completion":211,"start":4690,"enrollment":5548,"conditions":6086,"interventions":6087},[92],[34],[5551,5552,5553,1962],{"intervention":5553,"totalTrials":217,"cells":6089},{"EARLY_PHASE1":6090,"PHASE1":6092,"PHASE2":6094,"PHASE3":6096,"PHASE4":6098,"NA":6100},{"trials":6091,"activeCount":100},[],{"trials":6093,"activeCount":100},[],{"trials":6095,"activeCount":100},[],{"trials":6097,"activeCount":100},[],{"trials":6099,"activeCount":100},[],{"trials":6101,"activeCount":100},[6102],{"nctId":5545,"briefTitle":5546,"status":169,"phases":6103,"primaryCompletion":211,"completion":211,"start":4690,"enrollment":5548,"conditions":6104,"interventions":6105},[92],[34],[5551,5552,5553,1962],{"intervention":6107,"totalTrials":217,"cells":6108},"Ceftaroline",{"EARLY_PHASE1":6109,"PHASE1":6111,"PHASE2":6113,"PHASE3":6115,"PHASE4":6117,"NA":6119},{"trials":6110,"activeCount":100},[],{"trials":6112,"activeCount":100},[],{"trials":6114,"activeCount":100},[],{"trials":6116,"activeCount":100},[],{"trials":6118,"activeCount":100},[],{"trials":6120,"activeCount":100},[6121],{"nctId":6122,"briefTitle":6123,"status":169,"phases":6124,"primaryCompletion":6125,"completion":6126,"start":6127,"enrollment":2155,"conditions":6128,"interventions":6129},"NCT03771313","Pharmacokinetic and Pharmacodynamic Analysis of Ceftaroline in Children and Adolescents With Cystic Fibrosis",[],"2024-11-30","2025-07-31","2017-09-01",[20],[6107],{"intervention":6131,"totalTrials":217,"cells":6132},"pergolide",{"EARLY_PHASE1":6133,"PHASE1":6135,"PHASE2":6137,"PHASE3":6139,"PHASE4":6141,"NA":6143},{"trials":6134,"activeCount":100},[],{"trials":6136,"activeCount":100},[],{"trials":6138,"activeCount":100},[],{"trials":6140,"activeCount":100},[],{"trials":6142,"activeCount":100},[],{"trials":6144,"activeCount":100},[6145],{"nctId":6146,"briefTitle":6147,"status":169,"phases":6148,"completion":2386,"start":6149,"enrollment":6150,"conditions":6151,"interventions":6153},"NCT00004433","Randomized Study of Pergolide in Children With Tourette Syndrome",[92],"1994-12",74,[6152],"Tourette Syndrome",[6131],{"intervention":1408,"totalTrials":217,"cells":6155},{"EARLY_PHASE1":6156,"PHASE1":6158,"PHASE2":6160,"PHASE3":6162,"PHASE4":6164,"NA":6166},{"trials":6157,"activeCount":100},[],{"trials":6159,"activeCount":100},[],{"trials":6161,"activeCount":100},[],{"trials":6163,"activeCount":100},[],{"trials":6165,"activeCount":100},[],{"trials":6167,"activeCount":100},[6168],{"nctId":1400,"briefTitle":1401,"status":169,"phases":6169,"primaryCompletion":1403,"completion":1403,"start":1404,"conditions":6170,"interventions":6171},[92],[1406],[1408,1409,1410],{"intervention":6173,"totalTrials":217,"cells":6174},"Stiripentol",{"EARLY_PHASE1":6175,"PHASE1":6177,"PHASE2":6179,"PHASE3":6181,"PHASE4":6183,"NA":6185},{"trials":6176,"activeCount":100},[],{"trials":6178,"activeCount":100},[],{"trials":6180,"activeCount":100},[],{"trials":6182,"activeCount":100},[],{"trials":6184,"activeCount":100},[],{"trials":6186,"activeCount":100},[6187],{"nctId":6188,"briefTitle":6189,"status":6190,"phases":6191,"conditions":6192,"interventions":6194},"NCT01983722","Treatment Plan to Provide Expanded Access to Stiripentol for Patients With Dravet Syndrome","APPROVED_FOR_MARKETING",[],[6193],"Dravet Syndrome",[6173],{"intervention":6196,"totalTrials":217,"cells":6197},"Whole exome sequencing",{"EARLY_PHASE1":6198,"PHASE1":6200,"PHASE2":6202,"PHASE3":6204,"PHASE4":6206,"NA":6208},{"trials":6199,"activeCount":100},[],{"trials":6201,"activeCount":100},[],{"trials":6203,"activeCount":100},[],{"trials":6205,"activeCount":100},[],{"trials":6207,"activeCount":100},[],{"trials":6209,"activeCount":100},[6210],{"nctId":6211,"briefTitle":6212,"status":423,"phases":6213,"primaryCompletion":6214,"completion":6214,"start":6215,"enrollment":155,"conditions":6216,"interventions":6218},"NCT02964481","Malignant Hyperthermia Registry and Genetic Testing",[],"2017-02-28","2015-08-18",[6217],"Malignant Hyperthermia",[6196],{"intervention":6220,"totalTrials":217,"cells":6221},"Remifentanil-dexmedetomidine",{"EARLY_PHASE1":6222,"PHASE1":6224,"PHASE2":6226,"PHASE3":6228,"PHASE4":6230,"NA":6232},{"trials":6223,"activeCount":100},[],{"trials":6225,"activeCount":100},[],{"trials":6227,"activeCount":100},[],{"trials":6229,"activeCount":100},[],{"trials":6231,"activeCount":100},[],{"trials":6233,"activeCount":100},[6234],{"nctId":6235,"briefTitle":6236,"status":799,"phases":6237,"primaryCompletion":5897,"completion":5897,"start":6238,"enrollment":100,"conditions":6239,"interventions":6241},"NCT05654064","Comparing Fetoscopic Surgery Protocols",[92],"2022-04",[6240],"Minimally Invasive Fetoscopic Procedures",[6220,6242],"Dexmedetomidine-fentanyl",{"intervention":6242,"totalTrials":217,"cells":6244},{"EARLY_PHASE1":6245,"PHASE1":6247,"PHASE2":6249,"PHASE3":6251,"PHASE4":6253,"NA":6255},{"trials":6246,"activeCount":100},[],{"trials":6248,"activeCount":100},[],{"trials":6250,"activeCount":100},[],{"trials":6252,"activeCount":100},[],{"trials":6254,"activeCount":100},[],{"trials":6256,"activeCount":100},[6257],{"nctId":6235,"briefTitle":6236,"status":799,"phases":6258,"primaryCompletion":5897,"completion":5897,"start":6238,"enrollment":100,"conditions":6259,"interventions":6260},[92],[6240],[6220,6242],{"intervention":6262,"totalTrials":217,"cells":6263},"Hyperpolarized Helium-3 MRI",{"EARLY_PHASE1":6264,"PHASE1":6266,"PHASE2":6268,"PHASE3":6270,"PHASE4":6272,"NA":6274},{"trials":6265,"activeCount":100},[],{"trials":6267,"activeCount":100},[],{"trials":6269,"activeCount":100},[],{"trials":6271,"activeCount":100},[],{"trials":6273,"activeCount":100},[],{"trials":6275,"activeCount":100},[6276],{"nctId":6277,"briefTitle":6278,"status":169,"phases":6279,"primaryCompletion":6280,"completion":6280,"start":661,"enrollment":1896,"conditions":6281,"interventions":6283},"NCT02316392","Imaging and Understanding BOS in Lung Transplantation",[],"2017-02",[6282],"Bronchiolitis Obliterans Syndrome",[6262],{"intervention":6285,"totalTrials":217,"cells":6286},"Glutamine",{"EARLY_PHASE1":6287,"PHASE1":6289,"PHASE2":6291,"PHASE3":6293,"PHASE4":6295,"NA":6297},{"trials":6288,"activeCount":100},[],{"trials":6290,"activeCount":100},[],{"trials":6292,"activeCount":100},[],{"trials":6294,"activeCount":100},[],{"trials":6296,"activeCount":100},[],{"trials":6298,"activeCount":100},[6299],{"nctId":6300,"briefTitle":6301,"status":169,"phases":6302,"primaryCompletion":4999,"completion":4999,"start":2403,"enrollment":2043,"conditions":6303,"interventions":6309},"NCT01576003","Enteral Glutamine in Reducing Bloodstream Infections in Short Bowel Syndrome Infants",[92],[6304,6305,6306,6307,6308],"Bloodstream Infections","Short Bowel Syndrome","Development","Nutrition","Biological Markers",[6285]]